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ABSTRACT

THE EFFECT OF T CELL RECEPTOR SPECIFICITY ON CD4+CD25+
REGULATORY T CELL FUNCTION IN AN AUTOIMMUNE SETTING

Soyoung Oh

Andrew J. Caton, Ph.D.

The studies presented in this dissertation examine how the T cell receptor
(TCR) specificity of CD4+CD25+ regulatory T (Treg) cells affects their function in
a mouse model of autoimmune arthritis (TS1xHACII mice). TS1xHACII mice coexpress CD4+ T cells that express the transgenic 6.5 TCR, which is specific for
the S1 determinant of influenza virus PR8 hemagglutinin (HA), and HA as a neoself antigen under the MHC Class II I-Eα promoter. The majority of adult
TS1xHACII mice develop inflammatory arthritis that is driven by recognition of S1
peptide by 6.5+CD4+ T cells. Notably, arthritis develops despite the presence of
CD4+CD25+Foxp3+ Treg cells, including a population of 6.5+ cells that are
specific for the disease target antigen S1 peptide. However, the administration of
exogenous CD4+CD25+ Treg cells to pre-arthritic TS1xHACII mice can prevent
arthritis in TS1xHACII mice, demonstrating that the disease is susceptible to
CD4+CD25+ Treg cell activity.

iv

Interestingly, we have found that the ability of CD4+CD25+ Treg cells to
suppress arthritis in TS1xHACII mice is highly dependent on the TCR
specificity(s) of the Treg cell population. Polyclonal CD4+CD25+ Treg cells
(including cells that have not developed in the presence of the disease target
antigen S1 peptide), but not CD4+CD25+ Treg cells that are enriched for S1specific 6.5+ cells are able to prevent arthritis development in TS1xHACII mice.
Although polyclonal CD4+CD25+ Treg cells can suppress arthritis in TS1xHACII
mice, our data suggest that successful CD4+CD25+ Treg cell mediated
suppression of arthritis is remarkably sensitive to the balance of Treg cells and
pathogenic 6.5+CD4+ T cells. We also present data indicating that CD4+CD25+
Treg cells that are strongly reactive for a highly expressed disease target antigen
can be detrimental in the context of certain autoimmune diseases. Collectively,
these studies indicate that the antigen-specificity of CD4+CD25+ Treg cells is a
critical determinant of their ability to suppress arthritis in TS1xHACII mice.
Moreover the data presented here also suggest that the balance of certain TCR
specificities between CD4+CD25+ Treg and effector CD4+ T cells plays an
important role in determining the maintenance of tolerance versus the
development autoimmunity.
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Chapter 1: Introduction and Overview

1.1 Introduction

The adaptive immune system is designed to be highly diverse, allowing for
the recognition of a wide range of pathogens. However, this diversity must be
balanced with the requirement of self-tolerance, and within tightly controlled
numbers of peripheral lymphocytes. During T cell development, gene
rearrangement mechanisms produce an enormous array of T cell receptors
(TCRs). This diverse pool of TCRs is subsequently screened for autoreactivity,
and highly self-reactive T cells are eliminated or functionally suppressed via
central and peripheral tolerance mechanisms (Palmer 2003; Hogquist et al. 2005;
Mueller et al. 2010), which include the activity of CD4+CD25+ regulatory T (Treg)
cells (Sakaguchi 2004). The combination of these processes allows the adaptive
immune system to achieve a diverse T cell repertoire while maintaining selftolerance. However, these tolerance mechanisms are not foolproof, and
approximately 3 to 5 percent of the population develops autoimmunity (Jacobson
et al. 1997).

How and why CD4+CD25+ Treg cells fail to prevent the development of
autoimmunity is poorly understood. The studies presented in this dissertation
examine the role of CD4+CD25+ Treg cells in modifying a mouse model of
1

inflammatory arthritis that is dependent on the autoreactive CD4+ T cell
response. We also address how the antigen-specificity of the CD4+CD25+ Treg
cells affects their in vivo suppressor function. This introductory chapter begins
with an overview of rheumatoid arthritis and mouse models of arthritis with a
particular focus on how CD4+ T cells can contribute to disease. The following
section presents a summary of relevant topics in CD4+CD25+ Treg cell biology.
The chapter concludes with an overview of the current understanding of
CD4+CD25+ Treg cell activity in human arthritis and mouse models of disease.

1.2 Rheumatoid Arthritis

Approximately 0.8 percent of the population develops rheumatoid arthritis
(RA) (Lipsky). Although the etiology of the disease remains unknown, a major
genetic risk factor for RA is the MHC Class II allele HLA-DR4 (DRβ1*0401).
Interestingly, other MHC Class II alleles (HLA-DR5, HLA-DR2, HLA-DR3, and
HLA-DR7) may be protective, as they are found at lower frequencies in RA
patients than in individuals who have not developed RA (Lipsky). However, the
mechanisms (e.g. deletion of autoreactive T cells, selection of Treg cells) by
which these particular MHC Class II alleles could confer protection are unknown.
In addition to the MHC Class II allele HLA-DR4, the gene PTPN22 (protein
tyrosine phosphatase non-receptor type 22), which encodes the lymphoid
2

tyrosine phosphatase (Lyp) that participates in TCR signal transduction, has
been identified as another genetic risk factor for RA (Lipsky; (Lundy et al. 2007).
Collectively, the association of genes that encode MHC Class II and TCR
signaling molecules with RA development strongly supports a role for CD4+ T
cells in disease. Indeed, studies in multiple mouse models of arthritis have
identified a critical role for CD4+ T cells in arthritis development. A summary of
these findings is presented in the following section.

1.3 The role of CD4+ T cells in mouse models of arthritis

Mouse models of inflammatory arthritis possess several characteristics
that resonate with human RA, and have been an instrumental tool in gaining
better understanding of this autoimmune disorder. Work in several different
arthritis models has clearly demonstrated a requirement for autoreactive CD4+ T
cells in arthritis pathogenesis. One of the most commonly used systems to study
disease is the inductive model of collagen-induced arthritis (CIA). In CIA,
disease development is initiated by immunizing mice with bovine type II collagen
in complete Freund’s adjuvant. The ensuing antigen-specific CD4+ T cell
response is required for B cell generation of collagen-specific antibodies that
drive disease (Luross and Williams 2001). Although CD4+ T cells are necessary
for the initial immune response that leads to arthritis (Ranges et al. 1985), CIA is
3

ultimately dependent on the production of collagen-specific antibodies and
arthritis does not develop in B cell deficient mice (Svensson et al. 1998).

K/BxN mice develop spontaneous arthritis that also requires T and B cell
responses for disease development. Arthritis in K/BxN mice is initiated by KRN
transgenic TCR CD4+ T cell recognition of a glucose-6-phosphate isomerase
(GPI) peptide presented by the MHC Class II molecule Ag7, which activates GPIspecific B cells, leading to the production of pathogenic autoantibodies that bind
to articular surfaces and initiate an inflammatory cascade that leads to joint
damage (Kouskoff et al. 1996; Matsumoto et al. 1999; Matsumoto et al. 2002).
Chimeric mice, generated by administration of KRN.RAG-/- bone marrow to
irradiated BxN.TCRα-/- mice, develop arthritis, demonstrating that CD4+ T cells of
other specificities are not required for the initiation of arthritis development in
K/BxN mice (Mangialaio et al. 1999). The transfer of serum from arthritic K/BxN
mice into BxN.RAG-/- mice induces arthritis, indicating that the presence of
autoantibodies alone is sufficient to mediate arthritis development, and that T
cells are not required for the effector phase of disease (Korganow et al. 1999).
However, although CD4+ T cells are not necessary for the development of serum
transfer induced arthritis, they can contribute to disease as co-administration of
CD4+ T cells with the serum transfers exacerbates arthritis by a mechanism that
involves IL-17 (Jacobs et al. 2009).
4

While disease development in CIA and K/BxN arthritis models requires
both T and B cell responses, it has been also shown that autoreactive CD4+ T
cells alone can initiate arthritis. Sakaguchi and colleagues have described the
SKG mouse, which develops spontaneous arthritis that is attributed to a failure in
negative selection of autoreactive thymocytes due to a mutation in the ZAP-70
(ζ-associated protein of 70 kDa) gene (Sakaguchi et al. 2003). The adoptive
transfer of SKG CD4+ T cells into RAG-/- mice can induce arthritis, demonstrating
that B cell antibody production is not required for arthritis development, and that
CD4+ T cells alone can initiate disease (Hirota et al. 2007). However, while it is
evident that autoreactive CD4+ T cells drive arthritis development in SKG mice,
the nature of the peptide(s) that the cells recognize is unknown. Moreover,
arthritis development in SKG mice is also dependent on additional environmental
cues, as SKG mice housed in specific pathogen free conditions do not develop
disease (Yoshitomi et al. 2005). Our lab has recently described another mouse
model of arthritis that is dependent on autoreactive CD4+ T cells. TS1xHACII
mice develop spontaneous inflammatory arthritis that is driven by CD4+ T cell
recognition of a single systemically presented peptide and does not require B
cells (Rankin et al. 2008). Specific aspects of arthritis development in
TS1xHACII mice will be discussed in greater detail in Chapter 3 of this
dissertation.

5

While CD4+ T cells clearly play a critical role in the initiation of the immune
response that leads to arthritis development, other aspects of the immune
response can also contribute arthritis pathogenesis. Dysregulation of
inflammatory pathways can be a key contributing factor to disease, as the overexpression of cytokines such as TNF-α and IL-1α, or expression of a mutated IL6R gp130 that enhances gp130-mediated signal transducer and activator of
transcription (STAT3) activation also leads to arthritis development (Keffer et al.
1991; Niki et al. 2001; Sawa et al. 2006). Interestingly, the arthritis that develops
in the IL-6R gp130 mutant mice is attributed to CD4+ T cell activation resulting
from enhanced homeostatic proliferation, and disease can be ameliorated by
inhibiting the homeostatic proliferation of CD4+ T cells (Sawa et al. 2006). In
SKG mice, genetic deficiencies in IL-6, IL-1, and TNF-α resulted in either
complete protection from arthritis or delayed disease onset accompanied by
reduced incidence and disease severity (Hata et al. 2004), demonstrating that
the autoreactive CD4+ T cells are acting in concert with certain inflammatory
pathways. In addition to IL-6, IL-1, and TNF-α, there are reports that IL-17,
recently identified as defining a unique T helper cell lineage (Harrington et al.
2005; Park et al. 2005), is also involved in arthritis. In the next section we will
summarize the relevant findings on IL-17 in human arthritis and mouse models of
arthritis.

6

1.4 The role of IL-17 in arthritis

The cytokine IL-17 is thought to play a critical role in several autoimmune
diseases, including experimental autoimmune encephalitis (EAE), psoriasis, and
arthritis (Afzali et al. 2007; Korn et al. 2009). In human RA patients, IL-17 has
been detected in the peripheral blood, serum, synovial fluid, and/or synovium
(Chabaud et al. 1999; Kotake et al. 1999; Hirota et al. 2007; Sarkar et al. 2010).
Interestingly in the synovium, IL-17 is primarily found in T cell enriched areas,
and is mostly secreted by memory CD4+ T cells isolated from the peripheral
blood of RA patients (Sarkar et al. 2010), suggesting that CD4+ T cells are a
major source of IL-17 in RA. IL-17 has also been detected in the synovial fluid
and joints of arthritic mice (Hirota et al. 2007). IL-17 may contribute to arthritis
pathogenesis by a variety of mechanisms. IL-17 can induce the upregulation of
cytokines such as IL-1β, TNF-α, and IL-6 (Chabaud et al. 1998; Jovanovic et al.
1998; Sarkar et al. 2010), which not only contribute to arthritis pathogenesis but
can also promote additional differentiation of Th-17 cells (Weaver et al. 2007;
Korn et al. 2009). IL-17 can also recruit innate immune cells such as monocytes
or neutrophils, which are potential sources for the cytokines described above, to
sites of inflammation (Lundy et al. 2007; Shahrara et al. 2009; Pelletier et al.
2010). Moreover, the IL-17R is found on chondrocytes, synoviocytes, and
osteoclasts; and the activation of these cell types has direct implications for
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arthritis pathogenesis (Sarkar et al. 2010). Indeed, in vitro studies have
demonstrated that IL-17 can act upon osteoblasts to induce osteoclastogenesis
(Sato et al. 2006), and potentially contribute to bone resorption. Thus, IL-17 can
act upon cells in the joint and also activate and/or recruit other cell types to the
primary sites of inflammation and autoimmune pathology.

Studies in several mouse models of arthritis have demonstrated that IL-17
plays an important role in disease pathogenesis. Mice lacking the IL-1 receptor
antagonist (IL1-Ra-/-) develop inflammatory arthritis, and interestingly the CD4+ T
cells from these mice produce elevated amounts of IL-17 (Nakae et al. 2003).
When IL1-Ra-/- mice are bred onto an IL17-/- background, the mice are protected
from arthritis, demonstrating the critical role for IL-17 in mediating the disease
that develops in IL1-Ra-/- mice (Nakae et al. 2003). Moreover, treating arthritic
IL1-Ra-/- mice with anti-IL17 antibody can reduce disease severity (Koenders et
al. 2008). Work in the CIA model has shown that increasing systemic IL-17
production in mice by gene transfer with an adenoviral vector expressing IL-17
accelerates diseases onset and severity (Lubberts et al. 2001). Complementary
studies examining the effects of IL-17 or IL-17R blockade have demonstrated
that inhibiting the biological activity of IL-17 reduces the severity of CIA (Lubberts
et al. 2001; Lubberts et al. 2004; Egan et al. 2008). Furthermore, IL17-/- mice
exhibit much lower incidence of CIA and reduced disease severity than wildtype
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mice (Nakae et al. 2003). Similarly, in an LPS induced model of arthritis, disease
incidence and severity are reduced in IL17-/- mice (Sato et al. 2006).
Interestingly, studies in K/BxN and SKG mice indicate that IL-17 production by
CD4+ T cells is important in arthritis development. In the K/BxN arthritis model,
the augmentation of serum transfer induced disease by KRN CD4+ T cells is
inhibited by treatment with anti-IL17 antibody, indicating that CD4+ T cell
production of IL-17 was responsible for the exacerbation autoantibody induced
arthritis (Jacobs et al. 2009). Additionally, Sakaguchi and colleagues have
shown that IL-17+/+CD4+, but not IL-17-/-CD4+ T cells from SKG mice, can transfer
arthritis upon transfer into RAG-/- mice, demonstrating that CD4+ T cell generated
IL-17 is critical for disease induction (Hirota et al. 2007).

1.5 CD4+CD25+ regulatory T cells

The concept of suppressor T cells was first suggested by experiments in
which thymectomized mice and adult rats developed autoimmune diseases that
could be prevented by the transfer of spleen cells from healthy donors (Nishizuka
and Sakakura 1969; Penhale et al. 1976). In the extensive work following those
initial observations, Treg cell populations have been more clearly defined, and
can be very broadly separated into thymically generated or peripherally
generated (induced) Treg cells. Though several subpopulations of Treg cells
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have been characterized, the best defined is the thymically generated
CD4+CD25+ Treg cell population that comprises approximately 5 to 10 percent of
the human and murine peripheral CD4+ T cell repertoires. This population was
first characterized by constitutive expression of the IL-2 receptor α chain (CD25)
(Sakaguchi et al. 1995), which is also upregulated by activated CD4+ T cells.
Subsequently the forkhead transcription factor Foxp3 was identified as a more
reliable marker for CD4+CD25+ Treg cells (Fontenot et al. 2003; Hori et al. 2003),
and Foxp3 was considered to be the “master regulator” of the CD4+CD25+ Treg
cell lineage.

However a recent set of studies has challenged the notion of Foxp3 as the
key lineage commitment factor of CD4+CD25+ Treg cells. Multiple groups have
reported that a subset of cells that have developed in the absence of Foxp3
express a genetic signature that is consistent with that of CD4+CD25+Foxp3+
cells, suggesting that CD4+CD25+ Treg cell lineage commitment occurs upstream
of Foxp3 expression (Gavin et al. 2007; Hill et al. 2007; Lin et al. 2007).
Moreover, Foxp3 expression can be transiently upregulated in activated human T
cells, which do not acquire regulatory function (Gavin et al. 2006; Mantel et al.
2006; Wang et al. 2007). Nonetheless, it is clear that Foxp3 expression is critical
for CD4+CD25+ Treg cell function, as mice lacking Foxp3 develop severe
autoimmunity (Fontenot and Rudensky 2005; Kim et al. 2007). Furthermore, in
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humans, development of the autoimmune disorder IPEX has been attributed to
mutations in the FoxP3 gene (Bennett et al. 2001; Gambineri et al. 2003).

1.5.1 The role of TCR specificity in the thymic selection of CD4+CD25+ Treg cells

The initial day three thymectomy experiments indicated that the thymus
plays an important role in the generation of CD4+CD25+ Treg cells, however, the
exact nature of the signals (e.g. TCR engagement, cytokines, co-stimulation) that
guide the thymic development of CD4+CD25+ Treg cells remains unclear. While
the observation that there is overlap between the TCR repertoires of CD4+CD25+
Treg cells and conventional CD4+ T cells (Hsieh et al. 2004; Hsieh et al. 2006)
suggests that other signals (e.g. cytokines, co-stimulation) likely also play a role
in the thymic development of CD4+CD25+ Treg cells, a strong body of work
supports a significant role for TCR interactions with self-peptides in the thymic
selection of CD4+CD25+ Treg cells. The key findings in support of this concept
are presented below.

Experiments using transgenic TCRs provided the first evidence that
CD4+CD25+ Treg cells were selected via TCR interactions with self-peptide. It
was observed that mice containing CD4+ T cells expressing a transgenic TCR
specific for the myelin basic protein (MBP) only developed EAE when on a RAG-/11

background but not in intact mice (Olivares-Villagomez et al. 1998; Van de Keere
and Tonegawa 1998; Hori et al. 2002). Subsequent studies showed that mice on
an intact background did not develop disease because expression of a
secondary TCR, resulting from endogenous α chain rearrangements, allowed for
the selection of MBP-specific CD4+CD25+ Treg cells (Hori et al. 2002),
suggesting a role for TCR and self-peptide interactions in CD4+CD25+ Treg cell
selection. Indeed, studies in other transgenic systems have shown that
introducing the cognate antigen for the transgenic TCR onto a RAG-/- background
results in the development of CD4+CD25+ Treg cells expressing the transgenic
TCR (Apostolou et al. 2002; Kawahata et al. 2002; Walker et al. 2003).

Work from our laboratory has further demonstrated the importance of TCR
interactions with self peptides for the development of CD4+CD25+ Treg cells.
Studies in TS1xHA-transgenic mice have demonstrated that CD4+ T cells
expressing the 6.5 TCR (Kirberg et al. 1994), which confers specificity for the S1
determinant of PR8 HA, undergo efficient CD4+CD25+ Treg cell selection in
HA28 mice, which express PR8 HA driven by an SV40 promoter, demonstrating
that interactions with the agonist peptide can guide CD4+CD25+ Treg cell
development (Jordan et al. 2001). The requirement for peptide specificity for
CD4+CD25+ Treg cell selection appears to be quite stringent, as CD4+ T cells
bearing a TCR with low reactivity to the S1 peptide are not selected to be
12

CD4+CD25+ Treg cells (Jordan et al. 2001). Interestingly, while 6.5+CD4+CD25+
Treg cells can also be selected in other TS1xHA lineages, the numbers are lower
than what is generated in TS1xHA28 mice, and this appears to result from
enhanced deletion of 6.5+ thymocytes due to higher levels of HA expression in
the thymus (Picca et al. 2006; Simons et al. 2010), indicating that lower levels of
the cognate antigen favor more abundant CD4+CD25+ Treg cell selection.

1.5.2 The role of TCR specificity in CD4+CD25+ Treg cell function

TCR stimulation is required to activate CD4+CD25+ Treg cell suppressor
function (Takahashi et al. 1998; Thornton and Shevach 1998). However, in vitro
studies show that although CD4+CD25+ Treg cell activation is TCR specific,
CD4+CD25+ Treg cells are able to inhibit responder CD4+ T cells of different TCR
specificities (Takahashi et al. 1998; Thornton and Shevach 2000), indicating that
the suppression itself is not antigen-specific. Correspondingly, work in multiple
murine autoimmune diseases (e.g. CIA, colitis, EAE, diabetes, gastritis) have
shown that that the adoptive transfer of polyclonal CD4+CD25+ cells can prevent
or ameliorate disease (Olivares-Villagomez et al. 1998; Van de Keere and
Tonegawa 1998; Singh et al. 2001; Sarween et al. 2004; Morgan et al. 2005;
Zwar et al. 2006; Kelchtermans et al. 2009), indicating that CD4+CD25+ Treg
cells that are not enriched for disease-associated antigen specific cells can
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mediate suppression of an organ specific disease. However, there is also a
significant body of work suggesting that antigen-specific CD4+CD25+ Treg cells
are more effective than polyclonal CD4+CD25+ Treg cells at suppressing organspecific autoimmune diseases.

In the nonobese diabetes (NOD) model, the adoptive transfer of in vitro
expanded CD4+CD25+ cells expressing the BDC2.5 TCR, which recognizes a
pancreatic β cell islet antigen (Katz et al. 1993), into NOD.BDC2.5 mice (which
also express the transgenic TCR) can suppress diabetes (Tang et al. 2004;
Tarbell et al. 2004). Using a disease transfer model in which diabetes
development is induced by the administration of splenocytes from diabetic NOD
mice into NOD.scid mice, Steinman and colleagues also showed that lower
numbers of in vitro expanded antigen-specific CD4+CD25+ cells could suppress
disease, whereas greater numbers of in vitro expanded polyclonal CD4+CD25+ T
cells could not (Tarbell et al. 2004). Work with induced CD4+CD25+ Treg cells
also suggests that antigen-specific interactions are important for regulatory
function. TGF-β induced regulatory cells expressing the BDC-6.9 TCR can
suppress diabetes in NOD mice, which contain their cognate antigen, but not
NOD.C6 mice, which do not contain their cognate antigen (Tonkin et al. 2008). It
is possible that the inability to suppress diabetes in NOD.C6 mice may be linked
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to poor trafficking, expansion, and/or survival at the primary site of autoimmune
pathology.

Studies in the EAE model also emphasize that CD4+CD25+ Treg cell
specificity for the target autoantigen is important for the prevention of
autoimmunity. As described previously, mice expressing a transgenic TCR
specific for the encephalotegenic MBP protein spontaneously develop EAE when
on a RAG-deficient but not wildtype background, and the difference in disease
development can be attributed to the absence of CD4+CD25+ Treg cells specific
for EAE associated peptides in the RAG-/- mice (Hori et al. 2002). In another
model of EAE where disease is driven by the immune response to the myelin
proteolipid protein (PLP), the difference between two strains of mice with differing
susceptibilities to disease appears to be the enhanced representation of PLPpeptide specific CD4+CD25+ Treg cells in the more resistant strain (Reddy et al.
2004). Interestingly, CD4+CD25+ cells isolated from healthy individuals can
mediate better in vitro suppression of CD4+ T cell proliferation when stimulated
by MBP proteins than CD4+CD25+ cells isolated from multiple sclerosis (MS)
patients (Kumar et al. 2006), suggesting that in humans protection may also
correlate with the presence of CD4+CD25+ Treg cells that are specific for MSassociated peptides.
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Studies in day 3 thymectomized mice that develop autoimmune ovarian
disease (AOD), show that CD4+CD25+ Treg cells isolated from the draining
lymph nodes are superior to CD4+CD25+ Treg cells isolated from non-draining
lymph nodes at suppressing AOD (Samy et al. 2005; Samy et al. 2008). This
apparent enrichment for disease-specific CD4+CD25+ Treg cells in the draining
lymph nodes was evident for other organs as well, as CD4+CD25+ Treg cells
isolated from the lacrimal or prostate draining lymph nodes were the most
effective at suppressing dacryoadenitis and experimental autoimmune prostatitis
(EAP) respectively (Samy et al. 2008; Wheeler et al. 2009). Collectively, these
observations suggest that draining lymph nodes, which have been shown to
uniquely present organ-specific peptides (Hoglund et al. 1999; Gagnerault et al.
2002; Scheinecker et al. 2002), are enriched for CD4+CD25+ Treg cells that are
specific for antigens derived from the organ. Recent work examining the
CD4+CD25+ Treg cell repertoires from various lymph nodes further corroborates
the concept that regional lymph nodes may be biased towards CD4+CD25+ Treg
cells that recognize organ-specific antigens, as Treg cells showed distinct
patterns of TCR usage in different LNs, similar to the skewing of TCR usage
among antigen-experienced conventional CD4+ T cells in different anatomical
locations (Lathrop et al. 2008).
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1.5.3 Mechanisms of CD4+CD25+ Treg cell function

In spite of the clear observations that CD4+CD25+ Treg cells can suppress
immune responses and prevent autoimmune disease, how they exert their
regulatory function remains controversial. Indeed, a myriad of mechanisms by
which CD4+CD25+ Treg cells can mediate suppression have been reported. In
vitro studies indicate that direct cell contact between the regulatory and effector
populations is necessary, as suppression is prevented when the two cell
populations are separated in transwell experiments (Takahashi et al. 1998;
Thornton and Shevach 1998). Additional work indicates that CD4+CD25+ Treg
cell production of cytokines such as IL-10 or TGF-β is important for their
suppressor function (Huang et al. 2005). Alternatively CD4+CD25+ Treg cells
have been shown to act as a cytokine sink for cytokines such as IL-2, which can
promote apoptosis of effector CD4+ T cells (Pandiyan et al. 2007). It has also
been suggested that CD4+CD25+ Treg cells may suppress immune responses by
developing cytotoxic capabilities or modulating antigen presenting cells (APCs)
(Kryczek et al. 2006; Shevach et al. 2006; Vignali et al. 2008). Indeed,
Sakaguchi and colleagues have shown that a key contribution of CTLA-4 to
CD4+CD25+ Treg cell function may be through regulation of APCs (Wing et al.
2008). Interestingly, recent work has also demonstrated that CD4+CD25+ Treg
cells acquire the ability to suppress particular T-helper (Th) lineages by co-opting
the transcription factor pathways (IRF-4, RORγt, T-bet) that are key for the
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differentiation of the respective Th lineage cells (Chaudhry et al. 2009; Koch et
al. 2009; Zheng et al. 2009). It is possible that expression of transcription factors
specific for a certain Th lineage allows CD4+CD25+ Treg cells to acquire
properties (e.g expression of chemokine or cytokine receptors) that allow them to
traffic to the site of inflammation and/or compete for other soluble factors that
may potentiate the CD4+ Th cell response.

1.5.4 Plasticity of CD4+CD25+ Treg cells

CD4+CD25+Foxp3+ Treg cells can produce Th-1 and Th-17 associated cytokines

Recent studies have challenged the notion of CD4+CD25+ Treg cells as a
stable population of cells by demonstrating that under certain conditions
CD4+CD25+ Treg cells can differentiate to acquire properties that are normally
associated with effector CD4+ T cells. While multiple groups have documented
the loss of Foxp3 expression by CD4+CD25+ Treg cells (Hoffmann et al. 2006;
Duarte et al. 2009; Komatsu et al. 2009; Murai et al. 2009; Tsuji et al. 2009; Zhou
et al. 2009), there are also reports that CD4+CD25+ Treg cells that maintain
Foxp3 expression can develop phenotypic properties (e.g. cytokine production)
that are normally associated with effector CD4+ T cells. During Toxoplasma
gondii (T. gondii) infection, which induces a highly polarized Th-1 immune
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response, a subset of CD4+CD25+Foxp3+ Treg cells differentiates to express the
transcription factor T-bet and to produce IFN-γ (Oldenhove et al. 2009). The
acquisition of Th-1 cell properties by CD4+CD25+ Treg cells is at least partially
dependent on a lack of IL-2 in the infectious setting, since treatment of T. gondii
infected mice with an IL-2 α-IL-2 antibody complex that has been shown to
enhance the biological activity of IL-2 (Boyman et al. 2006) reduces the presence
of IFN-γ+CD4+CD25+Foxp3+ cells (Oldenhove et al. 2009).

In light of the complicated and interconnected relationship of CD4+CD25+
Treg cells and Th-17 cells (Bettelli et al. 2006; Veldhoen et al. 2006; Mucida et al.
2007; Zhang et al. 2008; Zhou et al. 2008), there has been much interest in
determining whether CD4+CD25+Foxp3+ Treg cells can differentiate to produce
IL-17. Several groups have shown that IL-17+CD4+CD25+Foxp3+ cells can be
isolated from human peripheral blood (Ayyoub et al. 2009; Beriou et al. 2009;
Voo et al. 2009). The IL-17 producing CD4+CD25+ Treg cells also express CCR6
(Ayyoub et al. 2009; Beriou et al. 2009; Voo et al. 2009), a chemokine receptor
that is associated with Th-17 cells (Acosta-Rodriguez et al. 2007; Annunziato et
al. 2007). It appears that while IL-1β and IL-6 promote IL-17 production by
human CD4+CD25+Foxp3+ Treg cells (Beriou et al. 2009; Voo et al. 2009), the
presence of TGF-β in in vitro cultures is inhibitory to this differentiation process
(Voo et al. 2009). Interestingly, there is also evidence that stronger TCR
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stimulation can favor IL-17 production, as a high but not low dose of α-CD3
induced IL-17 production by CD4+CD25+Foxp3+ cells (Voo et al. 2009).
However, despite producing IL-17, CD4+CD25+ Treg cells can inhibit responder
CD4+ T cells in in vitro suppression assays (Beriou et al. 2009; Voo et al. 2009).
Murine CD4+CD25+ Treg cells can also be differentiated in vitro to generate a
population of IL-17+CD4+CD25+Foxp3+ cells (Xu et al. 2007; Osorio et al. 2008;
Yang et al. 2008). CD4+CD25+Foxp3+ cells expressing RORγt, the transcription
factor that governs Th-17 differentiation (Ivanov et al. 2006; Yang et al. 2008),
can be found in mice in vivo, and while also present in the spleen are primarily
enriched in the lamina propria and mesenteric lymph nodes (Lochner et al.
2008).

CD4+CD25+ Treg cells can lose Foxp3 expression

Recent studies have demonstrated that the expression of Foxp3, which is
critical for maintenance of the CD4+CD25+ Treg cell phenotype (Wan and Flavell
2007; Williams and Rudensky 2007), can be unstable in CD4+CD25+ Treg cells.
Using Foxp3EGFP reporter mice, Hori and colleagues showed that a subset of
CD4+EGFP+ cells transferred into RAG-/- mice or lympho-replete mice lost Foxp3
expression, and this loss is exacerbated in the RAG-/- hosts (Komatsu et al.
2009). CD25 expression appeared to play a critical role in maintenance of Foxp3
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expression, as CD25+ cells were able to better maintain Foxp3 expression than
CD25- cells isolated from the same mice. This observation is consistent with
previous reports demonstrating that signaling through the IL-2R can potentiate
Foxp3 expression (Fontenot et al. 2005; Zorn et al. 2006). Additionally, Foxp3
loss was most prevalent in the CD4+CD25+ Treg cells that had undergone
extensive proliferation (Komatsu et al. 2009). This instability of Foxp3 can also
be seen in human CD4+CD25+ Treg cells, as prolonged in vitro stimulation and
expansion of CD4+CD25+ Treg cells isolated from peripheral blood mononuclear
cells results in the loss of Foxp3 expression in a subset of cells (Hoffmann et al.
2006; Hoffmann et al. 2009). While exposure to lymphopenia can induce loss of
Foxp3 expression in CD4+CD25+ Treg cells, exposure to inflammation during
autoimmune disease also contributes to the instability of Foxp3 expression
(Murai et al. 2009; Zhou et al. 2009). Interestingly, TCR engagement appears to
enhance this process, as a greater percentage of CD4+CD25+ Treg cells
expressing the BDC2.5 TCR, which is specific for a pancreatic islet antigen, lost
Foxp3 than polyclonal CD4+CD25+ Treg cells in NOD mice (Zhou et al. 2009).

The loss of Foxp3 in CD4+CD25+ Treg cells can be prevented or reduced
by the activity of cytokines such as TGF-β (Komatsu et al. 2009) or IL-10 (Murai
et al. 2009), although the mechanisms by which these cytokines are acting
remain unclear. Interestingly, a role for IL-10 in maintaining CD4+CD25+ Treg
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cell Foxp3 expression only becomes apparent in conditions of inflammation.
Kronenberg and colleagues showed that during colitis, wildtype CD4+CD25+ Treg
cells transferred into an IL10-/-RAG-/- host, or IL10Rβ-/- CD4+CD25+ Treg cells
transferred into a RAG-/- host fail to suppress disease, which is associated with
loss of Foxp3 expression in the CD4+CD25+ Treg cells (Murai et al. 2009).
However, when IL10Rβ-/- CD4+CD25+ Treg cells were co-transferred with
wildtype CD4+CD25+ Treg cells so that that RAG-/- mice did not develop colitis,
the IL10Rβ-/- CD4+CD25+ Treg cells were able to maintain Foxp3 expression,
indicating that IL-10 is important for the maintenance of Foxp3 expression only
during conditions of inflammation (Murai et al. 2009).

Recent studies in both human and murine CD4+CD25+ Treg cells indicate
that the methylation status of the Foxp3 promoter and the conserved noncoding
sequence 2 (CNS2) is an important determinant of Foxp3 expression (Kim and
Leonard 2007; Janson et al. 2008). Whereas natural CD4+CD25+ Treg cells
could be characterized by demethylation at the Foxp3 promoter and CNS2, the
DNA sequences remained methylated in induced CD4+CD25+ Treg cells or
conventional CD4+ T cells that had transiently upregulated Foxp3 (Baron et al.
2007; Floess et al. 2007; Polansky et al. 2008). Moreover, CD4+CD25+ Treg
cells in which the CNS2 region of the Foxp3 locus has been knocked out show
deficiencies in maintenance of Foxp3 expression when compared to wildtype
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CD4+CD25+ Treg cells (Zheng et al. 2010). Whereas wildtype CD4+CD25+ Treg
cells could maintain Foxp3 expression after multiple cell divisions, CNS2deficient CD4+CD25+ Treg cells exhibited dramatic loss of Foxp3 expression after
three to four cell divisions (Zheng et al. 2010). Interestingly, work with human
CD4+CD25+ Treg cells shows that the cells that lose Foxp3 upon repeated in
vitro stimulation have methylated the critical regions in the Foxp3 promoter
(Hoffmann et al. 2009).

CD4+CD25+ Treg cells lose Foxp3 expression can acquire effector properties

CD4+CD25+ Treg cells that lose Foxp3 can differentiate to acquire effector
functions. Strober and colleagues first showed that CD4+GFP+ cells purified from
Foxp3EGFP reporter mice could differentiate to generate both Foxp3+ and Foxp3IL-17 producing cells when cultured in vitro in the presence of IL-6 (Xu et al.
2007). Subsequently other groups have also demonstrated that CD4+CD25+
Treg cells can lose Foxp3 and acquire the ability to produce IL-17, and suggest
that the cytokines IL-6, IL-1, and IL-23 play important roles in this process
(Osorio et al. 2008; Yang et al. 2008). The dichotomy between CD4+CD25+ Treg
and Th-17 cells appears to be explained by antagonistic interactions between the
lineage specific transcription factors Foxp3 and RORγt (Yang et al. 2008; Zhang
et al. 2008; Zhou et al. 2008). Although a great deal of focus has been placed on
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the conversion of CD4+CD25+ Treg cells to Th-17 cells, it has also been shown
that CD4+CD25+ Treg cells that lose Foxp3 expression can acquire the ability to
produce other cytokines such as IL-2 and IFN-γ (Duarte et al. 2009; Hoffman et
al. 2009; Komatsu et al 2009; Murai et al 2009; Zhou et al 2009).

Upon transfer into T cell deficient mice, CD4+CD25+ Treg cells can lose
Foxp3 and differentiate into T follicular helper (TFH) cells, which promote germinal
center formation and IgA secretion by B cells, in the Peyer’s patches (Tsuji et al.
2009). Differentiation into TFH cells, but not Foxp3 downregulation, required B
cell interactions (Tsuji et al. 2009), indicating that environmental signals that do
not contribute to Foxp3 downregulation can influence the differentiation of
CD4+CD25+ Treg cells that have lost Foxp3 expression. The de-differentiation of
CD4+CD25+ Treg cells can also have overtly negative physiological
consequences. In the transfer colitis model, loss of Foxp3 by CD4+CD25+ Treg
cells results in a failure to prevent disease (Murai et al. 2009). Work in the NOD
mouse model of diabetes has demonstrated that the loss of Foxp3 expression in
CD4+CD25+ Treg cells can directly contribute to disease pathogenesis, as the
adoptive transfer of ex-Treg cells (CD4+CD25+Foxp3+ cells that no longer
express Foxp3) into NOD.RAG-/- mice can induce diabetes development (Zhou et
al. 2009).
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1.6 CD4+CD25+ Treg cells in human arthritis

In light of the compelling evidence that CD4+CD25+Foxp3+ Treg cells play
an active role in preventing the spontaneous development of systemic
autoimmunity, many recent studies have aimed at determining whether some
deficits in CD4+CD25+ Treg cell activity might contribute to the development of
autoimmune diseases such as RA. Interestingly, many of these studies have
reached the seemingly paradoxical conclusion that autoimmune arthritis can
develop despite the presence of CD4+CD25+ Treg cells. For example, it appears
that CD4+CD25+ Treg cells can be enriched in arthritic patients, since increased
frequencies of CD4+CD25+ T cells have been found in synovial fluid (i.e. the
primary disease site) (de Kleer et al. 2004; Mottonen et al. 2005; Ruprecht et al.
2005; Cao et al. 2006; Lawson et al. 2006) and in some cases also systemically
in the peripheral blood of arthritic patients (Han et al. 2008). Indeed, an
enhanced representation of CD4+CD25+ Treg cells in the joints and synovial fluid
of affected individuals has been observed in patients with RA, with juvenile
idiopathic arthritis (JIA), and with other rheumatic diseases in which arthritis is a
secondary manifestation of disease (de Kleer et al. 2004; Mottonen et al. 2005;
Ruprecht et al. 2005; Cao et al. 2006; Lawson et al. 2006; Han et al. 2008).
Identifying CD4+CD25+ Treg cells based only on CD25 expression is limiting,
however, in that it may also detect activated CD4+ T cells that have upregulated
the IL2Rα chain. However, analysis of Foxp3 mRNA and protein expression
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supported the conclusion that the CD4+CD25bright population isolated from RA
patients was indeed enriched for Treg cells (de Kleer et al 2004; Ruprecht et al.
2005; Cao et al. 2006). A potential explanation for the enrichment of CD4+CD25+
Treg cells in arthritic joints is that the expression of specific patterns of
chemokine receptors leads to preferential trafficking of CD4+CD25+ Treg cells to
the disease site(s). Studies of human peripheral blood CD4+CD25+ Treg cells
have shown that they express certain chemokine receptors, such as CCR4, and
studies of mouse CD4+CD25+ Treg cells indicated that there are many different
subsets of chemokine receptor expression on Treg cells, that could promote
trafficking to specific locations (Iellem et al. 2001; Wei et al. 2006). A comparison
of CD4+CD25+ T cells from the synovial fluid and peripheral blood of patients with
active RA showed a significant enrichment in the synovial fluid of CD4+CD25+
Treg cells expressing the chemokine receptors CCR4, CCR5, and CXCR4 which
are associated with migration to sites of inflammation (Jiao et al. 2007).
Additionally, comparison of the chemokine profiles of dendritic cells and synovial
tissue from RA patients and healthy individuals indicated that certain chemokines
are enriched during RA, potentially resulting in the preferential recruitment of a
variety of immune system cells, including CD4+CD25+ Treg cells (Radstake et al.
2005; Wei et al. 2006). Thus in RA patients, disease develops not only despite
the presence of CD4+CD25+ Treg cells, but in spite of an enrichment of the
CD4+CD25+ Treg cells at a primary site of autoimmune pathology.
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These observations raise the question of whether the CD4+CD25+ Treg
cells that are present in arthritic patients are perhaps dysfunctional, or are
functional and are either unable to prevent disease, or are modifying it in some
manner. There is evidence for both effective and dysfunctional CD4+CD25+ Treg
cell activity in disease settings. Support for the beneficial effects of CD4+CD25+
Treg cells that localize in arthritic joints arose in studies of patients with JIA,
where greater numbers of CD4+CD25+ T cells were found in patients with
persistent-oligoarticular JIA (which is a relatively mild form of the disease) than in
patients with the more severe extended-oligoarticular JIA (de Kleer et al. 2004).
Additionally, CD4+CD25+ Treg cells isolated from patients with the milder form of
JIA expressed higher levels of Foxp3 mRNA, which have been correlated with
better suppressor function, than did CD4+CD25+ Treg cells from patients with
more severe disease (de Kleer et al. 2004). Even within individual JIA patients,
there appeared to be a divergence of CD4+CD25+ Treg cell function based on the
location from which the CD4+CD25+ Treg cells were isolated. Results of in vitro
suppression assays indicated that CD4+CD25+ T cells from the synovial fluid of
JIA patients were more effective suppressors than those isolated from the
peripheral blood, suggesting that the CD4+CD25+ Treg cells at the primary
disease site possessed more potent regulatory function (de Kleer et al. 2004;
Ruprecht et al. 2005). From a clinical standpoint, it has also been reported that
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the duration of remission following corticosteroid treatment in JIA patients
showed a positive correlation with the number of CD4+CD25+ Treg cells present
in the synovial fluid (de Kleer et al. 2004). Thus, in JIA patients there seemed to
be a correlation between an increased frequency of CD4+CD25+ Treg cells and a
reduction in disease severity, with the possibility that more effective Treg cells
localize to the joints and synovial fluid.

The alternative concept of dysfunctional CD4+CD25+ Treg cells in RA has
been supported by findings that Treg cells isolated from RA patients exhibit
reduced suppressor function (Ehrenstein et al. 2004; Valencia et al. 2006). Much
of this work has examined the possible effects of the inflammatory environment
in RA on CD4+CD25+ Treg cell function. Several groups have shown that
CD4+CD25+ Treg cells isolated from RA patients post-Infliximab (anti-TNF-α)
treatment show improved regulatory activity in in vitro suppression assays
(Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni et al. 2007). CD4+CD25+
T cells isolated from patients with active RA, pre-Infliximab treatment, were able
to suppress the in vitro proliferation, but not cytokine production, of responder
CD4+ T cells. However, after Infliximab treatment, CD4+CD25+ Treg cells
originating from RA patients acquired the ability to suppress responder cytokine
production (Ehrenstein et al. 2004). The improved suppressive activity of the
CD4+CD25+ Treg cells also correlated with increased levels of Foxp3 mRNA, and
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correspondingly, it has been shown that treatment of healthy donor Treg cells
with TNF-α leads to a reduction in Foxp3 expression and loss of suppressor
function (Valencia et al. 2006). Other in vitro work has shown that addition of
cytokines such as IL-2, IL-7, and IL-15 to suppression assays can abrogate
CD4+CD25+ Treg cell function, suggesting that multiple cytokines that may be
elevated in RA patients can negatively affect Treg cell function (Ruprecht et al.
2005; Valencia et al. 2006; van Amelsfort et al. 2007).

There is also work suggesting that anti-TNF-α treatment may lead to the
induction of peripheral CD4+CD25+ Treg cells rather than an improvement in the
function of pre-existing Treg cells (Nadkarni et al. 2007). After Infliximab
treatment, an increased percentage of CD4+Foxp3+ cells was observed in the
peripheral blood of active RA patients. Corresponding in vitro studies showed
that upon culture with Infliximab, a subset of CD4+CD25- T cells from RA patients
expressed Foxp3, which could be prevented by TGF-β blockade. Interestingly,
this increase in Foxp3 expressing cells was not observed when CD4+CD25- T
cells from healthy donors were cultured with Infliximab (Nadkarni et al. 2007).
The lack of Foxp3 induction in conventional CD4+ T cells from healthy individuals
upon Infliximab treatment suggests that not only CD4+CD25+ Treg cells, but also
effector CD4+ T cells from RA patients exhibit phenotypic changes in response to
the inflammatory environment. Indeed, there is work suggesting that
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conventional CD4+ T cells isolated from the synovial fluid of RA patients are
refractory to suppression by CD4+CD25+ Treg cells (de Kleer et al. 2004; van
Amelsfort et al. 2007). While these studies of CD4+CD25+ T cells in RA have
predominantly focused on the possibility of detrimental effects of the
inflammatory environment on CD4+CD25+ Treg cell function, more recent work
has shown that Treg cells from RA patients can exhibit deficiencies in CTLA-4
regulation that may also affect their suppressor capabilities (Flores-Borja et al.
2008). It has also been shown that higher percentages of CD4+CD25+Foxp3+ T
cells and monocytes from RA patients express GITR and GITR-L respectively
than in healthy donors (Han et al. 2008). Ligation of GITR has been linked to
abrogration of CD4+CD25+ Treg cell function (Shimizu et al. 2002; Ji et al. 2004),
suggesting another possible mechanism by which Treg cells might be rendered
dysfunctional in RA patients.

1.7 CD4+CD25+ Treg cells in mouse models of arthritis

Studies in multiple mouse models of inflammatory arthritis have indicated
that CD4+CD25+ Treg cells are capable of modifying disease, and the role of
Treg cells has been most extensively studied in the collagen-induced and K/BxN
arthritis models. As seen in human arthritis, CD4+CD25+ Treg cells can be found
in the synovial fluid, joints, and draining lymph nodes of arthritic mice (Morgan et
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al. 2005; Gonzalez-Rey et al. 2007; Nguyen et al. 2007). CD4+CD25+ T cells
isolated from arthritic mice are capable of exerting suppressor function in in vitro
assays (Kang et al. 2008; Monte et al. 2008), although in some situations they
have been found to be less functional than their counterparts in healthy mice
(Manoury-Schwartz et al. 1997). CD4+CD25+ T cells from IFN-γ receptor
knockout mice, which develop accelerated and more severe CIA (ManourySchwartz et al. 1997; Vermeire et al. 1997), exhibit less potent suppressive
activity in vitro and express lower levels of Foxp3 mRNA, akin to the effects of
TNF-α on Treg cells seen in RA patients (Kelchtermans et al. 2005). Additional
work suggested that in the absence of IFN-γ, other cytokines such as IL-17 are
unchecked and contribute to exacerbated disease (Chu et al. 2007), suggesting
that the altered and perhaps more severe inflammatory environment in the IFN-γ
receptor knockout mice is affecting the phenotype and function of CD4+CD25+
Treg cells.

Work examining the impact of CD4+CD25+ Treg cell deficiency on arthritis
development, achieved by genetic means or antibody depletion, has provided
evidence that CD4+CD25+ Treg cells indeed modulate the autoimmune response
in inflammatory arthritis. K/BxN mice, which develop spontaneous inflammatory
arthritis initiated by a CD4+ T cell response to a GPI peptide, have been crossed
to Foxp3-scurfy (Foxp3-sf) mice to determine how a congenital absence of
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CD4+CD25+Foxp3+ Treg cells affects disease development. K/BxN.Foxp3-sf
mice were found to develop an accelerated and more severe disease than K/BxN
mice containing CD4+CD25+ Treg cells, suggesting that while the Treg cells do
not ultimately prevent arthritis, their activity is affecting disease pathogenesis and
severity (Nguyen et al. 2007). These mice did not suffer from the multi-organ
autoimmunity associated with Foxp3-sf mice, presumably because the TCR
repertoire was restricted by expression of the transgenic TCR. In contrast to the
effects of a genetic deficiency in CD4+CD25+ Treg cells, CD4+CD25+ T cell
depletion by antibody treatment did not appear to affect arthritis development in
K/BxN mice, as neither disease onset nor severity were affected (Kang et al.
2008). However, CD4+CD25+ T cell depleted K/BxN mice exhibited more
extensive lymphocyte infiltration into other organs and also an increase in serum
anti-dsDNA antibody levels, indicating that the endogenous CD4+CD25+ Treg
cells are able to modulate other aspects of an autoimmune response even as
arthritis develops (Kang et al. 2008). In the CIA model, depletion of CD4+CD25+
T cells by antibody treatment did lead to increased disease severity (Morgan et
al. 2003; Kelchtermans et al. 2005). The effect on arthritis development could be
reversed by transferring CD4+CD25+ T cells into Treg cell depleted mice,
suggesting that while the Treg cells are not able to prevent disease development,
they are reducing severity (Morgan et al. 2003).
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Complementary studies involving the transfer of exogenous CD4+CD25+ T
cells into pre-arthritic mice also suggest that Treg cells are capable of modifying
arthritis development. Transferring pre-activated CD4+CD25+ T cells from
healthy mice or Foxp3-transduced CD4+ T cells ameliorated disease in the CIA
model (Morgan et al. 2005; Ohata et al. 2007; Kelchtermans et al. 2009).
However, there appeared to be a limited time frame in which transferred Treg
cells could modulate arthritis severity. CD4+Foxp3+ T cells were best at
ameliorating CIA when they were transferred prior to the primary immunization
with collagen. At later time points, such as after a secondary immunization, a
greater number of transferred Treg cells was required to achieve a comparable
reduction in disease severity, and if transferred after the booster immunization
the Treg cells had no effect on arthritis development (Ohata et al. 2007). It has
been shown that as soon as one day post transfer, CD4+CD25+ T cells that have
been injected systemically can be found in the draining lymph node, synovial
fluid, and synovial tissue, indicating that the cells are trafficking to the disease
site (Morgan et al. 2005). Interestingly CD4+CD25+ T cell transfers were more
effective at modifying disease severity when the cells were injected systemically
rather than directly into the joints, raising questions about how and where the
Treg cells are acting to modulate arthritis (Ohata et al. 2007). Together, the
results of depletion and addition of Treg cells in multiple mouse models of
inflammatory arthritis suggest that functional CD4+CD25+ Treg cells are present
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and able to modulate disease severity and other aspects of the immune
response (such as lymphocyte infiltration into different tissues and the generation
of autoantibodies), but that their activity can fail to prevent the development of
autoimmune arthritis.

There is conflicting data as to whether CD4+CD25+ Treg cells are
modifying the immune response in an antigen-specific manner, and the
mechanisms by which Treg cells affect arthritis development remain unclear. In
K/BxN.Foxp3-sf mice, there is an accelerated accumulation of anti-GPI
antibodies in the absence of CD4+CD25+ Treg cells (Nguyen et al. 2007). There
is additional evidence for antigen-specific Treg cell-mediated changes in the CIA
model, with observations of increased collagen-specific T and B cell responses
after Treg cell depletion, as well as a reduction in collagen-specific antibodies
after transfer of exogenous Treg cells (Morgan et al. 2003; Ohata et al. 2007).
However, there is also data showing no alterations in the collagen-specific
immune response upon manipulation of CD4+CD25+ Treg cells in CIA (Morgan et
al. 2005; Kelchtermans et al. 2009). The same study did however find decreased
amounts of TNF-α and IL-6 in the serum of treated mice, which are two cytokines
that can contribute to arthritis development and have been shown to interfere
with Treg cell function (Keffer et al. 1991; Pasare and Medzhitov 2003;
Ehrenstein et al. 2004; Hata et al. 2004; Sawa et al. 2006; Valencia et al. 2006;
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Nadkarni et al. 2007). Thus another potential mechanism by which CD4+CD25+
Treg cells may affect arthritis development is by altering the inflammatory
environment. Indeed it appears that the balance of cytokines can play an
important role in arthritis development and pathogenesis. Recently, IL-35 has
been identified as an effector cytokine of CD4+CD25+ Treg cells, and separate
work has shown that IL-35 treatment reduces disease severity in CIA, possibly by
reducing IL-17 levels (Collison et al. 2007; Niedbala et al. 2007). Thus, IL-35
production by Treg cells may be able to modulate arthritis development by
altering the inflammatory environment. Other work also suggests that
CD4+CD25+ Treg cells may induce changes in the cytokine environment that lead
to inhibition of osteoclastogenesis. In an in vitro culture system, high levels of
cytokines that can inhibit osteoclastogenesis were found and accompanied by
reduced osteoclast formation when CD4+CD25+ Treg cells were present
(Kelchtermans et al. 2009). Given that endogenous CD4+CD25+ Treg cells are
present in the joints, and exogenously administered CD4+CD25+ Treg cells can
traffic to the disease site one to two days post transfer, it is possible then that
CD4+CD25+ Treg cells may reduce osteoclastogenesis in the joints and thereby
modify disease severity.

The studies presented in the following chapters further examine the role of
CD4+CD25+ Treg cells in a mouse model of spontaneous arthritis in which
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disease is driven by CD4+ T cell recognition of a single systemically presented
peptide. We also examine how specificity for the target antigen affects the ability
of CD4+CD25+ Treg cells to suppress arthritis development.
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Chapter 2: Materials and Methods

2.1 Transgenic mice

TS1 mice express a transgenic TCR (Vα4, Vβ8.1/2) that is specific for the
S1 determinant of influenza virus A/PR/8/34 (PR8) HA presented in the context
of MHC Class II I-Ed and can be identified by the monoclonal antibody 6.5
(Kirberg et al. 1994). TS1(SW) mice express a transgenic TCR (Vα8.3, Vβ10)
that is specific for an analog of S1 peptide that is derived from the influenza virus
A/SW/33 strain (Jordan et al. 2001). TS2 mice encode a transgenic TCR (Vβ8.3)
that is specific for the S2 determinant of PR8 HA presented in the context of
MHC Class II I-Ad (Scott et al. 1994).

HACII mice express the full length PR8 HA transgene driven by an MHC
Class II I-Eα promoter (Kouskoff et al. 1993; Reed et al. 2003). HA28 mice
express a truncated form of PR8 HA (the NH2-terminal 237 amino acids) driven
by the SV40 early promoter-enhancer region (Cerasoli et al. 1995).

PevSWHA mice (hereafter referred to as PevSW mice) were created by
linking DNA encoding the HA protein from influenza virus A/SW/33 (SWHA) to
the human β-globin locus control region. The SWHA protein contains an analog
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of the S1(110-120) determinant of PR8 HA, described as the S1(SW) peptide.
S1(SW) peptide contains two amino acid substitutions relative to the S1 peptide
from PR8 HA: (1) at position 113 R  K and (2) at position 120 E  T.

C.Cg-Foxp3tm2(EGFP)Tch/J mice (Haribhai et al. 2007), hereafter referred to
as Foxp3EGFP mice, were purchased from Jackson Laboratories (Bar Harbor,
ME). Foxp3EGFP mice were bred to TS1 or HA28 transgenic mice to generate
TS1.Foxp3EGFP and HA28.Foxp3EGFP mice. Expression of the EGFP allele was
determined by PCR and confirmed by flow cytometry.

TCRα-/- mice (Mombaerts et al. 1992) were purchased from Jackson
Laboratories and bred to homozygosity for the H-2d haplotype. TCRα-/- mice were
then backcrossed four generations with BALB/c mice before breeding with HA
transgenic mice.

All mice were bred and maintained on a BALB/c background. BALB/c
mice were purchased from Taconic (Germantown, NY). Mice were maintained in
specific pathogen free conditions in the Wistar Institute Animal Facility
(Philadelphia, PA), and all experiments were conducted under protocols
approved by the Wistar Institute Institutional Animal Care and Use Committee
(IACUC).
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2.2 Genotyping of transgenic mice

All transgenic mice were genotyped upon weaning at three to four weeks
of age. Tail samples (approximately 1 to 2 mm) were digested overnight at 55° C
in 180 µl of tail lysis buffer. Digestion was stopped by heat inactivation at 95° C
for 10 minutes. Samples were then used as template DNA for PCR. PCR was
performed in 50 µl reactions containing 5 µl 10X PCR amplification buffer, 50 ng
of appropriate primers, 2 µl of 5 mM dNTPs, 1 unit of Taq polymerase, and 3 µl
of tail DNA. PCR reactions were run in a thermocycler for 35 cycles. For HA and
TCR transgene tests each cycle consisted of a 1 minute annealing period at 50°
C (for HA transgene tests) and 65° C (for TCR transgene tests), a 2 minute
elongation period at 72° C, and a 1 minute denaturation period at 94° C. An
additional annealing and elongation step was performed prior to the end of the
amplification cycles. For EGFP transgene tests, each cycle consisted of a 3
minute denaturation period at 94° C, a 1 minute annealing period at 60° C, and a
1 minute elongation period at 72° C. An additional elongation step was
performed prior to the end of amplification cycles. PCR products were visualized
on a 1 % agarose gel containing ethidium bromide.

Primers for genotyping were purchased from Integrated DNA
Technologies (Coralville, IA). Primer sequences are shown below.
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HA
HA uni-5’

5’- CCA GCA GAT TTC ATC GAC TAT G -3’

HA uni-3’

3’- CCA GTA ATA GTT CAT CCT CCC -3’

TS1
V2.1 CDR3

5’- GAA CTG CTC AGC ATA ACT CCC -3’

VβCROSS5’

5’- GAG GCT GCA GTC ACC CAA AG -3’

TS1K
TS1K β JUNCTION

5’- CTC AGC ACC CCT GCC AGC CTG -3’

TS1K β Vgene

5’- ATG GGC TGT AGG CTC CTA AGC -3’

TS2
T2-5-5 CDR3

5’- CGA AGT ACT GTT CAG CCC AGT -3’

Vβ8 CROSS5’

5’- GAG GCT GCA GTC ACC CAA AG -3’

GFP
FORWARD

5’- GCG TAA GCA GGG CAA TAG AGG -3’

REVERSE

5’- GCA TGA GGT CAA GGG TGA TG -3’
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2.3 Arthritis assessment in TS1xHACII mice

TS1xHACII mice were assessed weekly for visible swelling in the four
distal joints from post-weaning at 5 to 6 weeks of age until 14 to 15 weeks of age.
Limbs were also measured with a digital caliper (Fisher Scientific). Mice were
assigned a score based on the following index: 0 – no swollen limbs, 1 – one
swollen limb, 2 – two swollen limbs, 3 – three swollen limbs, and 4 – swelling in
all four limbs.

2.4 Flow cytometry

Flow cytometry was performed on single cell suspensions prepared from
the lymph nodes (axillary, brachial, cervical, inguinal, mesenteric, and popliteal)
or spleens. 1x106 to 3x106 cells were plated in V bottom plates and washed with
FACS buffer and stained in 100 to 200 µl of FACS buffer with diluted antibodies
at 4° C for 30 minutes. The following antibodies were used: anti-CD4
PerCpCy5.5, PECy7, APC, APCeF780 (L3T4); anti-CD25 PE, PerCpCy5.5
(PC61); anti-CD44 Alexa700 (IM7); anti-CD62L PerCpCy5.5 (MEL14); anti-CD69
PE (H1.2F3); anti-CTLA PE (UC10-4B9); anti-GITR PECy7 (DTA-1); anti-IFN-γ
PE, PECy7, APC (XMG1.2); anti-IL-17 PE, APC (eBio17B7); anti-Thy1.1
PerCpCy5.5 (HIS51); anti-Vα8.3 FITC (B21.14), anti-Vβ10 PE (B21.5); and anti41

Vβ8.3 PE (1B3.3). Anti 6.5-biotin (Kirberg et al 1994) was detected using
Streptavidin-APC (eBioscience, San Diego, CA) or Streptavidin-Qdot655
(Invitrogen, Carlsbad CA). Intracellular Foxp3 was detected using anti-Foxp3 PE
or eF450 (FJK-16s) according to the manufacturer’s protocols (eBioscience). In
some experiments dead cells were identified using the LIVE⁄DEAD® Fixable
Aqua Dead Cell Stain Kit from Invitrogen. Greater than 100,000 events per
sample were collected on FACS Calibur or FACS LSR II flow cytometers (BD
Biosciences, San Jose, CA), and data was analyzed using FlowJo software
(Treestar, Ashland, OR).

2.5 Cell sorting

Single cell suspensions were prepared from lymph nodes (axillary,
brachial, cervical, inguinal, mesenteric) or spleens. Spleens were subjected to
red blood cell (RBC) lysis prior to antibody staining. Cells were resuspended at
1x107 cells/ml in FACS buffer (NaN3 deficient) and stained with the appropriate
antibodies at 4° C for 30 minutes. Cells were washed twice. When necessary
the antibody staining step was repeated with secondary reagents. Cells were
resuspended at 5x107 cells/ml in preparation for cell sorting. Sorted cells were
collected into a 1:1 mixture of Iscove’s Modified Dulbecco’s Medium (IMDM;
Mediatech, Inc., Herndon, VA) and fetal bovine serum (FBS; Gemini Bio42

products, West Sacramento, CA). Cells were sorted at the Wistar Institute’s cell
sorting facility using a DakoCytomation MoFlo (DakoCytomation) or a BD
FACSAria cell sorter (BD Biosciences).

2.6 anti-IL-17 antibody treatment of TS1xHACII mice

TS1xHACII mice were treated with an anti-IL17A antibody (clone M210,
Amgen), hereafter referred to as anti-IL17, or a Rat IgG2a isotype control
antibody. The antibody treatment regimen was three intraperitoneal injections of
150 µg of either anti-IL17 or the isotype control antibody per mouse three times
per week (Monday, Wednesday, Friday). All mice were treated from weaning for
a duration of nine weeks.

2.7 MACS purification of CD4+ cells

Single cell suspensions were prepared from lymph nodes (axillary,
brachial, cervical, inguinal, mesenteric) or spleens. Cells were resuspended at
1x107 cells/ml in FACS buffer (NaN3 deficient) and stained with biotinylated
antibodies to B220, CD8, and MHC Class II at 4° C for 30 minutes. Cells were
washed twice, resuspended at 2x108 cells/ml, and then incubated with
streptavidin bound microbeads (Miltenyi Biotec, Auburn, CA) at 4° C for an
additional 30 minutes. Cell suspensions were run through a CS column (Miltenyi
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Biotec, Auburn, CA) attached to a magnet. The purity of cells collected in the
flow through were analyzed by flow cytometry. CD4+ cell purity was consistently
≥ 90 percent.

2.8 CFSE labeling

Cells were resuspended at 1x107 cells/ml into sterile serum-free
Dulbecco’s Phosphate Buffered Saline (DPBS) (Mediatech, Manassas, VA). A
1:1000 dilution of CFSE (Invitrogen) was added to the cell suspension and
incubated at room temperature for approximately 3.5 to 4 minutes. At end of the
incubation, an equal volume of FBS was added to the cell suspension to quench
the CFSE-labeling reaction. Cells were then washed and resuspended into
either sterile serum-free DPBS for adoptive transfer experiments, or into
supplemented IMDM with 10% FBS and 100 µl/ml gentamycin for in vitro culture
experiments.

2.9 Adoptive transfers

Cells purified by cell sorting were washed once and then resuspended at
1x107 cells/ml in sterile DPBS and injected into the tail veins of recipient mice. In
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some experiments donor cells were labeled with CFSE prior to the adoptive
transfers.

2.10 Analysis of in vivo CD4+CD25+ Treg cell proliferation

Sorted CD4+CD25+ cells were CFSE-labeled and adoptively transferred
into recipient mice. Three to ten days post-transfer systemic LNs (axillary,
brachial, cervical, inguinal, mesenteric) were isolated and single cell suspensions
were prepared and stained with the appropriate antibodies. Cells were analyzed
by flow cytometry to determine proliferation as defined by CFSE dilution.

2.11 Intracellular cytokine staining

Cells were plated at 1x106 to 4x106 cells/ml in supplemented IMDM with
10% FBS and 100 µl/ml gentamycin and stimulated with 50 ng of PMA (SigmaAldrich, St. Louis, MO), 1µM ionomycin (Sigma-Aldrich), and a 1:1000 dilution of
Brefeldin-A (eBiosciences) for four hours. At the end of incubation, cells were
isolated and stained for appropriate antibodies as described previously. Cytokine
production was analyzed by flow cytometry.
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2.12 Unfractionated LN cultures

Systemic LN (axillary, brachial, cervical, inguinal, mesenteric) cells were
plated at 2x106 to 5x106 cells/ml in supplemented IMDM with 10% FBS and 100
µl/ml gentamycin and cultured for three to four days at 72° C. Culture
supernatants were collected for analysis by ELISA or Luminex.

2.13 In vitro CD4+CD25+ Treg cell suppression assays

CFSE-labeled MACS-purified CD4+ T cells from TS1 or TS2 mice were
cultured with either 0.1 µg/ml of soluble anti-CD3 (145-2C11), 0.3 or 1 µM of S1
peptide (110-120; SFERFEIFPKE), 1 µM of S2 peptide (HNTNGVTAACSHE), or
HACII splenocytes. Irradiated BALB/c splenocytes were used as feeder cells
when soluble anti-CD3 or peptide was used. Purified CD4+CD25+ cells from
TS1xHA28, TS1xHACII, or TS1(SW)xPevSW mice were added at a 1:2 Treg cell
to responder cell ratio. CD4+CD25+ cells were stimulated with either 0.1 µg/ml of
soluble anti-CD3, titrated doses of S1 peptide (0.3 or 1 µM), 1 µM of S1(SW)
peptide (SFEKFEIFPKT), or HACII splenocytes. Cells were resuspended in
supplemented IMDM with 10% FBS and 100 µl/ml gentamycin in 96- or 24-well
flat bottom plates and cultured for three to four days at 36° C. Cells were plated
at a final volume of 4x106 to 6x106 cells/ml. At the end of the culture period
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responder CD4+ T cell proliferation (based on CFSE profiles) and/or cytokine
production was analyzed by flow cytometry.

2.14 ELISA

ELISAs were performed on supernatants collected from unfractionated LN
cultures. Cytokine antibodies and standards were purchased from eBioscience
and ELISAs were conducted according to the manufacturer’s instructions.
Purified anti-IL17A (clone eBioTC11-18H10.1) was used as the capture antibody
and biotinylated anti-IL17A (eBio17B7) was used as the detection antibody.
ExtrAvidin® alkaline phosphatase was purchased from Sigma-Aldrich.

2.15 Luminex

Luminex analysis was run on unfractionated LN cell culture supernatants
using Milliplex kits (Millipore, Billerica, MA). Assays were conducted by the
University of Pennsylvania Human Immunology Core.
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2.16 Statistical analyses

Statistical analyses were conducted using unpaired two-tailed Student’s ttests assuming unequal variances. Results of arthritis incidence were analyzed
using two-tailed Fisher’s exact test. p ≤ 0.05 was considered significant.

2.17 Solutions

Phosphate buffered saline (PBS): 2.2 mM NaH2PO4 [Anhydrous], 12.6 mM
Na2HPO4 [Anydrous], 6.2 mM KCl, and 170mM NaCl (solution pH 7.4)

FACS buffer: PBS, 2 % fetal bovine serum (FBS; Gemini Bio-products, West
Sacramento, CA), 0.08 NaN3

Supplemented Iscove’s Modified Dulbecco’s Medium (IMDM; Mediatech, Inc.,
Herndon, VA), 10% FBS, 5x10-5 M 2-mercaptoethanol, 5 µg/ml iron saturated
human transferrin, and 100 µl/ml gentamycin

RBC lysis buffer: 0.15 M NH4Cl and 0.01 M Tris (pH 7.5)
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ELISA developing buffer: 0.1 M NaHCO3, 0.001 M MgCl2 (pH 9.8) and 1 mg/ml
PNPP (Sigma-Aldrich)

Tail lysis buffer: 50 mM Tris (pH 8.0), 50 mM KCl, 2.5 mM EDTA, 0.45 % Tween
20, 0.45% NP-40

10x PCR amplification buffer: 0.5M KCl, 0.1M Tris (pH 8.4), 25mM MgCl2-6H2O

TE: 0.01 M Tris-HCl (pH 8.0) and 0.01 M EDTA

5 mM dNTPs: 5 mM dATP, 5 mM dTTP, 5 mM, dCTP, 5 mM dGTP in TE
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Chapter 3: Polyclonal CD4+CD25+ Treg cells can prevent arthritis
development in TS1xHACII mice

3.1 Introduction

TS1 mice express a TCR transgene that recognizes the major I-Edrestricted T cell determinant from the influenza virus PR8 HA (termed S1) and
can be detected using the anti-clonotypic mAb 6.5 (Kirberg et al. 1994). HACII
mice express a transgene encoding the PR8 HA under the control of a MHC
class II I-Eα promoter (Reed et al. 2003). The majority of TS1xHACII mice,
which co-express S1-specific 6.5+CD4+ T cells and HA as a self-antigen, develop
spontaneous inflammatory arthritis that is driven by recognition of the S1 peptide
by 6.5+CD4+ T cells, since TS1xHACII mice on a RAG-/- background develop
disease (Rankin et al. 2008). Moreover, TS1xHACII mice on a JH-/- background,
which lack mature circulating B cells, also develop arthritis, demonstrating that
neither antibody production nor antigen presentation by B cells is required for
disease development. Despite extensive deletion of 6.5+ thymocytes, some
6.5+CD4+ T cells reach the periphery of TS1xHACII mice, interact with S1 peptide
presented by antigen presenting cells, and gradually accumulate in number.
TS1xHACII mice develop enlarged popliteal LNs, which drain the lower joints,
and increased cytokine (e.g. IL-17, IFN-γ, IL-6, TNF-α) production by systemic
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LN cells (Rankin et al. 2008). Additionally, arthritic TS1xHACII mice contain
CD4+CD25+Foxp3+ cells, including a population that is specific for the target
antigen S1 peptide that is recognized by the pathogenic 6.5+CD4+ T cells (Rankin
et al. 2008). A schematic summarizing the key aspects of arthritis development
in TS1xHACII mice is presented in Figure 3-1.

Finding that arthritis develops in TS1xHACII mice despite the presence of
CD4+CD25+Foxp3+ cells is consistent with observations of normal, and even
increased, frequencies of CD4+CD25+ Treg cells in human arthritis patients (de
Kleer et al. 2004; Mottonen et al. 2005; Ruprecht et al. 2005; Cao et al. 2006;
Lawson et al. 2006), and in other mouse models of arthritis (Morgan et al. 2005;
Gonzalez-Rey et al. 2007; Nguyen et al. 2007). Although the representation and
function of CD4+CD25+ Treg cells has been analyzed in human and murine
arthritis, the role of CD4+CD25+ Treg cells in disease development, and how the
antigen-specificity of the Treg cell population can affect this, remains unclear.
TS1xHACII mice are a powerful system in which to study how CD4+CD25+ Treg
cells can affect arthritis pathogenesis as identification of the disease initiating
target antigen (S1 peptide) allows us to more carefully examine whether and how
CD4+CD25+ Treg cells affect the pathogenic S1-specific 6.5+CD4+ T cells, other
CD4+ T cells (not specific for the disease initiating target antigen), or innate
immune cells that may contribute to arthritis pathogenesis.
51

6.5+CD4+ T cell

Thymus
DN

DP

Y Y
Y Y
Y

SP

x
x
x

A

HA-expressing APC
Foxp3+ Treg cell
B cell

ARTHRITIS

C

B

+

Cytokine secretion
IL-17, IFN-γ,
IL-6, TNF-α
Popliteal

D lymph node

+
Figure 3-1 Key steps in the development of spontaneous inflammatory arthritis in
TS1xHACII mice. TS1xHACII.JH-/- mice, which lack mature circulating B cells develop
arthritis, indicating that antibody production and/or antigen presentation by B cells is
not required for disease development. Moreover, TS1xHACII.RAG-/- mice also
develop arthritis, demonstrating that recognition of the S1 peptide by 6.5+CD4+ T cells
is sufficient to mediate disease. Although CD4+CD25+Foxp3+ Treg cells are present in
arthritic mice, whether and how they participate in arthritis development remains
unclear. (A) 6.5+ thymocytes undergo extensive deletion in response to S1 peptide
(B) 6.5+CD4+ T cells that have evaded negative selection accumulate in the periphery
of TS1xHACII mice. Interactions between 6.5+CD4+ T cells and HA-expressing APCs
results in reciprocal activation of the cell populations. (C) CD4+ T cells differentiate to
produce inflammatory cytokines. (D) An enhanced immune response develops in the
joint-draining popliteal LNs of TS1xHACII mice.
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We show here that pre-arthritic TS1xHACII mice contain expected
frequencies of CD4+CD25+Foxp3+ cells, indicating that arthritis development
cannot be attributed to an absence of CD4+CD25+Foxp3+ cells in young
TS1xHACII mice. The endogenous CD4+CD25+Foxp3+ cells in TS1xHACII mice
appear activated and are present in the joint-draining LNs. Additionally, purified
CD4+CD25+cells from TS1xHACII mice exhibit in vitro regulatory function.
Although these observations suggest that the arthritis that develops in
TS1xHACII mice may be refractory to CD4+CD25+ Treg cell activity, we show that
the administration of exogenous polyclonal CD4+CD25+ cells can prevent arthritis
development in TS1xHACII mice, most likely by inhibiting the pathogenic Th-17
response. Moreover, specificity for a critical disease target antigen within the
CD4+CD25+ Treg cell population is not required for disease suppression, as
BALB/c CD4+CD25+ cells, which have not developed in the presence of the HA
protein from which the S1 peptide is derived, can also prevent arthritis
development in TS1xHACII mice. Strikingly, transfer of TS1xHACII CD4+CD25+
cells that have been depleted of 6.5+CD4+CD25+ cells (which comprise Foxp3+
and Foxp3- cells) reduces arthritis incidence in TS1xHACII mice, demonstrating
that endogenous CD4+CD25+ cells from TS1xHACII mice do possess in vivo
regulatory function and suggesting that CD4+CD25+ Treg cell function can be
remarkably sensitive to the balance of Treg and effector cells.
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3.2 Results

3.2.1 Arthritis development in TS1xHACII mice is accompanied by the
accumulation of peripheral 6.5+CD4+ T cells

The majority of adult TS1xHACII mice develop spontaneous inflammatory
arthritis (Rankin et al. 2008). To better characterize the kinetics of disease, a
cohort of TS1xHACII mice were assessed weekly for arthritis development. Mice
with at least one affected limb (defined by visible swelling) were designated as
arthritic. The majority of mice did not exhibit disease symptoms until 11 weeks of
age, at which point over 50 percent of the cohort was arthritic (Figure 3-2 A).
Disease incidence increased in older mice, with 73 percent of TS1xHACII mice
developing arthritis by 14 weeks of age (Figure 3-2 A). Analysis of 16 week old
TS1xHACII mice showed that the majority (62.5 percent) of arthritic animals
developed disease in all four limbs, and no arthritic mice possessed fewer than
two affected limbs (Figure 3-2 B). Thus, the majority of TS1xHACII mice develop
spontaneous inflammatory arthritis in which all four limbs are affected.

The recognition of S1 peptide by 6.5+CD4+ T cells is a critical initiating step
in arthritis development in TS1xHACII mice (Rankin et al. 2008). We examined
the frequency of 6.5+CD4+ cells in unfractionated systemic LN (axillary, brachial,
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Figure 3-2 6.5+CD4+ T cells accumulate in the periphery of arthritic TS1xHACII mice
(A) Arthritis incidence over time in TS1xHACII mice. n=11. (B) Numbers of affected
limbs per mouse in 16 week old TS1xHACII mice. Each circle represents an individual
mouse. Line represents the average number of arthritic limbs. (C) Dot plots show
6.5+CD4+ cells in the LNs (axillary, brachial, cervical, inguinal, and mesenteric) of prearthritic TS1xHACII, arthritic TS1xHACII, and control TS1 mice. Numbers indicate the
percentage of 6.5+ cells among CD4+ cells. Graph shows the average percentage of
6.5+ cells in pre-arthritic and arthritic TS1xHACII mice. n ≥ 7 mice per age group.
Statistical significance was calculated using the Student’s t-test. (D) Numbers of total
CD4+ (left graph) and 6.5+CD4+ (right graph) cells in TS1xHACII (gray bars) and TS1
(black bars) mice of different ages. n ≥ 3 mice per age group. (E) Numbers of total
popliteal LN cells in TS1xHACII (gray bars) and TS1 (black bars) mice of different ages.
(F) The number of total CD4+ (gray bars) and 6.5+CD4+ (black bars) in 11 weeks and
older TS1xHACII and TS1 mice. For (E) and (F) n ≥ 4 mice per age group. Bar
graphs show average values ± SEM.
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cervical, inguinal, and mesenteric) cells from 6 week old TS1xHACII, 13 week old
TS1xHACII, and control single transgenic TS1 mice. In comparison to TS1 mice,
both pre-arthritic and arthritic TS1xHACII mice contained markedly reduced
percentages of 6.5+CD4+ cells (Figure 3-2 C, left panel). The decrease in
6.5+CD4+ T cells in TS1xHACII mice when compared to TS1 mice reflects their
development in the presence of HA as a self-antigen. The representation of
6.5+CD4+ cells appeared to be slightly higher in arthritic TS1xHACII mice in
comparison to pre-arthritic TS1xHACII mice (Figure 3-2 C, right panel), though
the difference was not statistically significant (p=0.08, Student’s t-test).

We next analyzed the numbers of CD4+ cells in the systemic LNs of
TS1xHACII and TS1 mice at different ages. At 6 to 7 weeks of age, TS1xHACII
mice possessed dramatically fewer total CD4+ and 6.5+CD4+ cells in comparison
to TS1 mice (Figure 3-2 D). Over time, total CD4+ and 6.5+CD4+ cell numbers
increased in TS1xHACII mice, with 12 to 13 week old arthritic mice containing the
highest numbers of both populations, although the cellularities did not equal
those of age-matched TS1 mice (Figure 3-2 D). We also examined the popliteal
LNs, which drain the lower joints, in TS1xHACII and TS1 mice at different ages.
Although the total cellularity of popliteal LNs was much lower in young
TS1xHACII mice in comparison to young TS1 mice, as TS1xHACII mice aged
popliteal LN cellularities increased dramatically, and arthritic mice (11 weeks and
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older) contained larger popliteal LNs than age-matched TS1 mice (Figure 3-2 E,
left panel). In contrast to what was observed in systemic LNs (Figure 3-2 D), the
popliteal LNs of older TS1xHACII and TS1 mice contained comparable numbers
of total CD4+ cells and of 6.5+CD4+ cells (Figure 3-2 E, right panel).

Collectively, these data demonstrate that 6.5+CD4+ T cells, which are
specific for the S1 autoantigen, accumulate in the periphery of TS1xHACII mice.

3.2.2 TS1xHACII mice contain CD4+CD25+Foxp3+ cells, including cells that
are specific for the target autoantigen that initiates disease development

To examine the representation of CD4+CD25+Foxp3+ cells within
TS1xHACII and TS1 mice of different ages, LN cells were stained for expression
of CD4, CD25, and the transcription factor Foxp3. The percentage of
CD25+Foxp3+ cells in CD4+ LN cells of young (6 to 7 week old) TS1xHACII mice
fell within the expected range of 5 to 10 percent of peripheral CD4+CD25+ Treg
cells (Figure 3-3 A). Additionally, TS1xHACII mice of all ages contained similar
frequencies of CD4+CD25+Foxp3+ cells, and within each age group the
percentages were higher than those in age-matched TS1 mice (Figure 3-3 A).
These data show that young, pre-arthritic TS1xHACII mice contain a normal
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Figure 3-3 TS1xHACII mice contain S1-specific CD4+CD25+Foxp3+ cells (A) Graph
shows the percentage of CD25+Foxp3+ cells among LN (axillary, brachial, cervical,
inguinal, mesenteric) CD4+ cells from TS1xHACII (gray bars) and TS1 (black bars)
mice of different ages. n ≥ 3 mice group. Bar graphs show average values ± SEM.
(B) LN cells from arthritic TS1xHACII mice were stained for 6.5, CD4, CD25, and
Foxp3. Dot plot on right shows 6.5 and Foxp3 expression within CD4+CD25+ cells
in TS1xHACII mice. Numbers indicate the percentages of cells within the respective
gates. (C) CTLA-4 and GITR expression on 6.5+ (solid line) and 6.5- (dotted line)
CD4+CD25+Foxp3+ LN cells from TS1xHACII mice. (D) CTLA-4 and GITR
expression on CD4+CD25+Foxp3+ LN cells from TS1xHACII (solid line) or control
(HACII or BALB/c) mice.
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representation of CD4+CD25+Foxp3+ cells that is similar to the frequency found in
arthritic TS1xHACII mice.

To determine whether TS1xHACII mice contain CD4+CD25+Foxp3+ cells
specific for the disease-initiating antigen (S1 peptide), we analyzed systemic LN
cells for expression of 6.5, CD4, CD25, and Foxp3. CD4+CD25+ LN cells from
TS1xHACII mice contained a 6.5+ population, which comprised both Foxp3+ and
Foxp3- cells (Figure 3-3 B). The majority of the cells within the CD4+CD25+ pool
that did not express the 6.5 TCR did express Foxp3 (Figure 3-3 B). To examine
the phenotype of 6.5+ and 6.5- CD4+CD25+Foxp3+ cells in TS1xHACII mice, we
analyzed their expression of the Treg cell markers CTLA-4 and GITR. Whereas
the 6.5-CD4+CD25+Foxp3+ cells exhibited more diffuse distribution of CTLA-4 and
GITR expression, 6.5+CD4+CD25+Foxp3+ cells had more uniform expression of
high levels of both CTLA-4 and GITR (Figure 3-3 C). The unfractionated
(including both 6.5+ and 6.5- cells) population of CD4+CD25+Foxp3+ cells from
TS1xHACII mice contained a larger population of cells that expressed high levels
of CTLA-4 and GITR than CD4+CD25+Foxp3+ cells from healthy mice (single
transgenic HACII or BALB/c) (Figure 3-3 D).

Together, these data show that TS1xHACII mice of all ages contain
normal frequencies of CD4+CD25+Foxp3+ cells. Moreover, a subset of the
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CD4+CD25+Foxp3+ cells expresses the 6.5 TCR, which confers specificity for the
target autoantigen that initiates arthritis development in TS1xHACII mice, and
appeared activated in comparison to 6.5-CD4+CD25+Foxp3+ cells.

3.2.3 CD4+CD25+ cells from TS1xHACII mice possess in vitro suppressor
function

We conducted in vitro suppression assays to determine whether
CD4+CD25+ cells from TS1xHACII mice possessed regulatory function. CFSElabeled CD4+ T cells were cultured alone or with FACS-purified CD4+CD25+cells
from TS1xHACII mice at a 1:2 Treg:responder cell ratio and stimulated with
soluble anti-CD3. Three days later we examined the CFSE division profile and
cytokine production of the responder CD4+ T cells. In the presence of
TS1xHACII CD4+CD25+ cells, a greater percentage of responder CD4+ T cells
remained undivided, and the cells that did proliferate underwent fewer rounds of
division (Figure 3-4 A, left panel). Additionally, when cultured alone, 48.6 percent
of responder CD4+ T cells produced IFN-γ, in contrast to 13.2 percent when cocultured with CD4+CD25+ cells from TS1xHACII mice (Figure 3-4 A, right panel).
These data indicate that CD4+CD25+ cells from TS1xHACII mice can suppress
proliferation and cytokine production by responder CD4+ T cells.
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Figure 3-4 CD4+CD25+ cells in TS1xHACII mice possess in vitro suppressor function
CFSE-labeled CD4+ TS1 T cells were cultured with CD4+CD25+ T cells purified from
TS1xHACII mice at a 1:2 Treg:responder cell ratio and stimulated with (A) soluble
anti-CD3 (0.1 μg/ml) or (B) with a high (1 μM) or low (0.3 μM) dose of S1 peptide.
(A) Three days later responder CD4+ T cell proliferation and cytokine production
were analyzed by flow cytometric analysis. Histogram shows the CFSE profiles of
responder CD4+ T cells when cultured alone (solid histogram) or in the presence of
TS1xHACII CD4+CD25+ cells (black line). Dot plots show IFN-γ production by
responder CD4+ T cells cultured alone (left) or with TS1xHACII CD4+CD25+ cells
(right). Numbers indicate the percentages of IFN-γ+ cells. (B) Histograms show the
CFSE profiles of responder CD4+ T cells after three days of culture in the absence
(left plots) or presence (middle plots) of TS1xHACII CD4+CD25+ cells. Numbers
indicate the percentage of undivided cells. Histograms on the right show overlaid
CFSE profiles of responder CD4+ T cells cultured alone (solid gray) or with
TS1xHACII CD4+CD25+ cells (dotted black line).
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To examine whether CD4+CD25+ cells from TS1xHACII mice could exert
suppressor function in response to stimulation by S1 peptide, we conducted in
vitro suppression assays using S1 peptide to stimulate the cells. CFSE-labeled
CD4+ cells from TS1 mice were cultured with or without CD4+CD25+ cells from
TS1xHACII mice with a high (1 µM) or low (0.3 µM) dose of S1 peptide as a
stimulus. At the high dose of S1 peptide, the presence of CD4+CD25+ cells from
TS1xHACII mice resulted in an increased percentage of undivided responder
CD4+ T cells (19.8 percent versus 9.6 percent when responder cells were
cultured alone), but had little effect on the extent of division of proliferating cells
(Figure 3-4 B, upper panel). In contrast, at the low dose of S1 peptide, co-culture
of TS1xHACII CD4+CD25+ cells not only resulted in a higher representation of
undivided cells (34.1 percent versus 18.3 percent), but also less accumulation of
responder CD4+ T cells at later cell divisions (Figure 3-4 B, lower panel).

These data show that CD4+CD25+ cells from TS1xHACII mice possess in
vitro suppressor function. Moreover, regulatory activity (as defined by inhibition
of responder CD4+ T cell proliferation) of the CD4+CD25+ cells can be activated
by interactions with S1 peptide.
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3.2.4 CD4+CD25+Foxp3+ cells are present in the joint-draining LNs of
TS1xHACII mice

Since alterations in CD4+CD25+ Treg cell distribution can contribute to the
development of autoimmune disease (Siegmund et al. 2005; Sather et al. 2007),
we examined whether CD4+CD25+Foxp3+ cells were equally distributed
throughout the lymphoid organs of TS1xHACII mice. To assess this we isolated
LNs that drain the lower joints (popliteal), upper limbs (axillary and brachial), as
well as the spleen and other LNs (cervical, inguinal, and mesenteric) that are not
primary joint-draining sites, and stained the cells for CD4, CD25, and Foxp3
expression. The different lymphoid organs contained comparable percentages of
CD4+CD25+Foxp3+ cells (Figure 3-5 A), indicating that the joint-draining LNs
were not deficient in CD4+CD25+Foxp3+ cells. Work in other autoimmune
disease systems suggests that draining LNs are enriched for target organ
antigen-specific CD4+CD25+ Treg cells (Samy et al. 2005; Samy et al. 2008;
Wheeler et al. 2009), and we wanted to examine whether the representation of
6.5+CD4+CD25+Foxp3+ cells (which are specific for the arthritis initiating antigen)
was enhanced in the popliteal LNs of TS1xHACII mice. To address this, we
compared the distribution of total CD4+CD25+Foxp3+ and 6.5+CD4+CD25+Foxp3+
cells in the popliteal and non-draining LNs of TS1xHACII mice. Interestingly,
while the distribution of total CD4+CD25+Foxp3+ cells was similar in draining and
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Figure 3-5 6.5+CD4+CD25+Foxp3+ cells are enriched in the popliteal LNs of
TS1xHACII mice (A) Foxp3 and CD25 expression in CD4+ cells from joint-draining
and non-draining lymphoid organs in TS1xHACII mice. Numbers indicate the
percentage of CD25+Foxp3+ cells within the CD4+ gate. (B) Graphs show the
percentages of Foxp3+ cells within total CD4+ (left graph) or 6.5+CD4+ (right graph)
cells in the popliteal and non-draining (cervical, inguinal, and mesenteric) LNs in
TS1xHACII mice. Two symbols connected by a line represent data from one
mouse.
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non-draining LNs (Figure 3-5, left panel), 6.5+CD4+CD25+Foxp3+ cells were
enriched in the popliteal LNs (Figure 3-5, right panel).

Together, these data demonstrate that unfractionated (including both 6.5+
and 6.5- cells) CD4+CD25+Foxp3+ cells are present at similar frequencies in
draining and non-draining LNs in TS1xHACII mice. However, the presence of
6.5+CD4+CD25+Foxp3+ cells, which are specific for the disease initiating target
antigen, is enriched in the popliteal LNs.

3.2.5 Polyclonal CD4+CD25+ Treg cells can prevent arthritis development in
TS1xHACII mice

We have shown that TS1xHACII mice develop arthritis despite the
presence of endogenous CD4+CD25+Foxp3+ cells (including a population that is
specific for the disease initiating target antigen) that are present in the joint
draining LNs and possess in vitro suppressor function. It is possible that the
arthritis that develops in TS1xHACII mice is refractory to Treg cell activity, and to
address this we examined whether arthritis could be modified by the
administration of exogenous CD4+CD25+ Treg cells prior to disease onset. To
test this, we purified CD4+CD25+ cells from HACII mice, which express the HA
transgene (under the same MHC II I-Eα promoter as TS1xHACII mice) without
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any additional transgenic modifications to the TCR repertoire, and are isogenic
with respect to the self peptides that are present in TS1xHACII mice. Thus,
although CD4+CD25+ cells from HACII mice do not contain any 6.5+Foxp3+ cells
(Figure 3-6 A), the CD4+CD25+Foxp3+ cells present in HACII mice have
developed in the presence of HA as a self-antigen.

We adoptively transferred 1x106 CD4+CD25+ cells purified from HACII
mice into pre-arthritic TS1xHACII mice and tracked the recipients weekly for
disease development. In comparison to a cohort of unmanipulated TS1xHACII
mice, mice that received HACII CD4+CD25+ cells showed a marked reduction in
arthritis development (Figure 3-6 B). In 15 week old TS1xHACII mice, arthritis
incidence was significantly lower in TS1xHACII mice that received HACII
CD4+CD25+ cells (18.2 percent) than in unmanipulated TS1xHACII mice (80
percent) (*p=0.0089, Fisher’s exact test) (Figure 3-6 C). Moreover, among
arthritic mice, the number of affected limbs was lower in TS1xHACII mice that
received HACII CD4+CD25+ cells (one affected limb) in comparison to
unmanipulated TS1xHACII mice (which had three to four affected limbs) (Figure
3-6 D). Therefore, the average number of affected limbs per mouse was
significantly lower in TS1xHACII mice that received HACII CD4+CD25+ cells than
in unmanipulated TS1xHACII mice (***p<0.0001, Mann-Whitney).
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Figure 3-6 The adoptive transfer of CD4+CD25+ cells from HACII mice can prevent
arthritis development in TS1xHACII mice (A) Dot plots show 6.5 and Foxp3 staining
of CD4+CD25+ LN cells from HACII mice. (B) 1x106 HACII CD4+CD25+ cells were
adoptively transferred into 5 to 6 week old TS1xHACII mice. Graph shows the
average number of arthritic limbs per mouse (±SEM) over time of unmanipulated
( , n=10) and HACII CD4+CD25+ cell recipient ( , n=11) TS1xHACII mice.
(C) Arthritis incidence in 15 week old unmanipulated or HACII CD4+CD25+ cell
recipient TS1xHACII mice. Statistical significance was calculated using Fisher’s
exact test. (D) The number of arthritic limbs per mouse in cohorts of unmanipulated
and HACII CD4+CD25+ cell recipient TS1xHACII mice. Each circle represents an
individual mouse. Statistical significance was calculated by the Mann-Whitney test.
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These data show that the administration of exogenous CD4+CD25+ cells
can prevent arthritis in TS1xHACII mice, demonstrating that the arthritis that
develops in TS1xHACII mice can be modified by CD4+CD25+ Treg cell activity.

3.2.6 Protective CD4+CD25+ Treg cells do not alter the accumulation or
activation of 6.5+CD4+ T cells in TS1xHACII mice

To determine whether the accumulation and activation of 6.5+CD4+ T cells
were altered in TS1xHACII mice that received protective CD4+CD25+ cells from
HACII mice (from here on referred to as protected TS1xHACII mice), we
examined the number and phenotype of CD4+ T cells in unfractionated systemic
LNs (axillary, brachial, cervical, inguinal, and mesenteric) of unmanipulated
TS1xHACII mice, and of mice that received HACII CD4+CD25+ cells. There was
little difference in the total cellularity of in the numbers of CD4+ cells in the LNs of
arthritic versus protected TS1xHACII mice (Figure 3-7 A). Additionally, the
administration of CD4+CD25+ cells from HACII mice did not affect the
accumulation of peripheral 6.5+CD4+ T cells, as unmanipulated arthritic and
protected TS1xHACII mice contained comparable numbers of 6.5+CD4+ cells
(Figure 3-7 B). To examine whether HACII CD4+CD25+ Treg cells altered the
activation phenotype of CD4+ T cells in TS1xHACII mice, we analyzed the
expression of CD62L, CD44, and CD69 on both 6.5+CD4+ and 6.5-CD4+ T cells.
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Figure 3-7 Protective HACII CD4+CD25+ Treg cells do not inhibit the accumulation
or activation of 6.5+CD4+ T cells in TS1xHACII mice. (A) Numbers of total (gray bar)
and CD4+ (black bar) cells in the systemic LNs (axillary, brachial, cervical, inguinal,
mesenteric) of unmanipulated and HACII CD4+CD25+ Treg cell recipient TS1xHACII
mice. n=11 per group. (B) Numbers of 6.5+CD4+ T cells in the systemic LNs of
unmanipulated and HACII CD4+CD25+ Treg cell recipient TS1xHACII mice. n=11 per
group. (C) CD62L, CD44, and CD69 expression on 6.5+ (upper panel) and 6.5- (lower
panel) CD4+ cells from unmanipulated TS1xHACII (dashed line), HACII CD4+CD25+
Treg cell recipient TS1xHACII (solid line), or control TS1 (solid histogram) mice. Bar
graphs show average values ± SEM.
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In comparison to control 6.5+CD4+ T cells from TS1 mice (which are not exposed
to HA as a self-antigen), 6.5+CD4+ T cells from both arthritic and protected
TS1xHACII mice appeared activated, and possessed very similar profiles of
CD62L, CD44, and CD69 expression (Figure 3-7 C, upper panel). In contrast,
the expression patterns of CD62L, CD44, and CD69 on 6.5-CD4+ T cells from
arthritic and protected TS1xHACII mice were nearly identical to those of 6.5-CD4+
T cells from single transgenic TS1 mice (Figure 3-7 C, lower panel), and reflected
a phenotype consistent with that of naïve cells.

Taken together, these data indicate that HACII CD4+CD25+ Treg cells do
not prevent arthritis development by inhibiting the accumulation or activation of
peripheral 6.5+ and 6.5- CD4+ T cells in TS1xHACII mice.

3.2.7 Preferential reduction of IL-17 in the popliteal LNs of TS1xHACII mice
that received protective CD4+CD25+ Treg cells

We analyzed protected TS1xHACII mice to determine whether HACII
CD4+CD25+ Treg cells modified the accumulation of popliteal LN cells that
normally occurs in TS1xHACII mice (Figure 3-2 E). TS1xHACII mice that
received HACII CD4+CD25+ cells contained significantly lower numbers of total
popliteal LN cells (*p=0.018, Student’s t-test), as well as lower, though not
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statistically significant (p=0.06, Student’s t-test), numbers of CD4+ cells (Figure 38 A). Although the numbers of popliteal LN CD4+ cells were not significantly
reduced in TS1xHACII mice that received HACII CD4+CD25+ cells, CD4+ cells in
protected TS1xHACII mice could possess altered effector properties, and to
examine this we analyzed intracellular cytokine production by popliteal LN CD4+
T cells in arthritic and protected TS1xHACII mice. Popliteal LN cells were
stimulated for four hours with PMA and ionomycin, and then stained for CD4 and
intracellular IL-17 and IFN-γ expression. Strikingly, TS1xHACII mice that
received HACII CD4+CD25+ cells exhibited a reduction in the representation of
IL-17, but not IFN-γ, producing CD4+ popliteal LN cells when compared to
unmanipulated TS1xHACII mice (Figure 3-8 B). Whereas the difference in the
percentages of IL-17+CD4+ popliteal LN cells was significantly lower in
TS1xHACII mice that received HACII CD4+CD25+ cells than in unmanipulated
TS1xHACII mice (*p=0.04, Student’s t-test), the representation of IFN-γ
producing cells was comparable between the two groups (Figure 3-8 C).
However, numbers of both IFN-γ+CD4+ (*p=0.04, Student’s t-test) and IL17+CD4+ (*p=0.02, Student’s t-test) cells were significantly lower in TS1xHACII
mice that received HACII CD4+CD25+ cells than in unmanipulated TS1xHACII
mice, consistent with the reduced total cellularity of the popliteal LNs.
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Figure 3-8 Protective HACII CD4+CD25+ Treg cells inhibit Th-17 cells in the popliteal
LNs of TS1xHACII mice (A) Numbers of total (gray bar) and CD4+ (black bar) cells in
the popliteal LNs of unmanipulated and HACII CD4+CD25+ Treg cell recipient
TS1xHACII mice. (total cells, *p=0.018; CD4+ cells, p=0.06). (B) Popliteal LN cells
were stimulated for 4 hours with PMA and ionomycin and stained for intracellular
IL-17 and IFN-γ. Dot plots show IL-17 and IFN-γ production by CD4+ T cells from
unmanipulated and HACII CD4+CD25+ Treg cell recipient mice. Numbers indicate the
percentage of cytokine-producing cells in each gate. (C) Average percentages of
IFN-γ and IL-17 producing CD4+ T cells in the popliteal LNs of unmanipulated and
HACII CD4+CD25+ Treg cell recipient TS1xHACII mice. (D) Numbers of IFN-γ+CD4+
and IL-17+CD4+ cells in the popliteal LNs of unmanipulated and HACII CD4+CD25+
Treg cell recipient TS1xHACII mice. Bar graphs show average values ± SEM.
Statistical significance was calculated using the Student’s t-test. n=11 per group for
all data.
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Together, these data show that the administration of HACII CD4+CD25+
Treg cells limits the accumulation of cells in the popliteal LNs of TS1xHACII mice.
Interestingly, the protective HACII CD4+CD25+ Treg cells appear to preferentially
inhibit Th-17 cell formation, which has been associated with several autoimmune
diseases, including arthritis (Afzali et al. 2007; Korn et al. 2009).

3.2.8 Protective CD4+CD25+ Treg cells suppress the systemic Th-17
response in TS1xHACII mice

To examine whether the transfer of HACII CD4+CD25+ cells suppressed
systemic IL-17 production in TS1xHACII mice, we set up unfractionated LN
(axillary, brachial, cervical, inguinal, and mesenteric) cultures with cells from
arthritic and protected TS1xHACII mice. Three days later, supernatants were
collected and analyzed for IL-17 production by ELISA. Unfractionated LN
cultures from unmanipulated arthritic TS1xHACII mice produced significantly
higher concentrations of IL-17 than LN cultures from healthy control TS1 mice
(*p=0.025, Student’s t-test) (Figure 3-9 A), indicating that increased levels of IL17 accompany arthritis development. Interestingly, protected TS1xHACII mice
exhibited reduced systemic IL-17 production, as unfractionated LN cultures from
TS1xHACII mice that received HACII CD4+CD25+ cells produced significantly
lower amounts of IL-17 in comparison to unmanipulated arthritic TS1xHACII mice
73

A

**
p=0.01

IL-17 (ng/ml)

12

*
p=0.03

8
4
0

ell
ed
lat II
g c ts
u
e
r
p
C
A
ni
ien
IT
ma xH ACI recip
un TS1
H
1

TS

B

**

p=0.016

p=0.059

6

15
p=0.08

IL1-α (pg/ml)

IL1-β (pg/ml)

8

4
2
0

*

p=0.047

10
5
0

ll
ted
ce
T
ula CII
eg nts
r
p
i
T
e
A
n
i
I
ma xH ACI recip
un TS1
H
S1

ell
ed
lat I
gc
ipu ACI I Tre ients
n
ma xH ACI recip
un TS1
H
1

TS

p=0.11

C
IL-6 (pg/ml)

40
30

p=0.3

20
10
0

ell
ted
g c ts
ula CII
e
r
p
i
A
n
ien
IT
ma 1xH ACI recip
n
S
u T
H
1

TS

Figure 3-9 Protective HACII CD4+CD25+ Treg cells inhibit systemic IL-17 production
in TS1xHACII mice. Unfractionated LN (axillary, brachial, cervical, inguinal, and
mesenteric) cells from unmanipulated TS1xHACII, HACII CD4+CD25+ Treg cell
recipient TS1xHACII, or control TS1 mice were cultured for three days, and
supernatants were collected and analyzed for (A) IL-17, (B) IL-1β and IL-1α, and
(C) IL-6. Statistical signficance was calculated using the Student’s t-test. All
TS1xHACII mice, n=5 per group. TS1 mice, n=3 per group.
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(*p=0.01, Student’s t-test) (Figure 3-9 A), again suggesting that IL-17 production
by LN cells serves as a correlate for disease status. Thus, HACII CD4+CD25+
cells not only reduce IL-17 production in the popliteal LNs (Figure 3-8 C), but also
reduce systemic IL-17 production in TS1xHACII mice.

To examine whether HACII CD4+CD25+ cells could also suppress
cytokines involved in the differentiation of IL-17 producing cells, we also analyzed
unfractionated LN culture supernatants for cytokines associated with Th-17
development (i.e. IL-1 and IL-6). LN cultures from protected TS1xHACII mice
produced significantly lower levels of IL-1β than LN cultures from arthritic
TS1xHACII mice (*p=0.016, Student’s t-test), and also lower, but not statistically
significant, levels of IL-1α (p=0.059, Student’s t-test) (Figure 3-9 B). Whereas IL1α concentrations were significantly higher in LN cultures from unmanipulated
TS1xHACII mice than LN cultures from control TS1 mice (*p=0.047, Student’s ttest), the difference in IL-1β levels was not significantly increased (p=0.08,
Student’s t-test). Therefore, although administration of HACII CD4+CD25+ cells
results in significant downregulation of IL-1β levels in unfractionated LN cultures
from TS1xHACII mice, unlike IL-17, production of IL-1β may not correlate with
disease status. Unfractionated LN cultures from TS1xHACII mice that received
HACII CD4+CD25+ cells did not produce significantly lower levels of IL-6 than LN
cultures from unmanipulated TS1xHACII mice (p=0.11, Student’s t-test) (Figure
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3-9 C). Additionally, the difference in IL-6 concentrations between LN cultures
from arthritic TS1xHACII and control TS1 mice did not reach statistical
significance (p=0.3, Student’s t-test).

Collectively, these data demonstrate that the administration of HACII
CD4+CD25+ cells inhibits systemic production of IL-17 and also IL-1β, which has
been linked to Th-17 differentiation (Sutton et al. 2006; Acosta-Rodriguez et al.
2007; Koenders et al. 2008). The amount of IL-17 produced by LN cultures
appeared to be a direct correlate to the disease status of TS1xHACII mice,
suggesting that this cytokine may be important for the development of arthritis.

3.2.9 IL-17 is critical for the development of spontaneous autoimmune
arthritis in TS1xHACII mice

The finding that arthritic TS1xHACII mice produced significantly higher
amounts of IL-17 than both healthy control TS1 mice (Figure 3-9 A) and
protected TS1xHACII mice that received HACII CD4+CD25+ Treg cells (Figure 38 C and Figure 3-9 A), suggested that increased IL-17 production correlates with
arthritis in TS1xHACII mice. To determine whether IL-17 is critical for arthritis
development in TS1xHACII mice, we treated TS1xHACII mice with either antiIL17 (blocks IL-17A, clone M210, Amgen) or an isotype control antibody and
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tracked the mice weekly for disease development. Blockade of IL-17
dramatically reduced arthritis incidence in TS1xHACII mice, as only 8.3 percent
(1 of 12) of anti-IL17 antibody treated TS1xHACII mice developed disease in
comparison to 100 percent of isotype control treated TS1xHACII mice
(**p=0.004, Fisher’s exact test) (Figure 3-10 A). Given that all of the isotype
control treated TS1xHACII mice had three or four arthritic limbs, whereas only
one anti-IL17 antibody treated TS1xHACII mouse developed arthritis (Figure 310 B), the average number of arthritic limbs per mouse in anti-IL17 treated
TS1xHACII mice was significantly lower than in unmanipulated TS1xHACII mice
(**p=0.001, Mann-Whitney).

These data clearly demonstrate that IL-17 activity is critical for arthritis
development in TS1xHACII mice. Moreover, this finding indicates that the
reduction in regional and systemic IL-17 production observed in TS1xHACII mice
that received HACII CD4+CD25+ cells (Figure 3-8 C and 3-9 A), may be the key
mechanism by which protective CD4+CD25+ Treg cells can prevent arthritis
development in TS1xHACII mice.
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Figure 3-10 IL-17 is critical for the development of arthritis in TS1xHACII mice
(A) Arthritis incidence in 14 week old TS1xHACII mice that were treated with
anti-IL17 antibody (n=12) or an isotype control antibody (n=6). Statistical significance
was calculated using Fisher’s exact test. (B) The numbers ofarthritic limbs per mouse
in 14 week old TS1xHACII mice treated with anti-IL17 or isotype control antibodies.
Each circle represents an individual mouse. Line represents the average number of
arthritic limbs. Statistical significance was calculated using the Mann-Whitney test.
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3.2.10 CD4+CD25+ cells from TS1xHACII mice can modify arthritis
development if 6.5+CD4+CD25+ cells are depleted

The ability of exogenously administered HACII CD4+CD25+ cells to
prevent arthritis development in TS1xHACII mice (Figure 3-6) demonstrates that
arthritis in TS1xHACII mice can be modulated by CD4+CD25+ Treg cell activity,
and raises the question of why the endogenous CD4+CD25+Foxp3+ cells in
TS1xHACII mice fail to prevent arthritis. One possibility is that despite containing
a normal percentage of CD4+CD25+Foxp3+ cells in arthritic TS1xHACII mice
(Figure 3-3 A), pre-arthritic TS1xHACII mice may not contain sufficient numbers
of the cells to prevent arthritis from developing (Figure 3-2 D). Thus, we
examined whether increasing the CD4+CD25+ Treg cell population by
administering CD4+CD25+ cells isolated from other TS1xHACII mice to prearthritic TS1xHACII mice would be able to prevent arthritis development.
However, CD4+CD25+ cells from TS1xHACII mice contain a population of 6.5+
cells, which comprise Foxp3+ and Foxp3- cells (Figure 3-3 B). Given that
recognition of S1 peptide by 6.5+CD4+ T cells is critical for disease initiation in
TS1xHACII mice, we decided to examine the effects of administering both
unfractionated (i.e. contains both 6.5+ and 6.5- cells) and 6.5-depleted
TS1xHACII CD4+CD25+ cells on arthritis development in TS1xHACII mice.
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To address this we purified CD4+CD25+ cells from TS1xHACII mice that
were either unfractionated or were depleted of 6.5+ cells (Figure 3-11 A, left
panel). We adoptively transferred 1x106 of these unfractionated or 6.5-depleted
TS1xHACII CD4+CD25+ cells into pre-arthritic TS1xHACII mice and tracked the
recipients for arthritis development. Unmanipulated TS1xHACII mice, and mice
that received unfractionated CD4+CD25+ TS1xHACII cells averaged a similar
number of arthritic limbs per mouse at each time point during the nine week
period of analysis. However, TS1xHACII mice that received 6.5-depleted
CD4+CD25+ TS1xHACII cells averaged fewer affected limbs per mouse (Figure
3-11 A, right panel). This lower average number of arthritic limbs could reflect
either an overall reduction in arthritis incidence within the population, or similar
disease incidence that is accompanied by arthritic TS1xHACII mice possessing
fewer numbers of affected limbs, which is indicative of reduced disease severity
in individual arthritic mice.

To further examine this we assessed the kinetics of arthritis incidence in
unmanipulated, unfractionated TS1xHACII CD4+CD25+ cell recipient, and 6.5depleted TS1xHACII CD4+CD25+ cell recipient TS1xHACII mice. Unmanipulated
TS1xHACII mice and those that received unfractionated CD4+CD25+ TS1xHACII
cells exhibited comparable kinetics in the development of disease incidence, and
by 15 weeks of age over 90 percent of unmanipulated and 100 percent of
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Figure 3-11 The adoptive transfer 6.5-depleted TS1xHACII CD4+CD25+ cells can
modify arthritis in TS1xHACII mice (A) 1x106 unfractionated CD4+CD25+cells or
6.5-CD4+CD25+ cells from TS1xHACII mice were adoptively transferred into prearthritic TS1xHACII mice. Dot plots show 6.5 staining in sorted CD4+CD25+ cells that
were or were not depleted of 6.5+ cells. Number indicates the percentage of 6.5+ cells.
Graph shows the average number of arthritic limbs per mouse (±SEM) over time of
unmanipulated ( , n=11), unfractionated TS1xHACII CD4+CD25+cell recipient ( , n=6),
and 6.5-depleted TS1xHACII CD4+CD25+ cell recipient ( , n=10) TS1xHACII mice.
(B) Arthritis incidence over time in unmanipulated, unfractionated TS1xHACII
CD4+CD25+ cell recipient, and 6.5-depleted TS1xHACII CD4+CD25+ cell recipient
TS1xHACII mice. Statistical significance was calculated using Fisher’s exact test.
(C) Graphs show the numbers of arthritic limbs per mouse in 12 week old (top) and 15
week old (bottom) unmanipulated, unfractionated TS1xHACII CD4+CD25+ cell recipient,
and 6.5-depleted TS1xHACII CD4+CD25+ cell recipient TS1xHACII mice. Each circle
represents an individual mouse. Line represents the average number of arthritic limbs
per mouse. Statistical significance was calculated using the Mann-Whitney test.
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unfractionated TS1xHACII CD4+CD25+ cell recipient mice had developed arthritis
(Figure 3-11 B). In contrast, TS1xHACII mice that received 6.5-depleted
TS1xHACII CD4+CD25+ cells showed much lower arthritis incidence at each time
point when compared to unmanipulated TS1xHACII mice, and by 15 weeks of
age only 50 percent of the mice had developed arthritis (Figure 3-11 B).
However, the difference in arthritis incidence between unmanipulated TS1xHACII
mice and TS1xHACII mice that received 6.5-depleted TS1xHACII CD4+CD25+
cells did not reach statistical significance (p=0.06, Fisher’s exact test).

Moreover, the administration of unfractionated CD4+CD25+ TS1xHACII
cells to TS1xHACII mice did not affect the number of affected limbs in arthritic
mice. Among 12 week old arthritic TS1xHACII mice, 55.6 percent (5 of 9) of
unmanipulated TS1xHACII mice and 50 percent (3 of 6) of unfractionated
CD4+CD25+ TS1xHACII cell recipient TS1xHACII mice had three or four affected
limbs (Figure 3-11 C, upper panel). By 15 weeks of age 60 percent (6 of 10) of
arthritic unmanipulated TS1xHACII mice and 83.3 percent (5 of 6) of arthritic
unfractionated CD4+CD25+ TS1xHACII cell recipient mice had three or four
affected limbs (Figure 3-11 C, lower panel). Thus, there was little difference in
the degree of arthritis incidence or in the numbers of affected limbs between
unmanipulated TS1xHACII mice and mice that received unfractionated
CD4+CD25+ TS1xHACII cells.
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Among TS1xHACII mice that received 6.5-depleted CD4+CD25+
TS1xHACII cells, only 20 percent (2 of 10) were arthritic, with two or four affected
limbs, by 12 weeks of age (Figure 3-11 C, upper panel). Furthermore, since the
majority of 12 week old 6.5-depleted CD4+CD25+ TS1xHACII cell recipient mice
were not arthritic, the average number of affected limbs was significantly lower
than in unmanipulated TS1xHACII mice (*p=0.019, Mann-Whitney). By 15 weeks
of age, 5 of 10 (50 percent) TS1xHACII mice that received 6.5-depleted
CD4+CD25+ TS1xHACII cells were arthritic, and among arthritic animals 60
percent (3 of 5) had three or four affected limbs (Figure 3-11 C, lower panel).
Although the average number of affected limbs in 15 week old TS1xHACII mice
that received 6.5-depleted TS1xHACII CD4+CD25+ cells was greater than in 12
week old mice, the difference in the average number of arthritic limbs between 15
week old 6.5-depleted CD4+CD25+ TS1xHACII cell recipient and unmanipulated
TS1xHACII mice remained significant (*p=0.05, Mann-Whitney).

Thus, the administration of CD4+CD25+ cells from TS1xHACII mice that
were depleted of the 6.5+ pool, but not unfractionated TS1xHACII CD4+CD25+
cells, could reduce arthritis incidence in TS1xHACII mice. Collectively, these data
demonstrate that endogenous CD4+CD25+ cells from TS1xHACII mice possess
in vivo regulatory activity and can modulate arthritis development in TS1xHACII
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mice, but that their efficacy is contingent upon depletion of the 6.5+CD4+CD25+
population, which is a mixture of Foxp3+ and Foxp3- cells.

3.2.11 Suppressor function of CD4+CD25+ Treg cells is highly sensitive to
balance of Treg and effector cells

Depletion of 6.5 TCR expressing cells allows endogenous CD4+CD25+
cells from TS1xHACII mice to modulate arthritis development (Figure 3-11).
Since the elimination of 6.5+CD4+CD25+ cells removes both Foxp3+ and Foxp3cells (Figure 3-3 B), the enhanced ability of 6.5-depleted TS1xHACII CD4+CD25+
cells to suppress arthritis could be explained by the absence of
6.5+CD4+CD25+Foxp3- cells specific for the disease initiating target antigen (S1
peptide). This result suggests that the efficacy of CD4+CD25+ Treg cell activity
could be highly sensitive to the balance of Treg and effector cells. To further
address this, we examined whether introducing a small population of
conventional 6.5+CD4+ T cells to HACII CD4+CD25+ Treg cells could affect the
ability of the protective Treg cells to suppress arthritis in TS1xHACII mice. We
purified CD4+CD25- cells from TS1xHA28 mice, which co-express the 6.5 TCR
and the HA transgene under an SV40 promoter (Jordan et al. 2001), to obtain a
source of potentially autoreactive 6.5+CD4+ T cells that have developed in the
presence of HA, as 6.5+CD4+CD25- cells in TS1xHA28 mice have evaded
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negative selection despite exposure to HA in the thymus (Jordan et al. 2001).
Approximately 30 percent of CD4+CD25- cells from TS1xHA28 mice are 6.5+ and
Foxp3- (Figure 3-12 A).

We adoptively transferred a mixture of 1x106 cells that contained 95
percent protective HACII CD4+CD25+ cells and 5 percent TS1xHA28 CD4+CD25cells (mixed cell) into pre-arthritic TS1xHACII mice and tracked the recipients for
arthritis development. Strikingly, the incidence of arthritis was the same (62.5
percent) in 15 week old unmanipulated TS1xHACII mice and mice that received
the mixture of HACII CD4+CD25+ cells and TS1xHA28 CD4+CD25- cells (Figure
3-12 B). Notably, arthritis incidence was higher in TS1xHACII mice that received
the mixture of protective HACII CD4+CD25+ cells and TS1xHA28 CD4+CD25cells than in TS1xHACII mice that received HACII CD4+CD25+ cells (Figure 3-12
B), although the difference between the two cohorts did not reach statistical
significance (p=0.07, Fisher’s exact test). The average number of arthritic limbs
per mouse was also higher, though not statistically significant (p=0.08, MannWhitney), among TS1xHACII mice that received the mixture of protective HACII
CD4+CD25+ cells and TS1xHA28 CD4+CD25- cells than in TS1xHACII mice that
received only HACII CD4+CD25+ cells (Figure 3-12 C).
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Figure 3-12 CD4+CD25+ Treg cell activity is sensitive to the balance of Treg and
effector cells (A) 6.5 and Foxp3 staining in CD4+CD25- LN cells from TS1xHA28
mice. Numbers indicate the percentage of cells in the respective quadrants. 1x106
cells from a mixture of 95 percent HACII CD4+CD25+ and 5 percent TS1xHA28
CD4+CD25- cells were adoptively transferred into pre-arthritic TS1xHACII mice.
(B) Arthritis incidence in unmanipulated TS1xHACII mice, TS1xHACII mice that
received the mixture of HACII and TS1xHA28 cells, and TS1xHACII mice that
received only HACII CD4+CD25+ cells. Statistical significance was calculated using
Fisher’s exact test. (C) Graphs show the numbers of arthritic limbs per mouse in
unmanipulated, HACII and TS1xHA28 mixed cell recipient, and HACII CD4+CD25+
Treg cell recipient TS1xHACII mice. Each circle represents an individual mouse.
Line represents the average number of arthritic limbs per mouse. Statistical
significance was calculated using the Mann-Whitney test.
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Collectively, these data show that the presence of a small population of
CD4+CD25- cells enriched for expression of the 6.5 TCR can alter the ability of
protective HACII CD4+CD25+ Treg cells to suppress arthritis in TS1xHACII mice.
These results suggest that the efficacy of CD4+CD25+ Treg cells is remarkably
sensitive to the balance of Treg and effector cells.

3.2.12 Polyclonal CD4+CD25+ Treg cells that have not developed in the
presence of HA can prevent arthritis development in TS1xHACII mice

We have shown that the transfer of CD4+CD25+ cells purified from HACII
mice to pre-arthritic TS1xHACII mice can prevent arthritis development in
TS1xHACII mice (Figure 3-6). Furthermore, the adoptive transfer of endogenous
CD4+CD25+ cells from TS1xHACII mice that have been depleted of
6.5+CD4+CD25+ cells can also ameliorate arthritis in TS1xHACII mice (Figure 311). Together, these data demonstrate that CD4+CD25+ cells that do not express
the 6.5 TCR (which is specific for the disease initiating target antigen) can modify
arthritis development in TS1xHACII. However, although the CD4+CD25+ cells
from HACII or TS1xHACII mice do not express the 6.5 TCR, both cell populations
have developed in the presence of S1 peptide as a self antigen. Therefore, it is
possible that CD4+CD25+ cells from HACII and TS1xHACII mice contain a
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population of S1-reactive cells, and that specificity for S1 peptide is required for
Treg cell modulation of arthritis in TS1xHACII mice.

To examine whether CD4+CD25+ cells that have not developed in the
presence of S1 peptide would also be able to prevent arthritis development in
TS1xHACII mice, we purified CD4+CD25+ cells from BALB/c mice, which have
the same genetic background as TS1xHACII mice, but contain no modifications
to the TCR repertoire and do not express HA as a self-peptide. Thus, BALB/c
CD4+CD25+ cells have not experienced the S1 peptide, which drives initiation of
arthritis in TS1xHACII mice. As expected CD4+CD25+ LN cells from BALB/c
mice express Foxp3 but no 6.5 (Figure 3-13 A). We adoptively transferred 1x106
BALB/c CD4+CD25+ cells into pre-arthritic TS1xHACII mice and tracked the
recipients for disease development. TS1xHACII mice that received BALB/c
CD4+CD25+ cells exhibited a marked reduction in arthritis development in
comparison to unmanipulated TS1xHACII mice (Figure 3-13 B). In contrast to
the 80 percent (8 of 10) of unmanipulated TS1xHACII mice that developed
arthritis, a significantly lower percentage (22 percent, 2 of 9) of BALB/c
CD4+CD25+ cell recipient TS1xHACII mice were arthritic by 15 weeks of age
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Figure 3-13 The adoptive transfer of CD4+CD25+ cells from BALB/c mice can prevent
arthritis in TS1xHACII mice (A) Dot plots show 6.5 and Foxp3 staining of CD4+CD25+
LN cells from BALB/c mice. (B) 1x106 BALB/c CD4+CD25+ cells were adoptively
transferred into 5 to 6 week old TS1xHACII mice. Graph shows the average number
of arthritic limbs per mouse (±SEM) over time of unmanipulated ( , n=10) and
BALB/c CD4+CD25+ cell recipient ( , n=9) TS1xHACII mice. (C) Arthritis incidence in
15 week old unmanipulated or BALB/c CD4+CD25+ cell recipient TS1xHACII mice.
Statistical significance was calculated using Fisher’s exact test. (D) The number of
arthritic limbs per mouse in cohorts of unmanipulated and BALB/c CD4+CD25+ cell
receipient TS1xHACII mice. Each circle represents an individual mouse. Line
represents the average number of arthritic limbs per mouse. Statistical significance
was calculated using the Mann-Whitney test.
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(*p=0.02, Fisher’s exact test) (Figure 3-13 C). Furthermore, similar to the
observations in TS1xHACII mice that received HACII CD4+CD25+ cells, arthritic
TS1xHACII mice that received BALB/c CD4+CD25+ cells had only one affected
limb in comparison to arthritic unmanipulated TS1xHACII mice, which developed
disease in three to four limbs (Figure 3-13 D). The reduction in the number of
affected limbs among arthritic TS1xHACII mice coupled with the decrease in
disease incidence, resulted in a significantly lower average number of arthritic
limbs per mouse in TS1xHACII mice that received BALB/c CD4+CD25+ cells in
comparison to unmanipulated TS1xHACII mice (***p=0.0001, Mann-Whitney).

These data demonstrate that CD4+CD25+ Treg cells that have not
developed in the presence of the disease initiating target antigen can effectively
suppress arthritis development in TS1xHACII mice.
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3.3 Summary of Results and Discussion

3.3.1 TS1xHACII mice contain endogenous CD4+CD25+Foxp3+ cells,
including a population that expresses the 6.5 TCR and recognizes the
disease initiating target antigen

A key feature of the TS1xHACII arthritis model is that we have defined the
disease-initiating antigen. TS1xHACII mice on a RAG-/- background develop
arthritis, demonstrating that recognition of the S1 peptide by 6.5+CD4+ T cells
alone is sufficient to mediate disease (Rankin et al. 2008). Arthritis develops in
TS1xHACII mice despite profound deletion of HA-specific thymocytes and is
accompanied by the gradual accumulation of total CD4+ and 6.5+CD4+ T cells in
the systemic LNs (Figure 3-2 D). Interestingly, older, arthritic TS1xHACII mice
and age-matched TS1 mice contain comparable numbers of total CD4+ cells and
6.5+CD4+ cells in the popliteal LNs, which drain the lower joints, but not in
systemic LNs (Figure 3-2 D and E). Moreover, the total cellularity of popliteal
LNs was also higher in older, arthritic TS1xHACII mice than in age-matched TS1
mice (Figure 3-2 E), suggesting an increased presence of other immune system
cells in addition to the accumulation of CD4+ cells. The accumulation of
6.5+CD4+ T cells and arthritis development in TS1xHACII mice occurs despite the
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presence of a normal frequency of CD4+CD25+Foxp3+ cells in TS1xHACII mice
of all ages (Figure 3-3 A). Furthermore, TS1xHACII mice also contain
6.5+CD4+CD25+Foxp3+ cells, which are specific for the S1 peptide that initiates
disease development.

We found that unfractionated (including both 6.5- and 6.5+ cells)
CD4+CD25+Foxp3+ cells from TS1xHACII mice and CD4+CD25+Foxp3+ cells
from healthy mice (HACII or BALB/c) had comparable patterns of CTLA-4 and
GITR expression, indicating that the disease environment does not significantly
alter the expression of these CD4+CD25+ Treg cell markers. CTLA-4 in particular
has been shown to be an important mediator of CD4+CD25+ Treg cell function
(Wing et al. 2008), and altered CTLA-4 regulation can be associated with
dysfunctional CD4+CD25+ Treg cell activity in RA patients (Flores-Borja et al.
2008). Indeed, CD4+CD25+Foxp3+ cells from TS1xHACII mice appeared to be
more activated than their counterparts from healthy mice, as a larger subset of
TS1xHACII CD4+CD25+Foxp3+ cells expressed higher levels of CTLA-4 and
GITR. Interestingly, we found that within the population of TS1xHACII
CD4+CD25+Foxp3+ cells, 6.5+ cells expressed higher levels of both CTLA-4 and
GITR in comparison to 6.5- cells (Figure 3-3 C), suggesting that the S1-specific
6.5+CD4+CD25+Foxp3+ cells may be more activated in response to interactions
with their cognate antigen. Thus CD4+CD25+Foxp3+ cells from TS1xHACII mice
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are not deficient in classic CD4+CD25+ Treg cells markers such as CTLA-4 and
GITR.

Although CD4+CD25+Foxp3+ cells are present in TS1xHACII mice, it was
possible that they possessed dysfunctional suppressor activity, as has been
reported with CD4+CD25+ Treg cells isolated from human RA patients
(Ehrenstein et al. 2004; Valencia et al. 2006). We found that unfractionated
CD4+CD25+ cells from TS1xHACII mice were able to inhibit both the proliferation
and cytokine production of responder CD4+ T cells in response to stimulation with
soluble anti-CD3 (Figure 3-4 A), demonstrating that the CD4+CD25+ cells that are
present in TS1xHACII mice possess effective in vitro suppressor function.
Furthermore, TS1xHACII CD4+CD25+ cells stimulated with S1 peptide could also
inhibit the in vitro proliferation of responder CD4+ T cells (Figure 3-4 B), indicating
that the CD4+CD25+ cells could exert suppressor function in response to the
disease-initiating target antigen. We found that the CD4+CD25+ cells from
TS1xHACII mice were more effective at inhibiting responder CD4+ T cell
proliferation when a low dose (0.3 µM) of S1 peptide was used as a stimulus
(Figure 3-4 B). However, it is possible that we are underestimating the regulatory
activity of S1-responsive CD4+CD25+ cells, as we did not isolate 6.5+CD4+CD25+
cells from TS1xHACII mice for the suppression assays. Therefore, although we
set up the assays using a 1:2 unfractionated TS1xHACII CD4+CD25+ cell to
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responder cell ratio, the effective ratio of S1-specific CD4+CD25+ cells to
responder cells is much lower. For a more accurate assessment of the in vitro
suppressor function of 6.5+CD4+CD25+ cells from TS1xHACII mice, the
suppression assay should be conducted using a 1:2 ratio of TS1xHACII
6.5+CD4+CD25+ cells to responder cells.

We also examined the presence CD4+CD25+Foxp3+ cells in lymphoid
organs throughout TS1xHACII mice, since alterations in CD4+CD25+ Treg cell
distribution in lymphoid organs and other tissues can precede the development of
autoimmune disease (Siegmund et al. 2005; Sather et al. 2007). Strikingly, while
we did not observe differences in the distribution of unfractionated
CD4+CD25+Foxp3+ cells between the draining and non-draining LNs in
TS1xHACII mice, we found that 6.5+CD4+CD25+Foxp3+ cells were enriched in
the popliteal LNs (which drain the lower joints and are the site of an enhanced
immune response in arthritic mice) in comparison to non-draining LNs in
TS1xHACII mice (Figure 3-5 B). Interestingly, studies have suggested that
draining LNs may be enriched for CD4+CD25+ Treg cells that are specific for
antigens derived from regional organs (Samy et al. 2005; Samy et al. 2008;
Wheeler et al. 2009). Indeed, although S1 peptide is presented systemically in
TS1xHACII mice, it is possible that there is increased presentation of HA-derived
peptides in the popliteal LNs, which could lead to an enrichment of
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6.5+CD4+CD25+Foxp3+ cells in the draining LNs. Thus, TS1xHACII mice develop
spontaneous inflammatory arthritis despite the presence of CD4+CD25+Foxp3+
cells (including a population of 6.5+CD4+CD25+Foxp3+ cells that recognize the
disease initiating target antigen) that are present in the LNs draining the joints,
which are a primary site of autoimmune pathology.

3.3.2 Exogenous CD4+CD25+ Treg cells can inhibit the pathogenic Th-17
response in TS1xHACII mice

We have shown that the administration of exogenous CD4+CD25+ cells
from HACII or BALB/c mice can prevent arthritis, demonstrating that the
endogenous effector CD4+ T cells (and other immune cells) that contribute to
arthritis pathogenesis in TS1xHACII mice are not refractory to CD4+CD25+ Treg
cell activity (Figure 3-6 and 3-13). The adoptive transfers of CD4+CD25+ cells
from HACII and BALB/c mice not only dramatically reduced arthritis incidence in
TS1xHACII mice, but also appeared to reduce disease severity because
TS1xHACII mice that received HACII or BALB/c CD4+CD25+ cells possessed
significantly fewer arthritic limbs than unmanipulated TS1xHACII mice. Thus,
HACII and BALB/c CD4+CD25+ Treg cells could modify the degree of disease in
an individual TS1xHACII mouse in addition to affecting arthritis incidence on a
population level.
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HACII CD4+CD25+ Treg cells did not mediate arthritis prevention by
inhibiting the accumulation of disease initiating S1-specific 6.5+CD4+ T cells in
TS1xHACII mice, as arthritic unmanipulated TS1xHACII mice and protected
TS1xHACII mice that received HACII CD4+CD25+ cells contained similar
numbers of total CD4+ and 6.5+CD4+ T cells in the systemic LNs. Furthermore,
protective HACII CD4+CD25+ Treg cells did not alter expression of CD62L,
CD44, and CD69 on 6.5+ or 6.5- CD4+ T cells in TS1xHACII mice (Figure 3-7 C),
as 6.5+CD4+ T cells appeared activated and antigen-experienced in both arthritic
and protected TS1xHACII mice. Thus, HACII CD4+CD25+ Treg cells do not
prevent arthritis development by suppressing the accumulation or activation of
the disease initiating 6.5+CD4+ T cells in TS1xHACII mice. Instead, HACII
CD4+CD25+ Treg cells appear to suppress arthritis development by inhibiting the
pathogenic Th-17 response. In comparison to arthritic unmanipulated
TS1xHACII mice, TS1xHACII mice that received protective HACII CD4+CD25+
cells exhibited a preferential reduction in the representation of IL-17+CD4+ cells in
the popliteal LNs (Figure 3-8 B and C), as well as a significant decrease in IL-17
production by systemic LNs (Figure 3-9 A). Work in the SKG model of arthritis
has suggested that homeostatic expansion of CD4+ T cells in a lymphopenic
environment can contribute to the development of Th-17 cells (Hirota et al. 2007).
Given the lymphopenia in young TS1xHACII mice, it is possible that the
accumulation of peripheral CD4+ T cells is a contributing factor to the
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development of IL-17 producing CD4+ T cells. However, as described previously,
protective HACII CD4+CD25+ Treg cells did not alter the accumulation of 6.5+ or
6.5- CD4+ T cells in TS1xHACII mice (Figure 3-7 A and B), suggesting that they
are inhibiting Th-17 differentiation by a different mechanism.

Interestingly, TS1xHACII mice that received protective HACII CD4+CD25+
cells also produced significantly lower amounts of systemic IL-1β (Figure 3-9 B),
a cytokine that is associated with promoting IL-17 production (Sutton et al. 2006;
Acosta-Rodriguez et al. 2007) and arthritis pathogenesis (Koenders et al. 2006;
Koenders et al. 2008). The reduction in IL-1β suggests that protective
CD4+CD25+ Treg cells may suppress IL-17+CD4+ cells by inhibiting other
cytokines that are required for Th-17 differentiation. While much work has been
done to identify the parameters defining in vitro Th-17 differentiation (Mangan et
al. 2006; Veldhoen et al. 2006; Korn et al. 2009), the key players in in vivo IL-17
induction remain unclear, though there is speculation that an as yet unidentified
innate immune system cell may play a role in in vivo Th-17 development (Korn et
al. 2009). CD4+CD25+ Treg cells can suppress the innate immune response
(Maloy et al. 2003), and a potential explanation for decreased IL-17 production in
protected TS1xHACII mice is that the exogenous CD4+CD25+ Treg cells are
acting upon an innate immune system cell that is instrumental in inducing the
differentiation of Th-17 cells. Moreover, IL-1β has also been shown to induce
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synoviocyte production of CCL20 (Hirota et al. 2007), the chemokine that binds
CCR6, which is preferentially expressed on Th-17 cells (Acosta-Rodriguez et al.
2007; Annunziato et al. 2007). Thus, it is possible that a decrease in IL-1β
production reduces not only Th-17 cell differentiation, but also the trafficking of
IL-17 producing CD4+ cells to the joints or joint-draining LNs. However, IL-17
can also act to induce IL-1 expression (Koenders et al. 2006), and it is possible
that lower levels of IL-1β result from direct CD4+CD25+ Treg cell suppression of
IL-17+CD4+ cells in protected TS1xHACII mice.

In addition to the reduction of regional and systemic cytokine responses,
protected TS1xHACII mice contained significantly smaller popliteal LNs than
unmanipulated arthritic TS1xHACII mice, indicating that the CD4+CD25+ Treg
cells may also inhibit the accumulation of popliteal LN cells that normally occurs
in TS1xHACII mice (Figure 3-2 E). Work in other murine autoimmune disease
models has illustrated the importance of the regional LN immune response in the
development of autoimmunity (Hoglund et al. 1999; Samy et al. 2005). In the
NOD diabetes model, excision of the pancreatic LNs in young mice prevented
diabetes onset, demonstrating that the local immune response is required for
disease pathogenesis (Gagnerault et al. 2002). Thus, although the disease
initiating target autoantigen is presented systemically in TS1xHACII mice, it is
possible that the popliteal LNs present elevated levels of S1 peptide that
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effectively prime the pathogenic 6.5+CD4+ T cells, and that inhibition of this
regional response by exogenous CD4+CD25+ Treg cells is sufficient to prevent
arthritis development. Indeed, recent work in other murine arthritis models
suggests that CD4+ T cells play a more prominent role in the joint-draining LNs
than in the joints themselves (Angyal et al. 2010).

It is also possible that CD4+CD25+ Treg cell suppression of regional IL-17
production prevents the accumulation of popliteal LN cells in TS1xHACII mice.
IL-17 can induce innate immune cell migration (Lundy et al. 2007; Pelletier et al.
2010), and the reduction of the local Th-17 response could inhibit the recruitment
of innate immune and antigen presenting cells, which make up the majority of the
cells in the popliteal LNs of TS1xHACII mice (Rankin et al. 2008). Indeed, IL-17
has been shown to induce monocyte trafficking in arthritis (Shahrara et al. 2009),
and additional work has demonstrated that monocytes isolated from human RA
patients can induce Th-17 differentiation of CD4+ T cells (Evans et al. 2009).
This relationship suggests the possibility of a feedback loop where IL-17 recruits
innate immune cells such as monocytes, which can further enhance local IL-17
production by promoting Th-17 cell differentiation. Thus, the effects of
exogenous CD4+CD25+ Treg cell inhibition on the Th-17 response would be
amplified by breaking this cycle.
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3.3.3 Specificity for the disease initiating target antigen is not required for
CD4+CD25+ Treg cell suppression of arthritis in TS1xHACII mice

The CD4+CD25+ Treg cells that most effectively suppressed arthritis
development in TS1xHACII mice were purified from single transgenic HACII or
BALB/c mice, which provide a polyclonal population of CD4+CD25+ Treg cells
without transgenic modifications to their endogenous T cell repertoires. HACII
mice express the HA transgene (under the same MHC Class II I-Eα promoter as
in TS1xHACII mice), but not the transgenic 6.5 TCR. Accordingly, CD4+CD25+
cells in HACII mice are the appropriate control population for 6.5-CD4+CD25+
cells from TS1xHACII mice in that they also develop in the presence of the HA
protein from which the disease target antigen (S1 peptide) is derived. Therefore,
while CD4+CD25+ cells from HACII mice do not express the 6.5 TCR that is
specific for S1 peptide, it is possible that there are other S1 peptide or HA
reactive cells within the population of CD4+CD25+ cells because they developed
in the presence of HA as a self antigen. Thus, it is possible that CD4+CD25+
Treg cells from HACII mice are capable of preventing arthritis development in
TS1xHACII mice because a subset of cells can recognize and respond to the S1
peptide or other HA-derived peptides. Indeed eight CD4+ T cell epitopes have
been identified in PR8 HA (Gerhard et al. 1991). However, BALB/c CD4+CD25+
Treg cells, which have not experienced the S1 peptide or the HA protein from
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which S1 peptide is derived, are also able to suppress arthritis in TS1xHACII
mice. This result clearly demonstrates that a population of CD4+CD25+ Treg
cells without any enrichment for S1-specific or other HA reactive cells can
effectively shut down S1 peptide initiated autoimmune arthritis in TS1xHACII
mice. How might CD4+CD25+ Treg cells from BALB/c mice suppress arthritis
development in TS1xHACII mice? One possibility is that CD4+ T cells of other
specificities have been recruited to the effector phase of arthritis, and that
CD4+CD25+ Treg cells from BALB/c mice are able to suppress the pathogenic
CD4+ T cells that are not S1-peptide or HA-specific.

3.3.4 CD4+CD25+ Treg cell activity is highly sensitive to the balance of Treg
and effector cells

Strikingly, whereas the administration of unfractionated (includes 6.5- and
6.5+ cells) TS1xHACII CD4+CD25+ cells could not suppress arthritis, TS1xHACII
CD4+CD25+ cells that had been depleted of 6.5+ cells could modulate arthritis
development in TS1xHACII mice. Since 6.5+CD4+CD25+ cells present in
TS1xHACII mice contain both Foxp3+ and Foxp3- cells, the enhanced ability of
TS1xHACII 6.5-CD4+CD25+ cells to reduce arthritis incidence in TS1xHACII mice
could be attributed to the absence of an activated population of
6.5+CD4+CD25+Foxp3- cells (which are specific for the disease initiating target
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antigen), suggesting that CD4+CD25+ Treg cell activity is sensitive to the balance
of Treg and effector cells. Indeed, the introduction of a small population of
6.5+CD4+CD25- cells (obtained from TS1xHA28 mice) to protective HACII
CD4+CD25+ cells altered the efficacy of the HACII CD4+CD25+ cells in preventing
arthritis development. The same percentage of unmanipulated TS1xHACII mice
and TS1xHACII mice that received the mixture of HACII CD4+CD25+ cells and
TS1xHA28 6.5+CD4+CD25- cells developed arthritis, whereas administration of
HACII CD4+CD25+ cells alone dramatically reduced arthritis incidence in recipient
TS1xHACII mice. Collectively, these data indicate that the balance of
CD4+CD25+ Treg and effector CD4+ T cells is an important determinant of
successful Treg cell activity. Moreover, the marked effects of either depleting or
introducing a small population of 6.5+CD4+ T cells in the adoptive Treg cell
transfers to pre-arthritic TS1xHACII mice further emphasizes the particular
importance of 6.5+CD4+ T cells for arthritis pathogenesis. Indeed, the
development of arthritis in TS1xHACII.RAG-/- mice demonstrates that 6.5+CD4+ T
cells alone are sufficient to mediate disease (Rankin et al. 2008), indicating that
CD4+ T cells of other specificities are not required in later stages of disease.

Although the administration of TS1xHACII 6.5-CD4+CD25+ cells reduced
arthritis incidence in TS1xHACII mice, the cells were not as effective as HACII or
BALB/c CD4+CD25+ cells at preventing arthritis development. The effect of the
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transferred 6.5-CD4+CD25+ cells appeared to wane over time, as the percentage
of arthritic mice among TS1xHACII mice that received the 6.5-CD4+CD25+ cells
continued to increase during the nine week period of analysis (Figure 3-11 B). It
is possible that TS1xHACII 6.5-CD4+CD25+ cells merely delay arthritis onset in
recipient in TS1xHACII mice, and that eventually disease incidence in
TS1xHACII mice that received TS1xHACII 6.5-CD4+CD25+ cells would be
comparable to that in unmanipulated TS1xHACII mice. Despite using expression
of the 6.5 TCR to deplete 6.5+CD4+CD25+ cells (which contain both Foxp3+ and
Foxp3- cells) from the endogenous CD4+CD25+ pool in TS1xHACII mice, it is
possible that some S1-specific 6.5+CD4+CD25+ remain in the depleted population
of TS1xHACII CD4+CD25+ cells. The 6.5+CD4+CD25+ cells may have
downregulated expression of the 6.5 TCR in response to interactions with the S1
peptide, or may express two TCRs (due to secondary TCR alpha chain
rearrangements) resulting in lower levels of 6.5 expression that are not detected
by staining with the mAb 6.5. Thus, it is possible that the presence of a
contaminating population of S1-specific CD4+CD25+ cells interferes with the in
vivo suppressor function of endogenous 6.5-CD4+CD25+ cells from TS1xHACII
mice.

Another explanation for the difference in efficacy of TS1xHACII 6.5CD4+CD25+ cells and HACII or BALB/c CD4+CD25+ cells in preventing arthritis
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development in TS1xHACII mice is that the 6.5-CD4+CD25+ cells from
TS1xHACII mice are less functional than their counterparts in healthy mice. This
is consistent with reports that CD4+CD25+ Treg cells from human RA patients are
dysfunctional due to their exposure to the inflammatory cytokines (e.g. TNF-α) in
the disease setting (Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni et al.
2007). However, it is clear that CD4+CD25+ cells from HACII or BALB/c mice are
able to maintain their regulatory effects for up to nine to ten weeks post transfer
in TS1xHACII mice, indicating that CD4+CD25+ Treg cell activity can occur in the
context of high levels of inflammatory cytokines. Still, the CD4+CD25+ T cells in
TS1xHACII mice might have unique properties that render them susceptible to
these effects. Thus, although we examined expression of CD4+CD25+ Treg cell
markers such as CTLA-4 and GITR on CD4+CD25+ cells from TS1xHACII and
HACII or BALB/c mice (Figure 3-3 D), we have not analyzed expression of
cytokine receptors on the respective CD4+CD25+ cell populations. CD4+CD25+
cells from TS1xHACII mice may express higher levels of certain cytokine
receptors than CD4+CD25+ cells from HACII or BALB/c mice, making them more
susceptible to the inhibitory effects of cytokines, such as IL-6 (Pasare and
Medzhitov 2003) or TNF-α (Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni
et al. 2007), on Treg cell regulatory activity. Indeed the impact of the presence of
S1-specific CD4+CD25+ cells described earlier, could be exacerbated if the
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TS1xHACII CD4+CD25+ cells possess dysfunctional, or less functional,
regulatory activity.

The data presented in this chapter show that CD4+CD25+ Treg cells from
HACII and BALB/c mice can effectively suppress arthritis development in
TS1xHACII mice. Interestingly, a fundamental difference between the two
populations is the antigen specificity of the CD4+CD25+ Treg cells. In contrast to
CD4+CD25+ cells in HACII mice, CD4+CD25+ cells in BALB/c mice have not
developed in the presence of HA, and thus could not be selected on S1 peptide
or any other HA-derived peptides. These results have interesting implications for
how the antigen specificity of CD4+CD25+ Treg cells can affect their ability to
suppress autoimmune disease. In the following chapter we address the role of
antigen specificity in CD4+CD25+ Treg cell function by examining how enrichment
in specificity for a target autoantigen (S1 peptide) affects the ability of
CD4+CD25+ Treg cells to suppress arthritis development in TS1xHACII mice.
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Chapter 4: CD4+CD25+ Treg cells that are enriched in specificity for a
disease target antigen fail to suppress arthritis in TS1xHACII mice

4.1 Introduction

Whereas a role for TCR specificity in the thymic development of
CD4+CD25+ Treg cells has been established (Jordan et al. 2001; Apostolou et al.
2002; Hori et al. 2002; Walker et al. 2003), how TCR specificity influences the
phenotype and function of peripheral CD4+CD25+ Treg cells is less clear. In vitro
studies have shown that while CD4+CD25+ Treg cells require antigen-specific
TCR engagement to activate their regulatory function, they are able to suppress
responder CD4+ T cells of different TCR specificities (Takahashi et al. 1998;
Thornton and Shevach 1998), indicating that the suppression itself is not antigenspecific. However, work in several different models of murine autoimmune
disease indicates that the activation of antigen- or disease-specific CD4+CD25+
Treg cells can be critical for the effective suppression of organ-specific
autoimmunity (Hori et al 2002; Reddy et al. 2004; Tarbell et al. 2004; Samy et al.
2005). In the EAE system, disease development has been linked to an absence
of CD4+CD25+ Treg cells that are specific for the EAE-associated peptides that
drive disease, demonstrating that CD4+CD25+ Treg cell recognition of the target
autoantigen is critical for EAE prevention (Hori et al. 2002; Reddy et al. 2004).
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However, while studies in both human arthritis patients and mouse models of
arthritis indicate that CD4+CD25+ Treg cells do modify the immune response
during arthritis (Morgan et al. 2003; de Kleer et al. 2004; Kelchtermans et al.
2005; Nguyen et al. 2007; Kang et al. 2008), whether and how the TCR
specificity for disease target antigen(s) affects CD4+CD25+ Treg cell function is
unknown.

TS1xHACII mice, in which arthritis development is driven by 6.5+CD4+ T
cell recognition of the systemically presented S1 peptide, provide a powerful
system with which to examine whether TCR specificity influences CD4+CD25+
Treg cell suppression of arthritis. In the previous chapter, we showed that
CD4+CD25+ Treg cells from BALB/c mice, which have not developed in the
presence of S1 peptide (or any other HA-derived peptide), could prevent arthritis
development in TS1xHACII mice. Here we examine whether CD4+CD25+ Treg
cells specific for the disease target antigen S1 peptide can also suppress arthritis
in TS1xHACII mice. TS1xHA28 mice are a rich source of 6.5+CD4+CD25+Foxp3+
Treg cells that are generated intrathymically based on the specificity of the 6.5
TCR for the S1 peptide (which is expressed at low levels driven by an SV40
promoter enhancer) (Jordan et al. 2001). Moreover, CD4+CD25+ cells from
TS1xHA28 mice possess in vivo regulatory function, as they have been shown to
suppress anti-double-stranded DNA B cell responses in an antigen-specific
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manner (Seo et al. 2002). Thus, use of TS1xHA28 CD4+CD25+ cells allows us to
examine whether expression of a TCR that possesses high reactivity for a
disease target antigen affects the ability of CD4+CD25+ Treg cells (which are
capable of suppressing other in vivo immune responses) to prevent arthritis
development in TS1xHACII mice.

The data presented in this chapter show that CD4+CD25+ Treg cells that
are enriched in specificity for a critical disease target antigen fail to prevent
arthritis development in TS1xHACII mice. CD4+CD25+ Treg cells from TS1xHA28
mice, which contain a high frequency of 6.5+Foxp3+ cells that possess high
reactivity for the S1 peptide, do not reduce either arthritis incidence or severity in
TS1xHACII mice. This result is recapitulated by the adoptive transfer of
GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP reporter mice, confirming that
a highly pure population of CD4+CD25+Foxp3+ Treg cells enriched for 6.5
expression cannot suppress a disease that is initiated by recognition of S1
peptide by the endogenous 6.5+CD4+ T cells in TS1xHACII mice. Interestingly,
CD4+CD25+ Treg cells from TS1(SW)xPevSW mice, which are enriched for
expression of a transgenic TCR (TS1(SW) TCR) with low reactivity for S1 peptide
are able to modulate arthritis development in TS1xHACII mice, although these
cells are not as effective as CD4+CD25+ Treg cells obtained from HACII or
BALB/c mice. In addition, we show that signals through the TCR can shape the
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phenotype and differentiation of CD4+CD25+ Treg cells, as interactions with high
levels of cognate antigen can induce cytokine production and CD25
downregulation by CD4+CD25+ Treg cells. Collectively, we demonstrate that the
presence of S1 peptide-reactive CD4+CD25+ Treg cells is detrimental to
CD4+CD25+ Treg cell mediated suppression of arthritis development in
TS1xHACII mice.
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4.2 Results

4.2.1 In vitro suppressor function of CD4+CD25+ cells from TS1xHA28 mice
can be activated by S1 peptide

In the previous chapter we showed that the prospective administration of
exogenous polyclonal CD4+CD25+ Treg cells could prevent arthritis in
TS1xHACII mice. We next addressed whether CD4+CD25+ Treg cells that
express the 6.5 TCR (which recognizes S1 peptide and is also expressed by the
endogenous pathogenic CD4+ T cells) would also be able to suppress arthritis
development in TS1xHACII mice. To examine this, we made use of TS1xHA28
mice, which produce a high frequency of 6.5+CD4+CD25+Foxp3+ Treg cells
(Jordan et al. 2001). Antibody staining and flow cytometric analysis of LN cells
from TS1xHA28 mice showed that the majority of CD4+CD25+cells co-express
high levels of the 6.5 TCR and the transcription factor Foxp3 (Figure 4-1 A). To
demonstrate that the regulatory activity of TS1xHA28 CD4+CD25+ cells could be
activated in an antigen-specific manner, we conducted in vitro suppression
assays using S1 peptide as a stimulus. CFSE-labeled CD4+ T cells were
cultured with or without TS1xHA28 CD4+CD25+ cells at a 1:2 Treg:responder cell
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Figure 4-1 CD4+CD25+ cells from TS1xHA28 mice are enriched in 6.5+Foxp3+ cells
(A) LN cells from TS1xHA28 mice were stained with the mAb 6.5, CD4, CD25, and
Foxp3. Number indicates the percentage of 6.5+Foxp3+ cells among CD4+CD25+
cells from TS1xHA28 mice. (B) CFSE-labeled CD4+ T cells were cultured alone or
in the presence of CD4+CD25+ cells from TS1xHA28 mice at a 1:2 Treg:responder
cell ratio. CD4+CD25+ cells were stimulated with S1 peptide. Dot plots show CFSE
versus IFN-γ production after three days of culture. Plots are gated on total CD4+
cells. Numbers in plots indicate the percentage of IFN-γ+ cells among the responder
CD4+ cell population.
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ratio. After three days of culture, the cells were stimulated with PMA and
ionomycin and stained for intracellular IFN-γ production. In the absence of
TS1xHA28 CD4+CD25+ cells, the responder CD4+ T cells underwent extensive
proliferation, and 42 percent of the cells produced IFN-γ (Figure 4-1 B). When
co-cultured with CD4+CD25+ cells from TS1xHA28 mice, responder CD4+ T cells
proliferated less, and only 2.5 percent of the cells produced IFN-γ (Figure 4-1 B).
Thus, S1 peptide can induce potent regulatory activity in CD4+CD25+ cells
purified from TS1xHA28 mice, which contain a high frequency of 6.5+Foxp3+
cells.

4.2.2 CD4+CD25+ Treg cells enriched in specificity for a disease target
antigen fail to suppress arthritis in TS1xHACII mice

To examine whether CD4+CD25+ cells enriched in specificity for S1
peptide could suppress arthritis in TS1xHACII mice, we purified and adoptively
transferred 1x106 CD4+CD25+ cells from TS1xHA28 mice into young, pre-arthritic
TS1xHACII mice and tracked the recipient mice for arthritis development.
Unmanipulated TS1xHACII mice and those that received TS1xHA28 CD4+CD25+
cells displayed similar kinetics of disease development (Figure 4-2 A), and by 14
weeks of age, 80 percent of unmanipulated (8 of 10) and 88.9 percent of
TS1xHA28 CD4+CD25+ cell recipient (8 of 9) TS1xHACII mice were arthritic
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Figure 4-2 TS1xHA28 CD4+CD25+ cells do not suppress arthritis development in
TS1xHACII mice (A) 1x106 CD4+CD25+ cells purified from TS1xHA28 mice were
adoptively transferred into pre-arthritic TS1xHACII mice. Graph shows the average
number of arthritic limbs per mouse (±SEM) over time for unmanipulated ( , n=10)
and TS1xHA28 CD4+CD25+ cell recipient ( , n=9) TS1xHACII mice. (B) Arthritis
incidence in 15 week old unmanipulated TS1xHACII mice and TS1xHACII mice that
received TS1xHA28 CD4+CD25+ cells. (C) The number of arthritic limbs per mouse
among unmanipulated TS1xHACII mice and TS1xHACII mice that received
TS1xHA28 CD4+CD25+ cells. Each circle represents an individual mouse. Line
represents the average number of arthritic limbs per mouse.
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(Figure 4-2 B). Furthermore, the majority (5 of 8) of arthritic mice from both the
unmanipulated cohort of TS1xHACII mice and the cohort that received
TS1xHA28 CD4+CD25+ cells developed disease in all four limbs (Figure 4-2 C).
Thus, in contrast to HACII and BALB/c CD4+CD25+ cells, which dramatically
reduced arthritis incidence in TS1xHACII mice (Figures 3-6 and 3-13),
CD4+CD25+ cells from TS1xHA28 mice were unable to prevent arthritis
development in TS1xHACII mice. Moreover, CD4+CD25+ cells from TS1xHA28
mice did not reduce disease severity in TS1xHACII mice, as arthritic mice that
did or did not receive TS1xHA28 CD4+CD25+ cells exhibited similar numbers of
affected limbs.

The use of CD4 and CD25 expression to purify Treg cells is limiting in that
it includes activated conventional CD4+ T cells that have upregulated IL2Rα
expression. Accordingly, it is possible that the failure of TS1xHA28 CD4+CD25+
cells to prevent arthritis in TS1xHACII mice is due to the presence of
contaminating 6.5+CD4+CD25+Foxp3- T cells. To more rigorously purify
CD4+CD25+ Treg cells based on Foxp3 and CD25 expression rather than on
CD25 expression alone, we crossed TS1xHA28 mice with Foxp3EGFP mice
(Haribhai et al. 2007), to generate TS1xHA28.Foxp3EGFP mice. We examined the
CD4+CD25+ Treg cell profile in TS1xHA28.Foxp3EGFP mice by staining LN cells
for expression of 6.5, CD4, CD25, and Foxp3. GFP+CD25+ cells were clearly
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identifiable among CD4+ cells, and the majority of GFP+CD4+CD25+ cells coexpressed high levels of the 6.5 TCR and Foxp3 (Figure 4-3 A). For adoptive
transfers into TS1xHACII mice, we purified CD4+CD25+ Treg cells from
TS1xHA28.Foxp3EGFP mice based on expression of CD4, CD25, and GFP.

We transferred 1x106 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells into
pre-arthritic TS1xHACII mice and evaluated the recipient mice for arthritis
development. Over the course of nine weeks, there was no significant difference
in the kinetics of disease development between unmanipulated TS1xHACII mice
and TS1xHACII mice that received GFP+CD4+CD25+ cells from
TS1xHA28.Foxp3EGFP mice (Figure 4-3 A). At 15 weeks of age, 85.7 percent of
unmanipulated TS1xHACII mice (6 of 7) and 72.7 percent of GFP+CD4+CD25+
cell recipient TS1xHACII mice (8 of 11) had developed arthritis (Figure 4-3 B).
Although arthritis incidence was lower in TS1xHACII mice that received
GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice, the percentage of
arthritic animals is consistent with previous observations of disease incidence in
unmanipulated cohorts of TS1xHACII mice (Figure 3-2 A). Furthermore, in a
second cohort of TS1xHACII mice that received TS1xHA28.Foxp3EGFP
GFP+CD4+CD25+ cells, approximately 90 percent of TS1xHACII mice developed
arthritis (data not shown), indicating that the GFP+CD4+CD25+ cells do not
reduce disease incidence in TS1xHACII mice. Among TS1xHACII mice that
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Figure 4-3 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells do not prevent arthritis in
TS1xHACII mice (A) 1x106 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells were
adoptively transferred into TS1xHACII mice. Graph shows the average number of
arthritic limbs per mouse (±SEM) over time for unmanipulated ( , n=7) TS1xHACII
mice and GFP+CD4+CD25+ cell recipient ( , n=11) TS1xHACII mice. Dot plots show
CD4, CD25, 6.5, and Foxp3 staining of LN cells from TS1xHA28.Foxp3EGFP mice.
(B) Arthritis incidence in 15 week old unmanipulated TS1xHACII mice and TS1xHACII
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116

developed arthritis, 50 percent of unmanipulated TS1xHACII mice (3 of 6) and
62.5 percent of TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cell recipient TS1xHACII
mice (5 of 8) developed disease in all four limbs, and in both cohorts of mice no
arthritic mouse possessed fewer than two affected limbs (Figure 4-3 C). Thus,
GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice, which are heavily
enriched for 6.5+Foxp3+ cells, fail to suppress arthritis development in TS1xHACII
mice.

Taken together, these data indicate that CD4+CD25+Foxp3+ Treg cells that
are enriched in specificity for the target antigen S1 peptide fail to suppress
arthritis development in TS1xHACII mice. Moreover, the adoptive transfer of
TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells and TS1xHA28 CD4+CD25+ cells
appear to have similar effects in TS1xHACII mice, indicating that the failure of
TS1xHA28 CD4+CD25+ cells to prevent arthritis in TS1xHACII mice cannot be
solely attributed to the presence of 6.5+CD4+CD25+Foxp3- cells in the initial
transfer population.
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4.2.3 Donor CD4+CD25+ Treg cells that are enriched for expression of the
6.5 TCR persist in TS1xHACII mice

Because CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice expressed
GFP, we could determine whether the donor GFP+CD4+CD25+ cells persisted in
arthritic TS1xHACII mice. Lymphoid organs from 15 week old TS1xHACII mice
were examined for the presence of TS1xHA28.Foxp3EGFP cells, which were
identified by co-expression of GFP and the Foxp3 antibody. Nine to ten weeks
after the initial transfer, the donor GFP+CD4+CD25+ cells could be detected in
LNs that drain the lower (popliteal) and upper (axillary & brachial) limbs, as well
is in the spleen and LNs (cervical, inguinal, and mesenteric) that are not primary
joint-draining sites (Figure 4-4 A). GFP+Foxp3+ cells were found at the highest
percentages in the spleens of TS1xHACII mice that received
TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells, and among LNs, the
representation of GFP+Foxp3+CD4+ cells was comparable between joint-draining
and non-draining LNs (Figure 4-4 B). Moreover, the recovered
CD4+GFP+Foxp3+ cells were enriched for high levels of CTLA-4 expression when
compared to endogenous CD4+CD25+Foxp3+ cells in TS1xHACII mice (Figure 44 C), suggesting that the 6.5+ cells within the TS1xHA28.Foxp3EGFP
GFP+CD4+CD25+ population were activated upon interactions with their cognate
antigen.
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Thus, GFP+CD4+CD25+ cells enriched in specificity for the target antigen
S1 peptide fail to suppress arthritis in TS1xHACII mice despite persisting in
TS1xHACII mice for up to ten weeks post transfer, trafficking to the joint draining
LNs, and upregulating functional markers such as CTLA-4.

4.2.4 CD4+CD25+ Treg cells enriched for expression of the 6.5 TCR do not
suppress the Th-17 response in popliteal LNs of TS1xHACII mice

We previously showed that protective HACII CD4+CD25+ cells could inhibit
the regional Th-17 response that develops in the popliteal LNs of TS1xHACII
mice (Figure 3-8). To determine whether the inability of TS1xHA28 CD4+CD25+
cells to suppress arthritis in TS1xHACII mice could be attributed to a failure to
inhibit the local Th-17 response, or if disease develops despite TS1xHA28
CD4+CD25+ cell mediated reduction of IL-17 producing CD4+ T cells in the
popliteal LNs in TS1xHACII mice, we analyzed IL-17 and IFN-γ production by
CD4+ T cells in the popliteal LNs of unmanipulated TS1xHACII mice, and of
TS1xHACII mice that received TS1xHA28 CD4+CD25+ cells. Popliteal LN cells
were stimulated for four hours with PMA and ionomycin, and then stained for
CD4 and intracellular IL-17 and IFN-γ. CD4+ cells in the popliteal LNs of
TS1xHACII mice that received TS1xHA28 CD4+CD25+ cells contained similar
percentages of IL-17-producing cells and slightly higher percentages of IFN-γ120

producing cells (ns, p=0.31, Student’s t-test) in comparison to unmanipulated
arthritic TS1xHACII mice (Figure 4-5 A and B). Thus, CD4+CD25+ cells from
TS1xHA28 mice did not reduce the Th-17 response in the popliteal LNs of
TS1xHACII mice.

Whereas the administration of HACII CD4+CD25+ cells resulted in
significantly smaller popliteal LNs in TS1xHACII mice (Figure 3-8 A), TS1xHACII
mice that received TS1xHA28 CD4+CD25+ cells did not exhibit a decrease in
popliteal LN cellularity, and actually averaged higher popliteal LN cellularities
than unmanipulated TS1xHACII mice, although the difference was not
statistically significant (p=0.16, Student’s t-test) (Figure 4-5 C). Correspondingly,
TS1xHA28 CD4+CD25+ cell recipient TS1xHACII mice also contained higher
numbers of IFN-γ+CD4+ (ns, p=0.09, Student’s t-test) and IL-17+CD4+ (ns,
p=0.18, Student’s t-test) cells when compared to unmanipulated TS1xHACII mice
(Figure 4-5 D). Although the difference in cell numbers did not reach statistical
significance, it is clear that unlike protective HACII CD4+CD25+ cells, CD4+CD25+
cells from TS1xHA28 mice were unable to inhibit the immune response that
develops in the popliteal LN cells of TS1xHACII mice.

Although we demonstrated that GFP+CD4+CD25+ cells from
TS1xHA28.Foxp3EGFP mice failed to suppress arthritis in TS1xHACII mice (Figure
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Figure 4-5 TS1xHA28 CD4+CD25+ cells do not suppress the Th-17 response in
popliteal LNs of TS1xHACII mice (A) Popliteal LN cells were stimulated for 4 hours
with PMA and ionomycin and then stained for intracellular IL-17 and IFN-γ. Dot
plots show IL-17 and IFN-γ production by CD4+ T cells from unmanipulated and
TS1xHA28 CD4+CD25+ cell recipient TS1xHACII mice. Numbers indicate the
percentage of cytokine-producing cells in each gate. (B) Percentages of IL-17 and
IFN-γ producing popliteal LN CD4+ T cells in unmanipulated and TS1xHA28
CD4+CD25+ cell recipient TS1xHACII mice. (C) Numbers of total (gray bar) and CD4+
(black bar) cells in the popliteal LNs of unmanipulated and TS1xHA28 CD4+CD25+
cell recipient TS1xHACII mice. (total cells, p=0.16) (D) Numbers of IFN-γ+CD4+ and
IL-17+CD4+ cells in the popliteal LNs of unmanipulated and TS1xHA28 CD4+CD25+
cell recipient TS1xHACII mice. Statistical significance was calculated using the
Student’s t-test. Bar graphs show average values ± SEM. unmanipulated TS1xHACII
mice, n=5; TS1xHA28 CD4+CD25+ cell recipient TS1xHACII mice, n=8
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4-3), we wanted to examine whether a more rigorously purified population of
CD4+CD25+Foxp3+ Treg cells enriched in specificity for S1 peptide could inhibit
the regional immune response that develops in the popliteal LNs of TS1xHACII
mice. Popliteal LN cells from unmanipulated TS1xHACII mice and TS1xHACII
mice that received TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells were stimulated
for four hours with PMA and ionomycin, and then stained for CD4 and
intracellular IL-17 and IFN-γ. In comparison to unmanipulated TS1xHACII mice,
TS1xHACII mice that received TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells
contained slightly higher percentages of IFN-γ producing CD4+ popliteal LN cells
and lower percentages of IL-17 producing CD4+ popliteal LN cells (Figure 4-6 A
and B). However, the changes in the representation of IFN-γ (ns, p=0.5,
Student’s t-test) and IL-17 (ns, p=0.25, Student’s t-test) producing CD4+ cells in
the popliteal LNs of TS1xHACII mice that received TS1xHA28.Foxp3EGFP
GFP+CD4+CD25+ cells were not statistically significant when compared to
unmanipulated TS1xHACII mice.

TS1xHACII mice that received GFP+CD4+CD25+ cells averaged higher,
though not statistically significant (p=0.13, Student’s t-test), numbers of popliteal
LN cells when compared to unmanipulated TS1xHACII mice (Figure 4-6 C).
Thus, despite the reduction in the percentage of IL-17-producing CD4+ cells in
the popliteal LNs, TS1xHACII mice that received TS1xHA28.Foxp3EGFP
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Figure 4-6 TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells do not suppress the Th-17
response in the popliteal LNs of TS1xHACII mice (A) Popliteal LN cells were
stimulated for 4 hours with PMA and ionomycin and then stained for intracellular
IL-17 and IFN-γ. Dot plots show IL-17 and IFN-γ production by CD4+ T cells from
unmanipulated and GFP+CD4+CD25+ cell recipient TS1xHACII mice. Numbers
indicate the percentage of cytokine-producing cells in each gate. (B) Percentages of
IL-17 and IFN-γ producing popliteal LN CD4+ T cells in unmanipulated TS1xHACII
mice and GFP+CD4+CD25+ cell recipient TS1xHACII mice. (C) Numbers of total
(gray bar) and CD4+ (black bar) cells in the popliteal LNs of unmanipulated and
GFP+CD4+CD25+ cell recipient TS1xHACII mice. (total cells, p=0.13) (D) Numbers
of IFN-γ+CD4+ and IL-17+CD4+ cells in the popliteal LNs of unmanipulated and
GFP+CD4+CD25+ cell recipient TS1xHACII mice. Statistical significance was
calculated using the Student’s t-test. Bar graphs show average values ± SEM. n=9
mice per group for all analyses.
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GFP+CD4+CD25+ cells averaged higher numbers of IL-17+CD4+ popliteal LN
cells than unmanipulated TS1xHACII mice (Figure 4-6 D). There was also a
corresponding increase in the numbers of IFN-γ+CD4+ cells in the popliteal LNs of
TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cell recipient TS1xHACII mice (Figure 46 D). Although the increases in total, IL-17+CD4+ (p=0.11, Student’s t-test), and
IFN-γ+CD4+ (p=0.5, Student’s t-test) popliteal LN cells of TS1xHACII mice that
received TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells did not reach statistical
significance, these data suggest that the TS1xHA28.Foxp3EGFP GFP+CD4+CD25+
Treg cells not only fail to inhibit the immune response in the popliteal LNs of
TS1xHACII mice, but may even exacerbate the accumulation of immune cells in
the joint-draining LNs.

Collectively, these data demonstrate that a highly pure population of
CD4+CD25+ Treg cells that are enriched for 6.5+Foxp3+ cells fails to inhibit the
regional Th-17 response and the accumulation of immune cells in the popliteal
LNs of TS1xHACII mice.

125

4.2.5 CD4+CD25+ Treg cells enriched for expression of the 6.5 TCR do not
suppress the systemic Th-17 response in TS1xHACII mice

To further analyze IL-17 production in TS1xHACII mice that received
CD4+CD25+ cells enriched for 6.5+ cells, we set up unfractionated LN (axillary,
brachial, cervical, inguinal, and mesenteric) cultures with cells from
unmanipulated TS1xHACII mice and TS1xHACII mice that received TS1xHA28
CD4+CD25+ cells. After three days of culture, supernatants were collected and
analyzed for IL-17 production. Unfractionated LN cultures from unmanipulated
and TS1xHA28 CD4+CD25+ cell recipient TS1xHACII mice contained
comparable concentrations of IL-17 (Figure 4-7 A). Indeed LN cells from
TS1xHACII mice that received TS1xHA28 CD4+CD25+ cells produced slightly
higher amounts of IL-17 than LN cells from unmanipulated TS1xHACII mice,
although the difference was not statistically significant (p=0.16, Student’s t-test).
Thus, CD4+CD25+ cells from TS1xHA28 mice failed to inhibit both the regional
and systemic Th-17 response in TS1xHACII mice.

We also examined whether TS1xHA28 CD4+CD25+ cells affected the
production of cytokines associated with Th-17 differentiation (i.e. IL-1 and IL-6) in
TS1xHACII mice. Interestingly, LN cultures from TS1xHACII mice that received
TS1xHA28 CD4+CD25+ cells produced significantly higher levels of IL-1α
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Figure 4-7 TS1xHA28 CD4+CD25+ cells fail to suppress the systemic Th-17 response
in TS1xHACII mice. Unfractionated LN (axillary, brachial, cervical, inguinal, and
mesenteric) cells from unmanipulated TS1xHACII, TS1xHA28 CD4+CD25+ Treg cell
recipient TS1xHACII, or control TS1 mice were cultured for three days, and
supernatants were collected and analyzed for (A) IL-17, (B) IL-1β and IL-1α , and
(C) IL-6. Statistical signficance was calculated using the Student’s t-test. Bar graphs
show average values ± SEM. unmanipulated TS1xHACII mice, n=5; TS1xHA28
CD4+CD25+ Treg cell recipient TS1xHACII mice, n=8; control TS1 mice, n=3.
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(*p=0.017, Student’s t-test) and increased, though not statistically significant
(p=0.1, Student’s t-test), amounts of IL-1β in comparison to LN cultures from
unmanipulated TS1xHACII mice (Figure 4-7 B). The production of IL-6 by
unfractionated LN cells from TS1xHACII mice that received TS1xHA28
CD4+CD25+ cells was also slightly higher than in unmanipulated TS1xHACII mice
(Figure 4-7 C), though the difference did not reach statistical significance (p=0.5,
Student’s t-test). Thus, TS1xHACII mice that received TS1xHA28 CD4+CD25+
cells produced similar or even increased levels of cytokines associated with Th17 differentiation in comparison to unmanipulated TS1xHACII mice. This stands
in marked contrast to TS1xHACII mice that received HACII CD4+CD25+ cells,
which averaged lower amounts of IL-1 and IL-6 than unmanipulated TS1xHACII
mice (Figure 3-9 B and C).

Collectively, these data demonstrate that CD4+CD25+ Treg cells enriched
in specificity for a disease target antigen not only fail to inhibit the pathogenic Th17 response in TS1xHACII mice, but may also enhance the production of
cytokines that can contribute to the differentiation of IL-17 producing cells.
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4.2.6 Strong antigenic stimulation coupled with lymphopenia can induce
CD4+CD25+Foxp3+ Treg cells to produce IL-17

While CD4+CD25+ Treg cells enriched for 6.5+ cells that possess high
reactivity for S1 peptide are unable to prevent arthritis development in
TS1xHACII mice, BALB/c CD4+CD25+ Treg cells that have no developmental
exposure to S1 peptide can suppress arthritis (Figure 3-13). Collectively, these
results suggest that expression of the 6.5 TCR, which possesses high reactivity
for the S1 peptide, may be detrimental to the ability of CD4+CD25+ Treg cells to
prevent arthritis TS1xHACII mice. Work in humans has shown that activated,
“memory” CD4+CD25+Foxp3+ Treg cells are capable of producing IL-17 (Ayyoub
et al. 2009; Beriou et al. 2009; Voo et al. 2009), and that cytokine production can
be preferentially induced by strong stimulation of the CD4+CD25+ Treg cells (Voo
et al. 2009). To examine whether 6.5+CD4+CD25+Foxp3+ cells exposed to
strong, chronic antigenic stimulation could develop the ability to produce IL-17,
we purified and adoptively transferred 6.5+GFP+CD4+CD25+ cells from
TS1xHA28.Foxp3EGFP mice into HACII.Tcrα-/- or Tcrα-/- recipient mice (Figure 4-8
A, upper panel). In both hosts, 6.5+GFP+CD4+CD25+ cells would enter a
lymphopenic environment (as is also the condition in young TS1xHACII mice),
but in HACII.Tcrα-/- mice the donor CD4+CD25+ Treg cells would also encounter
high levels of their cognate antigen S1 peptide.
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One week after transfer, LN cells were isolated from HACII.Tcrα-/- and
Tcrα-/- mice, stimulated for four hours with PMA and ionomycin, and stained with
intracellular IL-17 and IFN-γ to determine cytokine production. Donor
CD4+CD25+ Treg cells, which were identified by co-expression of GFP and
Foxp3, were present in the LNs of both HACII.Tcrα-/- and Tcrα-/- mice, though
there was a far greater percentage in HACII.Tcrα-/- mice (Figure 4-8 A, lower left
panel), most likely due to enhanced expansion of the 6.5+GFP+CD4+CD25+ cells
in response to S1 peptide. Although donor 6.5+GFP+CD4+CD25+ cells could be
detected in both HACII.Tcrα-/- and Tcrα-/- mice, we observed notable cytokine
production only in GFP+Foxp3+ cells recovered from HACII.Tcrα-/- mice (Figure 48 A, lower right panel), indicating that TCR interactions with self-peptide can
promote cytokine production in CD4+CD25+Foxp3+ Treg cells. Interestingly, the
GFP+Foxp3+ cells in HACII.Tcrα-/- mice preferentially produced IL-17 (7.6
percent) over IFN-γ (2.1 percent).

To examine the effects of exposure to high levels of cognate antigen
coupled with lymphopenia on Th-17 differentiation of conventional CD4+ T cells,
we purified CD4+ cells from TS1 Thy1.1+ mice (which are enriched for 6.5+ cells),
and adoptively transferred the cells into HACII.Tcrα-/-, Tcrα-/-, or BALB/c mice
which all expressed Thy1.2. One week post transfer LN cells from HACII.Tcrα-/-,
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Figure 4-8 6.5+CD4+CD25+Foxp3+ cells produce IL-17 and IFN-γ upon exposure to
high levels of cognate antigen in a lymphopenic environment (A) 1x106 6.5+GFP+
CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice were transferred into HACII.TCRα-/or TCRα-/- mice. One week later LN cells were stimulated for 4 hours with PMA and
ionomycin and stained for CD4, Foxp3, IL-17, and IFN-γ. Upper panel, Dot plots show
representative purities from cell sorts. Numbers indicate the percentages of
CD4+CD25+ cells and 6.5+GFP+ cells. Lower panel, Left dot plots show donor
GFP+Foxp3+ donor Treg cells within CD4+ cells. Numbers indicate the percentage of
GFP+Foxp3+ cells. Right dot plots show IL-17 and IFN-γ staining in GFP+Foxp3+CD4+
cells. Numbers indicate the percentages of the respective cytokines. (B) 1x106 CD4+
T cells from TS1 Thy1.1 mice were transferred into HACII.TCRα-/-, TCRα-/- , or BALB/c
mice. One week later LN cells were stimulated for 4 hours with PMA and ionomycin
and stained for Thy1.1, CD4, Foxp3, IL-17, and IFN-γ. Left dot plots show donor
Thy1.1+CD4+ cells among CD4+ cells. Numbers indicate the percentage of Thy1.1+
Foxp3- cells. Right dot plots show IL-17 and IFN-γ staining in Thy1.1+Foxp3-CD4+
cells. Numbers indicate the percentages of the respective cytokines.
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Tcrα-/-, and BALB/c mice were stimulated with PMA and ionomycin and stained
for Thy1.1, CD4, IL-17, and IFN-γ. The donor Thy1.1+CD4+ cells were present in
all recipient mice (Figure 4-8 B, left panel), albeit at the highest frequency in
HACII.Tcrα-/- mice, which most likely reflects the expansion of the 6.5+CD4+ T
cells in response to S1 peptide. Donor CD4+ cells produced cytokines in Tcrα-/but not BALB/c mice (Figure 4-8 B, right panel), indicating that exposure to
lymphopenic environments could induce the differentiation of conventional CD4+
T cells. In Tcrα-/- mice, the highest percentage of Thy1.1+CD4+Foxp3- cells
produced IL-17 (24.4 percent), followed by 13.1 percent of IFN-γ producing cells,
and 7.2 percent of IL-17+IFN-γ+ double-producers (Figure 4-8 B). In contrast, in
HACII.Tcrα-/- mice, Thy1.1+CD4+Foxp3- cells primarily produced IFN-γ (30.4
percent), with lower percentages of cells producing IL-17 (1.2 percent) or coproducing IL-17 and IFN-γ (1.2 percent) (Figure 5-1 B).

These data show that signals received through the TCR can induce
CD4+CD25+Foxp3+ Treg cells to differentiate to produce cytokines. Moreover,
upon exposure to a lymphopenic environment containing high levels of their
cognate antigen CD4+CD25+Foxp3+ Treg cells preferentially produced IL-17
rather than IFN-γ. Interestingly, while conventional CD4+ T cells preferentially
produced IL-17 in Tcrα-/- mice, introduction of high levels of HA skewed the cells
towards IFN-γ production. These results suggest that upon exposure to high
132

levels of cognate antigen in the context of a lymphopenic environment,
CD4+CD25+ Treg cells preferentially produce IL-17, whereas conventional CD4+
T cells preferentially produce IFN-γ.

4.2.7 6.5+CD4+CD25+ Treg cells from TS1xHA28.Foxp3EGFP mice do not
differentiate to produce IL-17 in TS1xHACII mice

We next examined whether 6.5+CD4+CD25+ Treg cells could also acquire
the ability to produce IL-17 or IFN-γ in TS1xHACII mice. To test this, we purified
and transferred 1x106 6.5+GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP
mice into young pre-arthritic TS1xHACII, older arthritic TS1xHACII, or control
HACII mice. Pre-arthritic and arthritic TS1xHACII mice were used to determine
whether the additional “space” available in young, lymphopenic TS1xHACII mice
contributes to the differentiation of CD4+CD25+ Treg cells. HACII mice were
used to examine how strong antigenic stimulation without the inflammation found
in TS1xHACII mice would affect cytokine production by CD4+CD25+ Treg cells.
Donor CD4+CD25+ Treg cells (identified by co-expression of GFP and Foxp3)
were present in the LNs of pre-arthritic TS1xHACII, older arthritic TS1xHACII,
and single transgenic HACII mice one week post transfer (Figure 4-9 A, upper
panel). The increased percentage of GFP+Foxp3+ cells in young, pre-arthritic
TS1xHACII mice is due to the lower number of CD4+ cells in young TS1xHACII
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mice, and GFP+Foxp3+ cell recoveries were comparable in the three different
recipients (data not shown). However, in contrast to what was observed in
HACII.Tcrα-/- mice, the transferred 6.5+GFP+CD4+CD25+ cells produced
negligible amounts of IL-17 and IFN-γ in all three recipients (Figure 4-9 A, lower
panel). Moreover, 6.5+GFP+CD4+CD25+ cells did not produce either IL-17 or
IFN-γ two or three weeks post transfer into pre-arthritic or arthritic TS1xHACII
mice (data not shown).

We next examined whether localization to the popliteal versus non-joint
draining LNs might affect the differentiation of CD4+CD25+Foxp3+ Treg cells in
TS1xHACII mice. To address, this we analyzed the cytokine profile of donor
GFP+CD4+CD25+ Treg cells from the popliteal and non-draining LNs in 15 week
old TS1xHACII mice that had received 1x106 TS1xHA28.Foxp3EGFP
GFP+CD4+CD25+ cells ten weeks earlier. Although GFP+Foxp3+ cells were
present in both the draining and non-draining LNs (Figure 4-9 B, left panel), the
GFP+Foxp3+ cells did not produce IL-17 or IFN-γ in either the popliteal or nondraining LNs of TS1xHACII mice (Figure 4-9 B, right panel). These data
demonstrate that GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice do not
differentiate to produce either IL-17 or IFN-γ even after ten weeks in TS1xHACII
mice. Furthermore, the micro-environment of the draining LN did not favor
induction of IL-17 or IFN-γ production by the donor CD4+CD25+ Treg cells, as
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Figure 4-9 TS1xHA28.Foxp3EGFP 6.5+CD4+CD25+Foxp3+ cells do not produce IL-17 or
IFN-γ in TS1xHACII mice (A) 1x106 TS1xHA28.Foxp3EGFP 6.5+GFP+CD4+CD25+ cells
were adoptively transferred into HACII, young pre-arthritic TS1xHACII, or arthritic
TS1xHACII mice. One week post transfer LN cells from recipient mice were
stimulated with PMA and ionomycin, and stained for CD4, Foxp3, IL-17, and IFN-γ.
Upper panel, dot plots show donor GFP+Foxp3+ Treg cells among CD4+ cells.
Numbers indicate the percentage of GFP+Foxp3+ cells. Lower panel, dot plots are
gated on GFP+Foxp3+CD4+ cells. Numbers indicate the percentages of IL-17 and
IFN-γ producing cells. (B) TS1xHACII mice that received 1x106 TS1xHA28.Foxp3EGFP
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described in part (A) to determine IL-17 and IFN-γ production by GFP+Foxp3+ cells.
Numbers indicate the percentages of GFP+Foxp3+ and cytokine-producing cells in the
respective dot plots.
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GFP+CD4+CD25+ cells in both the popliteal and non-draining LNs in TS1xHACII
mice did not produce either cytokine.

Thus, while 6.5+CD4+CD25+Foxp3+ cells can acquire the ability to produce
IL-17 in response to strong TCR signals, they do not undergo this phenotypic
change upon transfer into TS1xHACII mice, and it is unlikely that IL-17
production by 6.5+CD4+CD25+Foxp3+ cells explains the inability of CD4+CD25+
Treg cells enriched for S1-specificity to prevent arthritis development in
TS1xHACII mice.

4.2.8 Strong antigenic stimulation induces CD4+CD25+ Treg cell
downregulation of CD25

In addition to observations that CD4+CD25+Foxp3+ Treg cells can produce
cytokines (such as IL-17 and IFN-γ) that are associated with activated
conventional CD4+ T cells (Ayyoub et al. 2009; Beriou et al. 2009; Oldenhove et
al. 2009; Voo et al. 2009), recent work has demonstrated that CD4+CD25+ Treg
cells can also lose Foxp3 expression and subsequently acquire effector functions
(Xu et al. 2007; Osorio et al. 2008; Yang et al 2008; Duarte et al. 2009; Hoffman
et al. 2009; Komatsu et al. 2009; Murai et al. 2009; Zhou et al. 2009). The
plasticity of the CD4+CD25+ Treg cell population has been most apparent in
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conditions of lymphopenia and inflammation (Komatsu et al. 2009; Murai et al.
2009; Zhou et al. 2009). While we have shown that 6.5+CD4+CD25+Foxp3+ cells
do not differentiate to produce IL-17 or IFN-γ in TS1xHACII mice, we could not
eliminate the possibility that a subset of TS1xHA28 CD4+CD25+ Treg cells in
TS1xHACII mice might undergo phenotypic changes that could contribute to the
loss of Foxp3 expression and regulatory function. CD25 has been shown to play
an important role not only in the survival of CD4+CD25+ Treg cells (D'Cruz and
Klein 2005; Fontenot et al. 2005; Setoguchi et al. 2005), but also in the
maintenance of Foxp3 expression (Fontenot et al. 2005; Zorn et al. 2006).
Indeed, recent work showed CD4+CD25-Foxp3+ cells were more susceptible to
losing Foxp3 expression than CD4+CD25+Foxp3+ cells (Komatsu et al. 2009).

To determine the effects of the the environment in TS1xHACII mice on
CD25 expression by CD4+CD25+ Treg cells from TS1xHA28 mice upon
exposure, we adoptively transferred CFSE-labeled CD4+CD25+ cells purified
from TS1xHA28 mice into TS1xHACII, HACII, or BALB/c mice and analyzed the
donor cells three days post transfer. CFSE-labeling the TS1xHA28 CD4+CD25+
cells allows us to examine their proliferation in the respective host mice, and also
to distinguish the donor 6.5+ cells from endogenous 6.5+CD4+ cells in TS1xHACII
mice. As expected, we observed no CFSE dilution by TS1xHA28 CD4+CD25+
cells in BALB/c mice, which do not express HA as a self antigen (Figure 4-10,
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upper panel). In contrast, TS1xHA28 CD4+CD25+ cells underwent extensive
proliferation in both TS1xHACII and HACII mice (Figure 4-10, upper panel), since
the 6.5+CD4+CD25+ cells encounter high levels of their cognate antigen (S1
peptide) in both hosts. Proliferation of TS1xHA28 CD4+CD25+ cells was
comparable in TS1xHACII and HACII mice, indicating that competition for S1
peptide with endogenous TS1xHACII 6.5+CD4+ T cells was not inhibitory to
TS1xHA28 CD4+CD25+ cell proliferation in TS1xHACII mice.

Three days post transfer, the majority of transferred TS1xHA28
CD4+CD25+ cells maintained high levels of CD25 expression in BALB/c mice,
and only 7.1 percent of the cells were Foxp3+CD25- (Figure 4-10, lower panel).
In contrast, a larger population of Foxp3+CD25- cells was present among donor
TS1xHA28 CD4+CD25+ cells in TS1xHACII and HACII mice. In TS1xHACII mice,
27.3 percent of the transferred TS1xHA28 CD4+CD25+ cells were Foxp3+CD25-,
and 35.2 percent of donor TS1xHA28 CD4+CD25+ cells were Foxp3+CD25- in
HACII mice (Figure 4-10, lower panel). The enhanced loss of CD25 expression
by TS1xHA28 CD4+CD25+ cells in TS1xHACII and HACII mice but not BALB/c
mice demonstrates that TCR signals and/or cell proliferation contribute to CD25
downregulation by CD4+CD25+ Treg cells. Moreover, TS1xHA28 CD4+CD25+
cells exhibited similar degrees of CD25 downregulation in TS1xHACII and HACII
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Figure 4-10 Exposure to high levels of cognate antigen induces CD25 downregulation
in CD4+CD25+ Treg cells. 1x106 CFSE-labeled CD4+CD25+ cells from TS1xHA28 mice
were adoptively transferred into BALB/c, TS1xHACII, or HACII mice. Three days post
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Flow plots are gated on CFSE+ cells. Lower panel, Numbers indicate the percentage
of cells in each quadrant.
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mice, indicating that a strong antigenic stimulus alone, rather than high levels of
antigen in addition to inflammation can induce CD25 downregulation.

Together, these data show CD4+CD25+ cells from TS1xHA28 mice can
undergo in vivo proliferation in response to S1 peptide, and that a subset of cells
loses CD25 expression upon exposure to high levels of their cognate antigen in
TS1xHACII and HACII mice.

4.2.9 CD4+CD25+ Treg cells can maintain CD25 expression in the presence
of low levels of their cognate antigen

We next examined whether the maintenance of CD25 expression by
TS1xHA28 CD4+CD25+ cells differed in conditions that induced strong (defined
as high levels of HA) versus weak (defined as low levels of HA) proliferation by
transferring CFSE-labeled TS1xHA28 CD4+CD25+ cells into HACII or HA28
mice, which contain high and low levels of HA respectively. Three and ten days
post transfer LN cells were isolated from HACII and HA28 recipient mice and
stained for 6.5, CD4, CD25, and Foxp3 expression. At three days post transfer,
the majority of TS1xHA28 CD4+CD25+ cells in HACII mice had undergone
several rounds of division, whereas in HA28 mice most of the TS1xHA28
CD4+CD25+ cells remained CFSE bright and only a small subset of cells had
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begun to proliferate (Figure 4-11 A, left panel). By ten days post transfer,
TS1xHA28 CD4+CD25+ cells had proliferated further in HACII mice, and some
cells had completely diluted their CFSE (Figure 4-11 A, right panel). TS1xHA28
CD4+CD25+ cells in HA28 mice also proliferated more by day ten in comparison
to day three post transfer, with some cells undergoing three or four cell divisions
(Figure 4-11 A, right panel). Consistent with our previous observations (Figure 410), by three days after the initial transfer a subset of TS1xHA28 CD4+CD25+
cells in HACII mice downregulated CD25 expression (Figure 4-11 B, left panel),
and by ten days post transfer into HACII mice the representation of both
Foxp3+CD25- and Foxp3-CD25- cells was increased within the donor TS1xHA28
CD4+CD25+ cell population (Figure 4-11 B, right panel). In contrast, TS1xHA28
CD4+CD25+ cells maintained high levels of CD25 expression at both three and
ten days post transfer into HA28 mice (Figure 4-11 B, left panel).

Taken together, these data demonstrate that CD4+CD25+ Treg cells can
maintain high levels of CD25 expression when exposed to low, but not high,
levels of their cognate antigen. Moreover, maintenance of CD25 expression
appears to be inversely related to the extent of proliferation by the CD4+CD25+
Treg cells.
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Figure 4-11 CD4+CD25+ Treg cells can maintain high levels of CD25 expression
upon exposure to low, but not high, levels of cognate antigen (A) 1x106 CFSElabeled TS1xHA28 CD4+CD25+ cells were adoptively transferred into HACII (high
HA levels) or HA28 (low HA levels) mice. Proliferation of the donor cells (identified
by CFSE and the mAb 6.5) was analyzed at days 3 (left panel) and 10 (right panel)
post transfer. Dot plots are gated on CD4+ cells. (B) Dot plots show Foxp3 and
CD25 staining of donor TS1xHA28 CD4+CD25+ Treg cells in HACII and HA28 mice
at days 3 (left panel) and 10 (right panel) post transfer. Data is representative of
three separate experiments.
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4.2.10 S1 peptide can activate the in vitro suppressor function of
CD4+CD25+ cells expressing a TCR with low reactivity for S1

The finding that BALB/c CD4+CD25+ Treg cells (which have no exposure
to S1 peptide or HA), but not TS1xHA28 CD4+CD25+ Treg cells (which are
enriched for highly reactive S1-specific cells), can prevent arthritis development
in TS1xHACII mice strongly suggests that enrichment for cells that recognize S1
peptide is detrimental to CD4+CD25+ Treg cell suppression of arthritis. Data
presented in this chapter also demonstrate that interactions with high levels of
cognate antigen can induce phenotypic changes (i.e. cytokine production, CD25
downregulation) in CD4+CD25+ Treg cells that express the 6.5 TCR, which
possesses high reactivity for S1 peptide. However, TS1xHA28 CD4+CD25+ Treg
cells were able to maintain high levels of CD25 expression when exposed to low
levels of S1 peptide, suggesting that the strength of signal through the TCR can
affect the phenotype of CD4+CD25+ Treg cells. Thus, we examined whether a
population of CD4+CD25+ Treg cells that was enriched for cells expressing a
TCR with low reactivity for S1 peptide would be able to modulate arthritis in
TS1xHACII mice by using TS1(SW)xPevSW mice which co-express CD4+ T cells
that express the TS1(SW) TCR and the SW virus HA (driven by a β-globin locus
control region) as a self-antigen. The TS1(SW) TCR (identified by antibodies to
Vα8.3 and Vβ10) is specific for the S1(SW) peptide, which differs from the PR8
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S1 peptide by two amino acid substitutions, and possesses much lower reactivity
for the S1 peptide (Jordan et al. 2001). TS1(SW)xPevSW mice generate a high
frequency of CD4+CD25+Foxp3+ cells that are enriched for expression of the
TS1(SW) TCR (Figure 4-12 A).

To confirm that suppressor function in CD4+CD25+ cells from
TS1(SW)xPevSW mice can be triggered in an antigen-specific manner, we
conducted in vitro assays using S1(SW) peptide to stimulate the CD4+CD25+
cells. CFSE-labeled responder CD4+ T cells were cultured alone or with
TS1(SW)xPevSW CD4+CD25+ cells at a 1:2 Treg:responder cell ratio. Three
days later we examined proliferation and cytokine production by responder CD4+
T cells. When cultured alone responder CD4+ T cells underwent extensive
proliferation and approximately 75 percent of the cells produced IFN-γ (Figure 412 B, left panel). In contrast, when CD4+CD25+ cells from TS1(SW)xPevSW
mice were present, responder CD4+ T cells proliferated less and only 10.4
percent of the cells differentiated to produce IFN-γ (Figure 4-12 B, left panel).
This inhibition was also reflected in the recoveries of total and IFN-γ+ responder
CD4+ T cells, which were far lower in the presence of TS1(SW)xPev(SW)
CD4+CD25+ cells than when responder CD4+ T cells were cultured alone (Figure
4-12 B, right panel).
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Figure 4-12 The suppressor function of CD4+CD25+ cells expressing the TS1(SW)
TCR can be activated by non-cognate interactions with S1 peptide (A) Vα8.3+Vβ10+
cells in CD4+CD25+Foxp3+ LN cells from TS1(SW)xPevSW mice. Numbers indicate
the percentage of cells in the respective gates. (B) CFSE-labeled CD4+ T cells were
cultured alone or with TS1(SW)xPevSW CD4+CD25+ cells at a 1:2 Treg:responder
cell ratio. CD4+CD25+ cells were stimulated with S1(SW) peptide. Left panel, Dot
plots show CFSE versus IFN-γ production after three days of culture. Numbers
indicate the percentage of IFN-γ+ cells among the responder CD4+ cells. Right panel,
Graphs show the numbers of total and IFN-γ+ responder cells in the respective culture
conditions. (C) CFSE-labeled CD4+ T cells were cultured alone or in the presence of
CD4+CD25+ cells from TS1xHA28 or TS1(SW)xPevSW mice at 1:2 Treg:responder
cell ratio. HACII splenocytes (which present S1 peptide) were used to stimulate the
cultures. Left panel, Dot plots show CFSE versus IFN-γ production after three days
of culture. Numbers indicate the percentage of IFN-γ+ cells among the responder CD4+
cells. Right panel, Graphs show the numbers of total and IFN-γ+ responder cells in the
respective culture conditions.
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We next determined whether CD4+CD25+ cells from TS1(SW)xPevSW mice
could exert in vitro regulatory function when activated by S1 peptide, which is
less reactive with the TS1(SW) TCR. CFSE-labeled responder CD4+ T cells were
co-cultured with CD4+CD25+ cells from TS1(SW)xPevSW mice, or as a control
for 6.5+CD4+CD25+ Treg cells, TS1xHA28 mice. HACII splenocytes, which
present S1 peptide, were used to stimulate the cultured cells. After three days of
culture, we examined proliferation and cytokine production by responder CD4+ T
cells. When cultured alone, responder CD4+ T cells underwent robust
proliferation, and approximately 45 percent of the cells produced IFN-γ (Figure 412 C, left panel). The addition of TS1xHA28 CD4+CD25+ cells reduced
responder CD4+ T cell proliferation and cytokine production, as only 1.5 percent
of the cells produced IFN-γ (Figure 4-12 C, left panel). When co-cultured with
CD4+CD25+ cells from TS1(SW)xPevSW mice, responder CD4+ T cells also
proliferated less and only 9.1 percent of the cells produced IFN-γ (Figure 4-12 C,
left panel).

CD4+CD25+ Treg cell suppression of responder CD4+ T cells was also
evident in the numbers of total responder CD4+ T cells in the cultures, which
were much lower in the presence of either set of CD4+CD25+ cells than when the
responder CD4+ T cells were cultured alone (Figure 4-12 C, lower panel).
Moreover, the numbers of total responder CD4+ T cells were comparable in
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cultures with either TS1xHA28 or TS1(SW)xPevSW CD4+CD25+ cells. In
comparison to when responder CD4+ T cells were cultured alone, co-culture of
CD4+CD25+ cells also dramatically reduced the numbers of IFN-γ+ responder
CD4+ T cells. However, reflecting the difference in percentages of IFN-γ+ cells in
cultures with TS1xHA28 or TS1(SW)xPevSW CD4+CD25+ cells (Figure 4-12 C,
upper panel), more IFN-γ producing responder CD4+ T cells were recovered from
cultures with TS1(SW)xPevSW CD4+CD25+ cells than TS1xHA28 CD4+CD25+
cells (Figure 4-12 C, lower panel).

Thus, the in vitro suppressor function of CD4+CD25+ Treg cells enriched
for expression of the TS1(SW) TCR can be activated by both cognate (S1(SW)
peptide) and non-cognate interactions (S1 peptide). Moreover, although the
TS1(SW) TCR has much lower reactivity for the S1 peptide than the 6.5 TCR,
stimulation with S1 peptide induced comparable suppression of responder CD4+
T cells by both TS1(SW)xPevSW and TS1xHA28 CD4+CD25+ cells.

4.2.11 CD4+CD25+ Treg cells expressing a TCR with low reactivity for S1
peptide can modulate arthritis development in TS1xHACII mice

We have established that CD4+CD25+ Treg cells expressing the TS1(SW)
TCR can be activated S1 peptide, and to examine the ability of
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TS1(SW)xPevSW CD4+CD25+ cells to modulate arthritis development in
TS1xHACII mice we purified and transferred 1x106 CD4+CD25+ cells from
TS1(SW)xPevSW mice into pre-arthritic TS1xHACII mice and tracked the
recipients for disease development. At each time point during the nine week
period of analysis, TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+
cells averaged fewer arthritic limbs per mouse than unmanipulated TS1xHACII
mice (Figure 4-13 A). To determine whether this was a reflection of reduced
disease incidence or lower numbers of affected limbs per arthritic mouse, we
examined the kinetics of arthritis incidence in both cohorts of TS1xHACII mice.
TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+ cells exhibited a
slightly delayed kinetics in disease development, but by 15 weeks of age 75
percent of both TS1(SW)xPevSW CD4+CD25+ cell recipient and unmanipulated
TS1xHACII mice had developed arthritis (Figure 4-13 B).

We also examined 12 and 15 week old TS1xHACII mice to determine
whether the administration of TS1(SW)xPevSW CD4+CD25+ cells reduced the
number of affected limbs in arthritic TS1xHACII mice. Among 12 week old
arthritic mice, the majority (6 of 9, 66.7 percent) of unmanipulated TS1xHACII
mice had three or four affected limbs, where as the majority (4 of 6, 66.7 percent)
of TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+ cells had two or
one affected limbs (Figure 4-13 C, upper left panel). Thus, in 12 week old mice,
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Figure 4-13 TS1(SW)xPevSW CD4+CD25+ cells modify arthritis development in
TS1xHACII mice (A) 1x106 TS1(SW)xPevSW CD4+CD25+ cells were adoptively
transferred into TS1xHACII mice. Graph shows the average number of arthritic
limbs per mouse (±SEM) over time for unmanipulated TS1xHACII mice ( , n=12)
and TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+ cells ( , n=12)
(B) Arthritis incidence over time in cohorts of unmanipulated TS1xHACII mice
and TS1(SW)xPevSW CD4+CD25+ cell recipient TS1xHACII mice. (C) Graphs
show the number of arthritic limbs per mouse in 12 week old (left) and 15 week
old (right) cohorts of unmanipulated TS1xHACII mice and TS1xHACII mice that
received TS1(SW)xPevSW CD4+CD25+ cells (upper panel) or TS1xHA28
CD4+CD25+ cells (lower panel). Each circle represents an individual mouse.
Line represents the average number of arthritic limbs per mouse. Statistical
significance was calculated using the Mann-Whitney test.
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the reduction in arthritis incidence in TS1xHACII mice that received
TS1(SW)xPevSW CD4+CD25+ cells was accompanied by a decrease in the
number of affected limbs per arthritic TS1xHACII mouse. By 15 weeks of age
despite having the same incidence of arthritis development, 77.8 percent (7 of 9)
of arthritic unmanipulated TS1xHACII mice possessed three or four affected
limbs, in comparison to 44.4 percent (4 of 9) of TS1xHACII mice that received
TS1(SW)xPevSW CD4+CD25+ cells (Figure 4-13 C, right graph). Moreover, 44.4
percent (4 of 9) of arthritic TS1xHACII mice that received TS1(SW)xPevSW
CD4+CD25+ cells had only one affected limb, whereas only 11.1 percent (1 of 9)
of arthritic unmanipulated TS1xHACII mice had one affected limb.

In contrast, the transfer of TS1xHA28 CD4+CD25+ cells into TS1xHACII
mice (Figure 4-2) did not result in a reduction in the number of affected limbs in
arthritic mice. Among 12 week old arthritic mice, 50 percent of unmanipulated
TS1xHACII mice and 57.1 percent of TS1xHACII mice that received TS1xHA28
CD4+CD25+ cells had three or four affected limbs (Figure 4-13 C, lower left
panel). Moreover, by 15 weeks of age, the representation of arthritic mice with
three or four affected limbs had increased to 87.5 percent in TS1xHACII mice
that received TS1xHA28 CD4+CD25+ cells (Figure 4-13 C, lower right panel).
These data suggest that CD4+CD25+ Treg cells possessing low reactivity for S1
peptide can ameliorate arthritis severity in TS1xHACII mice.
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Collectively, these data show that CD4+CD25+ Treg cells enriched for
expression of the TS1(SW) TCR, which possesses low reactivity for the disease
target antigen S1 peptide, can modulate arthritis development in TS1xHACII
mice by delaying the kinetics of disease incidence and reducing arthritis severity.

4.2.12 CD4+CD25+ Treg cells enriched for the TS1(SW) TCR proliferate less
and can maintain CD25 expression upon exposure to high levels of the
mis-matched S1 peptide

We previously showed that CD4+CD25+ cells from TS1xHA28 mice
downregulate CD25 in response to high levels of HA present in TS1xHACII or
HACII mice (Figure 4-10). Given the low reactivity of the TS1(SW) TCR for S1
peptide, we hypothesized that CD4+CD25+ Treg cells from TS1(SW)xPevSW
mice might be less susceptible to CD25 downregulation upon exposure to the
high levels of HA present in TS1xHACII mice. Since TS1xHACII mice do not
contain endogenous CD4+ cells that express the TS1(SW) TCR, we could
identify the donor CD4+CD25+ cells from TS1(SW)xPevSW mice by staining for
co-expression of Vα8.3 and Vβ10, and examine the Foxp3 and CD25 profiles of
the donor Vα8.3+Vβ10+CD4+ cells. LN and spleen cells from unmanipulated
TS1xHACII mice and mice that received TS1(SW)xPevSW CD4+CD25+ cells
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were stained for Vα8.3, Vβ10, CD4, Foxp3, and CD25. Nine weeks after
transfer, donor Vα8.3+Vβ10+CD4+ cells could be detected in the LNs and spleens
of TS1xHACII mice that received TS1(SW)xPevSW CD4+CD25+ cells (Figure 414 A, upper panel). Among Vα8.3+Vβ10+CD4+ cells recovered from the LNs of
TS1xHACII mice, approximately 50 percent of the cells were Foxp3+CD25+, and
36.9 percent expressed neither Foxp3 nor CD25 (Figure 4-14 A, lower left panel).
In Vα8.3+Vβ10+CD4+ cells recovered from the spleens of TS1xHACII mice, up to
72.6 percent of cells retained Foxp3 and CD25 expression, 13.9 percent of cells
were Foxp3+CD25-, and 5.8 percent of the cells expressed neither Foxp3 nor
CD25 (Figure 4-14 A, lower right panel).

The maintenance of Foxp3 and CD25 expression in Vα8.3+Vβ10+CD4+
cells recovered from TS1xHACII mice was striking when compared to TS1xHA28
CD4+CD25+ cells, which had dramatically downregulated CD25 expression after
just three days in TS1xHACII or HACII mice (Figure 4-10). Indeed, after ten days
in HACII mice, the majority of TS1xHA28 CD4+CD25+ cells were either
Foxp3+CD25- or Foxp3-CD25- (Figure 4-11). To examine whether CD4+CD25+
cells from TS1(SW)xPevSW mice could better maintain CD25 expression in
response to high levels of HA we purified and adoptively transferred CFSElabeled CD4+CD25+ cells from TS1(SW)xPevSW mice into PevSW (which
contain low levels of the cognate S1(SW) peptide) or HACII (which contain high
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Figure 4-14 Foxp3 and CD25 profile of TS1(SW)xPevSW CD4+CD25+ cells exposed
to high levels of the mis-matched S1 peptide (A) LN cells from TS1xHACII mice that
received 1x106 TS1(SW)xPevSW CD4+CD25+ cells were stained for CD4, CD25,
Foxp3, Vα8.3, and Vβ10 expression ten weeks post transfer. Upper panel, Dot plots
show Vα8.3+Vβ10+ cells in the LNs and spleen of TS1xHACII mice. Right plot shows
representative staining from a control TS1xHACII mouse that did not receive cells.
Lower panel, Foxp3 and CD25 profile of recovered Vα8.3+Vβ10+CD4+ cells. (B) 1x106
CFSE-labeled TS1(SW)xPevSW CD4+CD25+ cells were adoptively transferred into
PevSW or HACII mice. Three days later donor cells were analyzed for their CFSE
and Foxp3 and CD25 expression profiles. Upper panel, histograms show CFSE
profiles of donor cells in PevSW and HACII mice. Lower panel, Foxp3 and CD25
profiles of CFSE+ cells from PevSW and HACII mice. Numbers indicate the
percentage of cells in the respective quadrants.
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levels of the mis-matched S1 peptide) mice. Three days post transfer we
examined the CFSE and Foxp3 and CD25 expression profiles of the donor cells.

At three days post transfer, a subset of TS1(SW)xPevSW CD4+CD25+
cells had proliferated in PevSW mice, with some cells undergoing up to five
divisions (Figure 4-14 B, upper panel). The dividing cells are most likely the
Vα8.3+Vβ10+ population responding to the presence of their cognate antigen
S1(SW) peptide in PevSW mice. In contrast, TS1(SW)xPevSW CD4+CD25+
cells proliferated less in HACII mice, and the cells that did expand underwent
fewer cell divisions than proliferating cells in PevSW mice (Figure 4-14 B, upper
panel). Additionally, the majority of TS1(SW)xPevSW CD4+CD25+ cells
recovered from PevSW mice maintained high levels of CD25 expression (Figure
4-14 B, lower panel), similar to what was observed with TS1xHA28 CD4+CD25+
cells in HA28 mice (Figure 4-11). Interestingly, the majority of TS1(SW)xPevSW
CD4+CD25+ cells recovered from HACII mice also maintained high levels of
CD25 expression (Figure 4-14, lower panel), which is in marked contrast to the
phenotype of TS1xHA28 CD4+CD25+ cells after transfer into HACII mice.

Collectively these data demonstrate that CD4+CD25+ cells from
TS1(SW)xPevSW mice proliferate more extensively in response to lower levels
of the cognate antigen S1(SW) peptide in PevSW mice than to high levels of the
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mis-matched S1 peptide (which can activate their suppressor function) present in
HACII mice. Moreover, although a subset of TS1(SW)xPevSW CD4+CD25+ cells
lost CD25 expression upon transfer into TS1xHACII mice, our data suggest that
the phenotypic changes may occur more slowly than in 6.5+CD4+CD25+ Treg
cells, since TS1(SW)xPevSW CD4+CD25+ cells but not TS1xHA28 CD4+CD25+
cells could maintain high levels of CD25 expression after three days in HACII
mice. These data suggest that the low reactivity of the TS1(SW) TCR for S1
peptide counters the high levels of HA present in TS1xHACII or HACII mice.
Therefore, although the mis-matched S1 peptide can activate comparable in vitro
suppressor function in TS1xHA28 and TS1(SW)xPevSW CD4+CD25+ Treg cells,
it has disparate effects on the in vivo proliferation and CD25 maintenance of
CD4+CD25+ Treg cells enriched for expression of the 6.5 TCR (cognate
interaction) versus the TS1(SW) TCR (non-cognate interaction).
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4.3 Summary of Results and Discussion

4.3.1 CD4+CD25+ Treg cells that are enriched in specificity for a disease
target antigen fail to suppress arthritis development in TS1xHACII mice

The recognition of S1 peptide by 6.5+CD4+ T cells is required for arthritis
development in TS1xHACII mice. Strikingly, we found that CD4+CD25+ Treg
cells enriched in specificity for S1 peptide were unable to modulate arthritis
development in TS1xHACII mice, as the administration of CD4+CD25+ cells from
TS1xHA28 mice, which generate a high frequency of 6.5+Foxp3+ cells (Jordan et
al. 2001), did not reduce arthritis incidence or disease severity (as defined by the
number of affected limbs per arthritic mouse) in TS1xHACII mice.
GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP mice, a more stringently
isolated CD4+CD25+ Treg cell population (since GFP was used as a surrogate for
Foxp3 expression), also failed to suppress arthritis development in TS1xHACII
mice. Collectively, these data demonstrate that CD4+CD25+ Treg cells with high
reactivity for a critical disease target antigen fail to prevent arthritis in TS1xHACII
mice. Moreover, the failure of TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells to
suppress arthritis development in TS1xHACII mice indicates that the inability of
TS1xHA28 CD4+CD25+ cells (in which GFP expression was not used as a
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parameter for CD4+CD25+ Treg cell purification) to prevent disease in TS1xHACII
mice is not solely due to the presence of 6.5+CD4+CD25+Foxp3- cells in the initial
transfer population.

Donor TS1xHA28.Foxp3EGFP GFP+CD4+CD25+ cells could be detected in
lymphoid organs throughout TS1xHACII mice (including the popliteal LNs) for up
to ten weeks post transfer, indicating that the failure of CD4+CD25+ Treg cells
that are enriched for 6.5 TCR expression to prevent arthritis in TS1xHACII mice
could not be attributed to deletion of the donor CD4+CD25+ Treg cells or an
inability to traffic to the joint-draining LNs, which are a primary site of
autoimmune pathology. However despite accessing the joint draining LNs,
CD4+CD25+ Treg cells from TS1xHA28 and TS1xHA28.Foxp3EGFP mice could not
suppress the accumulation of immune cells or the Th-17 response that develops
in the popliteal LNs of TS1xHACII mice, whereas both responses were
significantly diminished in TS1xHACII mice that received protective HACII
CD4+CD25+ cells. Furthermore, TS1xHA28 CD4+CD25+ cells were also unable
to suppress IL-17 production by systemic LN cells in TS1xHACII mice. Strikingly,
beyond an inability to suppress the systemic Th-17 response in TS1xHACII mice,
CD4+CD25+ cells from TS1xHA28 mice appeared to enhance production of other
cytokines that could contribute to Th-17 differentiation, as unfractionated LN
cultures from TS1xHACII mice that received TS1xHA28 CD4+CD25+ cells
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contained significantly higher levels of IL-1β, and also slightly higher levels of IL1α and IL-6 in comparison to unmanipulated TS1xHACII mice (Figure 4-7 B and
C). Thus, CD4+CD25+ Treg cells that are enriched in specificity for a disease
target antigen not only fail to suppress a cytokine that is critical for arthritis
development in TS1xHACII mice, but also appear to enhance the production of
other cytokines that not only contribute to Th-17 differentiation, but also have
roles in arthritis pathogenesis.

4.3.2 Interactions with high levels of cognate antigen can induce
phenotypic changes in CD4+CD25+ Treg cells

Recent work has shown that activated human CD4+CD25+Foxp3+ Treg
cells can produce IL-17 (Ayyoub et al. 2009; Beriou et al. 2009; Voo et al. 2009),
and interestingly, there is some indication that strong TCR signals are more
effective at inducing IL-17 production by CD4+CD25+Foxp3+ Treg cells (Voo et al.
2009). We found that 6.5+GFP+CD4+CD25+ cells from TS1xHA28.Foxp3EGFP
mice could differentiate to produce both IL-17 and IFN-γ in HACII.Tcrα-/- but not
Tcrα-/- mice (Figure 4-8), indicating that high levels of cognate antigen coupled
with lymphopenia but not lymphopenia alone could induce CD4+CD25+Foxp3+
Treg cells to produce cytokines. Moreover, we also observed that
6.5+CD4+CD25+Foxp3+ Treg cells in HACII.Tcrα-/- mice preferentially produced
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IL-17 over IFN-γ, whereas conventional CD4+ T cells that were enriched for 6.5
expression produced more IFN-γ than IL-17 upon transfer into HACII.Tcrα-/- mice,
suggesting that CD4+CD25+ Treg cells may be predisposed towards IL-17
production. Studies in human CD4+CD25+ Treg cells have shown that memory
CD4+CD25+ Treg cells produce more IL-17 than IFN-γ (Ayyoub et al. 2009), and
attempts to induce in vitro cytokine production by murine CD4+CD25+Foxp3+
Treg cells suggest that CD4+CD25+ Treg cells may favor IL-17 production (Xu et
al. 2007; Osorio et al. 2008).

However, despite our observation that 6.5+CD4+CD25+Foxp3+ Treg cells
could acquire the ability to produce cytokines in response to strong TCR signals,
TS1xHA28.Foxp3EGFP 6.5+GFP+CD4+CD25+ cells did not produce IL-17 or IFN-γ
upon transfer into TS1xHACII mice regardless of the duration of exposure (up to
ten weeks post transfer) or localization (popliteal versus non-draining LNs) in
TS1xHACII mice. These data indicate that the inability of CD4+CD25+ Treg cells
enriched for S1-specificity to prevent arthritis in TS1xHACII mice is not due to IL17 production by the donor CD4+CD25+Foxp3+ Treg cells. It is interesting that
6.5+CD4+CD25+Foxp3+ Treg cells differentiate to produce IL-17 and IFN-γ in
HACII.Tcrα-/-, but not TS1xHACII mice, which not only contain high levels of their
cognate antigen, but also an inflammatory environment that supports the
differentiation of endogenous pathogenic IL-17 producing cells. Indeed, work in
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both humans and mice have demonstrated the important role that cytokines (e.g.
IL-6, IL-1β, IL-23) play in inducing IL-17 production by CD4+CD25+Foxp3+ Treg
cells (Koenen et al. 2008; Beriou et al. 2009; Voo et al. 2009). One possibility is
that competition for cytokines between donor 6.5+CD4+CD25+ Treg cells and
endogenous CD4+ T cells in TS1xHACII mice prevents the donor CD4+CD25+
Treg cells from differentiating to produce IL-17. However, it is also possible that
CD4+CD25+ Treg cells must be exposed to high levels of cognate antigen
coupled with extreme lymphopenia for in vivo differentiation to produce cytokines
and although young TS1xHACII mice are lymphopenic, they do not recapitulate
the condition in HACII.Tcrα-/- mice, which completely lack αβ TCR T cells.

In addition to the observation that Foxp3+ Treg cells are capable of
producing Th-1 or Th-17 cytokines, recent work has further highlighted the
plasticity of the CD4+CD25+ Treg cell population, as multiple groups have shown
that CD4+CD25+ Treg cells can lose Foxp3 expression and undergo
differentiation to acquire effector T cell properties (Komatsu et al. 2009; Murai et
al. 2009; Zhou et al. 2009). Thus, although GFP+CD4+CD25+Foxp3+ cells from
TS1xHA28.Foxp3EGFP mice did not differentiate to produce IL-17 in TS1xHACII
mice, we could not eliminate the possibility that a subset of 6.5+CD4+CD25+ Treg
cells had lost Foxp3 expression and acquired effector functions that could
contribute to arthritis pathogenesis in TS1xHACII mice. Indeed work in the NOD
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diabetes model has shown that CD4+CD25+ Treg cells that have lost Foxp3
expression can become pathogenic and promote diabetes development (Zhou et
al. 2009). In the absence of a congenic mismatch between TS1xHA28
CD4+CD25+ Treg cells and TS1xHACII cells, we could not distinguish between
the donor and endogenous 6.5+CD4+ cells to analyze whether a subset of
6.5+CD4+CD25+ Treg cells lost Foxp3 expression after long term exposure to the
environment in TS1xHACII mice. However, to begin to address the potential
instability of 6.5+CD4+CD25+ Treg cells we conducted short term experiments
with CFSE-labeled TS1xHA28 CD4+CD25+ cells in TS1xHACII mice, and
extended analyses in single HA-transgenic mice that did contain any
endogenous 6.5+CD4+ cells to examine whether TS1xHA28 CD4+CD25+ cell
might undergo phenotypic changes that could lead to loss of Foxp3 expression.

Interestingly, we observed that CD4+CD25+ cells from TS1xHA28 mice
downregulated CD25 expression upon transfer into arthritic TS1xHACII or
healthy HACII mice, but not in BALB/c mice. This demonstrated that strong TCR
signals (via high levels of HA) alone could induce the loss of CD25 expression,
and that the inflammatory environment present in TS1xHACII mice was not
required for this change. CD25 has been shown to be critical for CD4+CD25+
Treg cell survival and also for maintenance of Foxp3 expression (D’Cruz et al.
2005; Fontenot et al. 2005; Setoguchi et al. 2005; Zorn et al. 2006), as signaling
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through the IL2Rα chain has been shown to potentiate both CD25 and Foxp3
expression (Fontenot et al. 2005). Since TS1xHA28 CD4+CD25+ cells
downregulate CD25 upon exposure to high levels of HA in TS1xHACII mice, it is
possible that with time some of the Foxp3+CD25- cells will also lose Foxp3
expression. This would generate a population of 6.5+CD4+CD25-Foxp3- cells that
possess high reactivity for S1 peptide in TS1xHACII mice, and the potential to
differentiate and develop effector functions that could contribute to arthritis
development.

Interestingly, whereas TS1xHA28 CD4+CD25+ cells downregulated CD25
after transfer into HACII mice, the cells were able to maintain high levels of CD25
expression in HA28 mice, which express low levels of HA, suggesting that the
amount of cognate antigen correlates with the degree of CD25 downregulation.
However, it is also possible that the differences in maintenance of CD25
expression by TS1xHA28 CD4+CD25+ cells in HACII and HA28 mice are due to
the more extensive proliferation of TS1xHA28 CD4+CD25+ cells in HACII mice.
Indeed, TS1xHA28 CD4+CD25+ cells at day ten post transfer in HA28 mice had
undergone fewer rounds of division than TS1xHA28 CD4+CD25+ cells in HACII
mice at day three post transfer. Accordingly, it is possible that TS1xHA28
CD4+CD25+ cells would also begin to downregulate CD25 expression in HA28
mice after undergoing additional rounds of proliferation. Therefore, while
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exposure to high levels of cognate antigen can induce rapid downregulation of
CD25 by CD4+CD25+ Treg cells, low levels of the same antigen either do not
induce or significantly delay CD25 downregulation.

4.3.3 CD4+CD25+ Treg cells enriched for cells with low reactivity for S1
peptide can modify arthritis in TS1xHACII mice

We have shown that interactions with high levels of cognate interaction
can induce phenotypic changes in TS1xHA28 CD4+CD25+ Treg cells that could
contribute to their failure in preventing arthritis development in TS1xHACII mice.
Furthermore, the ability of CD4+CD25+ Treg cells from HACII or BALB/c mice,
neither of which contain 6.5+ cells, to suppress arthritis development in
TS1xHACII mice demonstrates that CD4+CD25+ Treg cells that are not enriched
for cells with high reactivity for S1 peptide can prevent disease. Taken together,
these data suggest that interactions with high levels of cognate antigen are
detrimental to the ability of 6.5+CD4+CD25+ Treg cells to suppress arthritis in
TS1xHACII mice. Indeed, interactions with high levels of cognate antigen can
promote cytokine production and CD25 downregulation by CD4+CD25+ Treg cells
(Figures 4-8 and 4-11). However, CD4+CD25+ Treg cells were able to maintain
high levels of CD25 expression when exposed to lower levels of their cognate
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antigen, indicating that adjusting the strength of TCR signaling could alter the
CD4+CD25+ Treg cell response to the same S1 peptide.

Thus, we examined whether reducing the reactivity of the CD4+CD25+
Treg cell TCR for S1 peptide would allow CD4+CD25+ Treg cells that were
enriched for S1 peptide reactive cells to modulate arthritis development in
TS1xHACII mice. We found that CD4+CD25+ Treg cells from TS1(SW)xPevSW
mice, which are enriched for cells expressing the TS1(SW) TCR (identified by
Vα8.3+Vβ10+ staining) that possesses low reactivity for S1 peptide, could delay
the kinetics of arthritis development in TS1xHACII mice and also appeared to
ameliorate disease severity among arthritic TS1xHACII mice. We found that
TS1(SW)xPevSW CD4+CD25+ cells proliferated better in response to low levels
of their cognate S1(SW) peptide than to high levels of the mis-matched S1
peptide in HACII mice, indicating that increased amounts of antigen cannot
overcome the low reactivity of the TS1(SW) TCR to induce robust proliferation of
the CD4+CD25+ cells. However, the poor proliferation of TS1(SW)xPevSW
CD4+CD25+ cells in HACII mice may explain the interesting result that
TS1(SW)xPevSW CD4+CD25+ cells were able to maintain high levels of CD25
expression in the presence of both low levels of their cognate antigen S1(SW)
peptide (in PevSW mice) and high levels of the mis-matched S1 peptide (in
HACII mice). These data suggest that the lower reactivity of the TS1(SW) TCR
164

for S1 peptide counteracts the effects of high HA levels in HACII mice, similar to
the effect of reducing HA levels on CD25 maintenance by TS1xHA28
CD4+CD25+ cells. However, it is clear that TS1(SW)xPevSW CD4+CD25+ cells
can lose CD25 expression and potentially Foxp3 expression in TS1xHACII mice
(Figure 4-14), and it is therefore possible that the lower reactivity TCR simply
delays this process.

Although CD4+CD25+ cells from TS1(SW)xPevSW mice were more
effective than CD4+CD25+ cells from TS1xHA28 mice at modulating arthritis in
TS1xHACII mice, they were not as successful as HACII or BALB/c CD4+CD25+
cells, suggesting that the presence of CD4+CD25+ Treg cells that recognize the
S1 peptide is detrimental to CD4+CD25+ Treg cell suppression of arthritis in
TS1xHACII mice, regardless of whether the CD4+CD25+ Treg cells express
TCRs possessing high or low reactivity for the S1 peptide. Indeed the different
abilities of TS1(SW)xPevSW CD4+CD25+ cells and TS1xHA28 CD4+CD25+ cells
to modulate arthritis in TS1xHACII mice could be due to differences in the
representation of cells that can recognize the S1 peptide rather than differences
in the respective TCR reactivities for S1 peptide. Whereas approximately 30
percent of TS1(SW)xPevSW CD4+CD25+ cells express the TS1(SW) TCR,
upwards of 60 percent of CD4+CD25+ cells from TS1xHA28 mice express the 6.5
TCR. Thus, if CD4+CD25+ Treg cells that are enriched for cells that recognize S1
165

peptide are unable to prevent arthritis development in TS1xHACII mice because
of the de-differentiation of CD4+CD25+Foxp3+ Treg cells to Foxp3- cells, it is likely
that the transfer of TS1xHA28 CD4+CD25+ cells into TS1xHACII mice would
result in a larger population of effector cells originating from former CD4+CD25+
Treg cells, due to both the increased size of the starting 6.5+ population and also
enhanced proliferation of 6.5+CD4+CD25+ cells in response to S1 peptide. The
most accurate way to assess how reactivity alone affects the ability of
CD4+CD25+ Treg cells to suppress arthritis in TS1xHACII mice would be to use
clonotype in addition to CD4 and CD25 to sort 6.5+CD4+CD25+ cells from
TS1xHA28 mice and Vα8.3+Vβ10+CD4+CD25+ cells from TS1(SW)xPevSW
mice.

4.3.4 CD4+CD25+ Treg cells enriched in specificity for S1 peptide may be
unable to suppress arthritis development in TS1xHACII mice

While we have considered whether TCR specificity for S1 peptide could
lead to dysfunctional CD4+CD25+ Treg cell activity that renders CD4+CD25+ Treg
cells unable to suppress arthritis in TS1xHACII mice, another possibility is that
CD4+CD25+ Treg cells that are enriched for S1-specificity function normally in
TS1xHACII mice, but do not prevent disease development. Activated TS1xHA28
CD4+CD25+ Treg cells could promote the differentiation of pathogenic IL-17166

producing CD4+ cells by producing high levels of the regulatory cytokines TGF-β,
which in the context of cytokines such as IL-6 and IL-1 (which are present in
TS1xHACII mice) can induce Th-17 differentiation. Indeed, early studies
examining Th-17 differentiation identified TGF-β as a key factor in IL-17
production because of the presence of CD4+CD25+ Treg cells in the in vitro
cultures (Veldhoen et al. 2006). Thus, it is possible that upon transfer into
TS1xHACII mice, TS1xHA28 CD4+CD25+ Treg cells become activated, undergo
extensive proliferation, produce TGF-β, and thus foster an environment that is
even more supportive of the development of pathogenic IL-17 producing cells.

Another possibility is that CD4+CD25+ Treg cells from TS1xHA28 or
TS1(SW)xPevSW mice, while enriched for cells that recognize S1 peptide, do not
contain the appropriate specificities to suppress cells that are mediating the
effector stage of arthritis in TS1xHACII mice. Although recognition of S1 peptide
by 6.5+CD4+ T cells is important for arthritis development in TS1xHACII mice, as
disease progresses other autoreactive CD4+ T cells may be recruited to
participate in subsequent stages of arthritis pathogenesis in TS1xHACII mice.
Indeed, epitope spreading has been reported in a variety of murine autoimmune
diseases (Vanderlugt and Miller 2002). An intriguing aspect of this possibility is it
that it implies that in vivo CD4+CD25+ Treg cell suppression of target cells is
antigen specific, as opposed to in vitro studies demonstrating that while
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CD4+CD25+ Treg cells require antigen-specific TCR engagement for activation,
they are capable of suppressing responder CD4+ T cells regardless of their
specificity. Therefore, if CD4+CD25+ Treg cells from TS1xHA28 or
TS1(SW)xPevSW mice can suppress 6.5+CD4+ T cells that initiate arthritis
development in TS1xHACII mice, it would be interesting to examine whether
adoptive transfers of TS1xHA28 or TS1(SW)xPevSW CD4+CD25+ into
TS1xHACII mice that are younger than 5 to 6 weeks of age could prevent arthritis
development.
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Chapter 5: Discussion and Speculation

5.1 Introduction

It is well established that CD4+CD25+ Treg cells play a critical role in the
prevention of autoimmunity (Bennett et al. 2001; Gambineri et al. 2003; Fontenot
and Rudensky 2005; Kim et al. 2007), but how CD4+CD25+ Treg cells mediate
suppression remains unknown. In particular, the role that TCR specificities play
in guiding the in vivo regulatory function of CD4+CD25+ Treg cells is unclear.
While studies in several different models of murine autoimmune disease (e.g.
AOD, diabetes, EAE) indicate that CD4+CD25+ Treg cells that are specific for
disease-associated antigens are more effective at suppressing organ-specific
autoimmune diseases than polyclonal CD4+CD25+ Treg cells (Hori et al. 2002;
Tarbell et al. 2004; Samy et al. 2005; Samy et al 2008; Wheeler et al. 2009), how
the antigen-specificity of CD4+CD25+ Treg cells affects their ability to modulate
autoimmune arthritis is unknown. We have shown that CD4+CD25+ Treg cells
that are enriched in specificity for a critical disease target antigen fail to prevent
arthritis development in TS1xHACII mice, whereas CD4+CD25+ Treg cells that
have not been educated by the disease target antigen can suppress disease.
This chapter discusses these results in the context of antigen-specificity and
CD4+CD25+ Treg cell mediated suppression of other autoimmune disease
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models, and also examines how expression of a TCR with high reactivity for a
target antigen may contribute to the failure of antigen-specific Treg cells to
prevent arthritis in TS1xHACII mice.

5.2 The role of CD4+CD25+ Treg cells in arthritis development

Studies in human arthritis patients and in mouse models of inflammatory
arthritis have reached the seemingly paradoxical conclusion that arthritis
develops despite the presence of CD4+CD25+Foxp3+ Treg cells. The presence
of a normal and in some instances increased representation of
CD4+CD25+Foxp3+ cells in arthritis patients and arthritic mice raises questions
about whether CD4+CD25+ Treg cells are capable of modifying the disease.
However, several studies have provided some evidence for CD4+CD25+ Treg cell
activity during arthritis as CD4+CD25+ cells isolated from human arthritis patients
(Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni et al. 2007) and arthritic
mice (Kang et al. 2008; Monte et al. 2008) have been shown to possess in vitro
suppressor function. More importantly, there are indications that CD4+CD25+
Treg cells are exerting regulatory effects in vivo. Among individuals with JIA, an
enrichment of CD4+CD25+ T cells correlates with persistent oligoarticular JIA, a
milder form of the disease (de Kleer et al. 2004), suggesting that CD4+CD25+
Treg cells may modulate disease severity in human arthritis patients. In mice,
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depletion of CD4+CD25+ Treg cells by anti-CD25 treatment results in more
severe CIA (Morgan et al. 2003; Kelchtermans et al. 2005), and in lymphocytic
infiltration into otherwise unaffected organs in K/BxN mice (Kang et al. 2008).
Moreover, K/BxN.Foxp3-sf mice, which lack CD4+CD25+Foxp3+ cells, develop an
accelerated and more severe disease (Nguyen et al. 2007). Collectively, these
data indicate that CD4+CD25+ Treg cells are active in arthritic patients and in
arthritic mice, and while they are unable to fully prevent arthritis, they can
ameliorate disease severity and/or modify other aspects of the autoimmune
response.

TS1xHACII mice contain CD4+CD25+Foxp3+ cells, including a population
of 6.5+CD4+CD25+Foxp3+ cells that recognize S1 peptide (Figure 3-3 A and B),
and similar to observations in the CIA and K/BxN arthritis models,
CD4+CD25+Foxp3+ cells are present in the joint-draining LNs of TS1xHACII mice
(Figure 3-5). Additionally CD4+CD25+ cells isolated from arthritic TS1xHACII
mice possess in vitro suppressor function (Figure 3-4). Thus, TS1xHACII mice
develop arthritis despite the presence of endogenous CD4+CD25+Foxp3+ cells,
including a population of cells that are specific for the disease target antigen S1
peptide. However, the arthritis that develops in TS1xHACII mice is susceptible to
CD4+CD25+ Treg cell activity, as the administration of exogenous polyclonal
CD4+CD25+ Treg cells can prevent arthritis development in TS1xHACII mice
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(Figures 3-6 and 3-13). Given the ability of exogenous CD4+CD25+ Treg cells to
suppress arthritis in TS1xHACII mice, why do the endogenous
CD4+CD25+Foxp3+ cells fail to prevent disease? Studies in human arthritis
patients have indicated that effector CD4+ T cells isolated from individuals with
RA are resistant to CD4+CD25+ Treg cell mediated suppression (de Kleer et al.
2004; van Amelsfort et al. 2007). Additionally, work in the EAE system has also
demonstrated that effector CD4+ T cells can become refractory to CD4+CD25+
Treg cell activity, as wildtype CD4+CD25+ Treg cells could not suppress CD4+ T
cells isolated from the CNS (which is the primary disease site) of mice with acute
EAE (Korn et al. 2007). However, it is clear that in TS1xHACII mice effector
CD4+ T cells (or other immune system cells) that contribute to arthritis
development are not refractory to CD4+CD25+ Treg cell activity, since the
administration of exogenous CD4+CD25+ Treg cells can modulate disease.

Another possibility is that CD4+CD25+ Treg cells are functional in
TS1xHACII mice, and are able to suppress autoimmune responses in other
organs, but not in the joints, as the joints or draining LNs may be enriched for
cytokines such as IL-6 or TNF-α that have been shown to interfere with
CD4+CD25+ Treg cell function (Pasare and Medzhitov 2003; Ehrenstein et al.
2004; Valencia et al. 2006; Nadkarni et al. 2007). Indeed, although HA
expression is systemic in TS1xHACII mice, the primary manifestation of
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autoimmunity is the development of inflammatory arthritis, with some mice also
exhibiting a pulmonary lymphocyte infiltration and/or valvulitis. We do not
observe lymphocyte infiltration in most organs (e.g. kidney, liver, salivary glands)
(Rankin et al. 2008), and it is possible that the regulatory activity of endogenous
CD4+CD25+Foxp3+ cells prevents the development of more systemic
autoimmunity in TS1xHACII mice. Interestingly, recent work demonstrates that
CD4+CD25+ Treg cell mediated suppression of spontaneous lympophenia
induced proliferation, which is thought to favor the expansion of more highly selfreactive T cells (Min et al. 2004; Min et al. 2005), helps to generate a more
diverse repertoire of T cells (Winstead et al. 2010). Accordingly, the CD4+CD25+
Treg cells present in TS1xHACII mice may limit the expansion of other (non S1specific) CD4+ T cells with high reactivity for different self-antigens in young,
lymphopenic TS1xHACII mice and thus prevent a more systemic manifestation of
autoimmunity. Moreover, the ability of TS1xHACII CD4+CD25+ cells that have
been depleted of 6.5+CD4+CD25+ cells (which comprise Foxp3+ and Foxp3- cells)
to modulate arthritis development in TS1xHACII mice (Figure 3-11), clearly
demonstrates that CD4+CD25+ Treg cells from arthritic TS1xHACII mice are
functional in vivo. In contrast to CD4+CD25+ cells used in the CIA model, which
were obtained from healthy mice, this is a unique demonstration that CD4+CD25+
cells isolated from arthritic mice are capable of ameliorating disease.
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Although TS1xHACII 6.5-CD4+CD25+ cells can modulate arthritis in
TS1xHACII mice, they are less effective than CD4+CD25+ cells obtained from
HACII or BALB/c mice. Studies in human arthritis patients have demonstrated
that CD4+CD25+ cells isolated from RA patients are less effective in vitro
suppressors than CD4+CD25+ cells isolated from healthy individuals (Ehrenstein
et al. 2004; Valencia et al. 2006). However, the suppressor function of
CD4+CD25+ cells from RA patients was improved upon anti-TNF-α treatment
(Ehrenstein et al. 2004; Valencia et al. 2006; Nadkarni et al. 2007), suggesting
that the inflammatory disease environment negatively impacts CD4+CD25+ Treg
cells. In the CIA model, CD4+CD25+ T cells from IFN-γ receptor knockout mice,
which develop accelerated and more severe arthritis (Manoury-Schwartz et al.
1997; Vermeire et al. 1997), exhibit less potent suppressor activity in vitro, and
express lower levels of Foxp3 mRNA, akin to the effects of TNF-α on
CD4+CD25+ Treg cells in RA patients (Manoury-Schwartz et al. 1997). Thus, it is
possible that CD4+CD25+ Treg cells in TS1xHACII mice are less functional due to
development in or prolonged exposure to the inflammatory environment
associated with autoimmune arthritis. Moreover, the diminished function of
CD4+CD25+ Treg cells could be a contributing factor to arthritis development in
TS1xHACII mice, as the progressive loss of CD4+CD25+ Treg cell function could
ultimately tip the balance between tolerance and autoimmunity in favor of the
pathogenic immune response and arthritis development in TS1xHACII mice. In
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NOD mice, a reduction in CD4+CD25+ Treg cell function and numbers prior to
disease onset has been linked to diabetes development (Tang et al. 2008; Tritt et
al. 2008).

Thus, the administration of exogenous CD4+CD25+ cells to TS1xHACII
mice may mediate arthritis prevention by increasing the representation of
CD4+CD25+ Treg cells relative to pathogenic effector CD4+ T cells. In NOD
mice, the diminished function of CD4+CD25+ Treg cells mice (Tritt et al. 2008)
essentially results in a decrease in the representation of effective CD4+CD25+
Treg cells in relation to the diabetogenic CD4+ T cells. The striking observation
that endogenous TS1xHACII CD4+CD25+ cells can ameliorate arthritis in
TS1xHACII mice upon depletion of 6.5+CD4+CD25+ cells, which recognize the
disease target S1 peptide, also supports the concept that altering the balance
between Treg cells and pathogenic effector T cell influences the development of
autoimmunity. As described previously, 6.5+CD4+CD25+ cells in TS1xHACII
mice include both Foxp3+ and Foxp3- cells (Figure 3-3 B), and thus it is possible
that elimination of 6.5+CD4+CD25+Foxp3- cells allows the endogenous 6.5CD4+CD25+ cells to be more effective suppressors by reducing the
representation of pathogenic cells that drive arthritis development in TS1xHACII
mice. Furthermore, the concomitant transfer of a population of CD4+ cells
enriched for 6.5+Foxp3- cells rendered HACII CD4+CD25+ cells less protective in
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TS1xHACII mice (Figure 3-12), indicating that even a subtle increase in the
representation of 6.5+CD4+ T cells could alter CD4+CD25+ Treg cell function.

Collectively, these observations suggest that a contributing factor to the
development of arthritis (and autoimmunity in general) may be an imbalance of
CD4+CD25+ Treg cells relative to pathogenic effector cells during the time period
that precedes disease development. Moreover, observations in TS1xHACII mice
suggest that the presence of certain TCR specificities may play a more critical
role in altering the equilibrium between successful CD4+CD25+ Treg cell activity
and the development of a pathogenic autoimmune response. For the adoptive
transfer experiments, endogenous CD4+CD25+ cells were purified from arthritic
TS1xHACII mice, and it is therefore likely that other CD4+ cells (which do not
express the 6.5 TCR) within the population have acquired pathogenic properties,
such as the ability to produce IL-17. However, the elimination of a very small
population of 6.5+CD4+CD25+ cells rendered the remaining 6.5-CD4+CD25+ cells
better able to modulate arthritis in TS1xHACII mice, demonstrating the particular
importance of the representation of 6.5+CD4+ T cells that recognize S1 peptide
for arthritis development in TS1xHACII mice. These data also argue against the
idea that the CD4+CD25+ Treg cell repertoire itself is somehow compromised in
TS1xHACII mice because of the severe thymocyte deletion that occurs in young
TS1xHACII mice.
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What conditions might contribute to creating an imbalance between
CD4+CD25+ Treg cells and pathogenic autoreactive CD4+ T cells? One
possibility is that lymphopenia, which has been associated with the development
of autoimmunity (King et al. 2004; Khoruts and Fraser 2005; Marleau and
Sarvetnick 2005), has differing effects on distinct T cell populations. Both
conventional CD4+ T cells and CD4+CD25+ Treg cells undergo proliferation in
lymphopenic settings (Min et al. 2004; Min et al. 2005; Zhang et al. 2005), but
how differences in their responses may contribute to the maintenance of
tolerance as opposed to the development of autoimmunity remain unclear.
Studies in human patients who have undergone allogeneic hematopoetic stem
cell (HSC) transplantation have documented that while both conventional and
CD4+CD25+ Treg cells undergo extensive proliferation in the lymphopenic
environment induced by the treatment, CD4+CD25+ Treg cells appear to be more
susceptible to apoptosis than conventional CD4+ T cells (Matsuoka et al. 2010).
Moreover, humans that had more severe and prolonged lymphopenia had
greater defects in the CD4+CD25+ Treg cell pool after reconstitution of the
immune system, and a greater incidence of graft-versus-host disease (GVHD)
(Matsuoka et al. 2010). These findings suggest that the differential responses of
conventional CD4+ T cells and CD4+CD25+ Treg cells in response to
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lymphopenia can result in a decreased representation of CD4+CD25+ Treg cells
that may contribute to the development of systemic autoimmunity.

Work in the NOD diabetes model has shown that conventional CD4+ T
cells undergo more extensive proliferation than CD4+CD25+ Treg cells in
lymphopenic environments (Le Campion et al. 2009). Moreover, in NOD.scid
mice, diabetes development (which is induced by the adoptive transfer of CD4+
cells) was reduced when higher numbers of CD4+ cells were transferred,
effectively reducing the degree of lymphopenia in the recipient mice, and
protection correlated with a higher percentage of Foxp3+ cells among the
transferred CD4+ cells (Le Campion et al. 2009). Interestingly, it appears that
lymphopenia induced proliferation of CD4+CD25+ Treg cells is dependent on
interactions with self-peptides (Cozzo et al. 2003; Hsieh et al. 2004), whereas
conventional CD4+ T cells can undergo lymphopenia induced proliferation in the
absence of their cognate antigen (Cozzo et al. 2003). Moreover, conventional
CD4+ T cells expressing the 6.5 TCR underwent more extensive proliferation in
response to low levels of S1 peptide in an irradiation induced lymphopenic
environment than CD4+CD25+ Treg cells expressing the same 6.5 TCR (Cozzo
et al. 2003), indicating that even in the presence of their cognate antigen,
CD4+CD25+ Treg cells proliferate less than conventional CD4+ T cells in a
lymphopenic setting. These observations suggest that TCR specificity for self178

peptides exerts ongoing effects on conventional CD4+ T cells and CD4+CD25+
Treg cells, and can play an important role in shaping the balance of these
respective cell populations in response to lymphopenia and potentially influence
the development of autoimmunity.

Accordingly, it is possible that the lymphopenia in young, pre-arthritic
TS1xHACII mice promotes the expansion of not only S1-specific 6.5+CD4+ T
cells, which are exposed to high levels of their cognate antigen, but also 6.5CD4+ T cells that can differentiate to acquire pathogenic properties. Moreover it
seems likely that 6.5+CD4+ T cells (and also other CD4+ T cells with high
reactivity for other self-peptides) would undergo more extensive proliferation than
CD4+CD25+Foxp3+ cells, including the population of 6.5+CD4+CD25+Foxp3+
cells. Thus, differences in lymphopenia induced proliferation between
conventional CD4+ T cells and CD4+CD25+ Treg cells may lead to the
preferential expansion of 6.5+ and other highly self reactive CD4+ T cells in
TS1xHACII mice. Therefore, while functional CD4+CD25+ Treg cells are present
in pre-arthritic TS1xHACII mice, it is possible that they are not present in
sufficient numbers to inhibit the response of 6.5+CD4+ T cells (and other
pathogenic cells) in young TS1xHACII mice.
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Both the studies presented here and work in the CIA system have shown
that increasing the representation of CD4+CD25+ Treg cells by administering
exogenous Treg cells to pre-arthritic mice can ameliorate or prevent arthritis.
However, many questions remain regarding where and how CD4+CD25+ Treg
cells are acting to modulate the immune response in arthritis. In the CIA model,
protective exogenous CD4+CD25+ T cells that have been injected systemically
can be found in the draining lymph node, synovial fluid, and synovial tissue as
early as one day post transfer, indicating that the cells are trafficking to the
disease site (Morgan et al. 2005). Interestingly, it has also been reported that
CD4+CD25+ T cell transfers were more effective at modifying disease severity
when the cells were injected systemically rather than directly into the joints,
raising questions about where the CD4+CD25+ Treg cells are acting to modulate
disease (Ohata et al. 2007). Moreover, although CD4+ T cells have been found
in the joints of arthritic mice (Hirota et al. 2007; Jacobs et al. 2009), recent work
suggests that CD4+ T cells may play a more important role in the joint-draining
LNs, as CD4+ T cells that were blocked from exiting the LNs were still able to
contribute to arthritis pathogenesis (Angyal et al. 2010).

We found that protective HACII CD4+CD25+ Treg cells could inhibit the
accumulation of cells in the joint draining popliteal LNs that normally occurs in
TS1xHACII mice (Figures 3-2 E and 3-8 A). Work in the NOD diabetes model
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has illustrated the importance of the regional LN immune response in the
development of autoimmunity (Hoglund et al. 1999; Gagnerault et al. 2002).
Excision of the pancreatic LNs in young NOD mice prevented diabetes onset,
demonstrating that the local immune response is required for disease
pathogenesis (Gagnerault et al. 2002). However, while removal of the pancreatic
LN could prevent diabetes development in young mice, it was no longer
protective in 10 week old mice (Gagnerault et al. 2002), suggesting that once a
certain threshold is achieved it becomes more difficult to alter the course of
disease. Therefore, it is possible that protective CD4+CD25+ Treg cells suppress
arthritis in TS1xHACII mice by preventing the development of an enhanced
immune response in the popliteal LN, which may be a critical step for arthritis
pathogenesis.

Studies in other murine arthritis models suggest that another potential
mechanism by which CD4+CD25+ Treg cells may affect arthritis development is
by altering the inflammatory environment. In the CIA model, mice that received
Treg cells had reduced serum levels of TNF-α and IL-6 (Morgan et al. 2005;
Kelchtermans et al. 2009). Additionally, treatment with IL-35, which has been
identified as a CD4+CD25+ Treg cell effector cytokine (Collison et al. 2007), can
reduce disease severity in CIA, which is associated with a decrease in IL-17
levels (Niedbala et al. 2007), suggesting that CD4+CD25+ Treg cell production of
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IL-35 could inhibit IL-17 production in arthritic mice. We found that protective
HACII CD4+CD25+ Treg cells inhibit the pathogenic Th-17 response in
TS1xHACII mice (Figures 3-8, 3-9, and 3-10). While the mechanism by which
the exogenous CD4+CD25+ Treg cells inhibit IL-17 production in TS1xHACII mice
remains unknown, TS1xHACII mice that received protective HACII CD4+CD25+
Treg cells also produced decreased amounts of IL-1 and IL-6 (Figure 3-10), two
cytokines that can contribute to Th-17 cell differentiation (Acosta-Rodriguez et al.
2007). Innate immune cells, which are potential sources of cytokines such as IL1 and IL-6, may play an important role in the in vivo development of IL-17
producing CD4+ T cells (Korn et al. 2009), and recent work has shown that
monocytes from arthritic patients can induce Th-17 cell differentiation (Evans et
al. 2009). Thus, protective CD4+CD25+ Treg cells may decrease IL-17
production in TS1xHACII mice by acting upon an innate immune system cell(s)
that is instrumental in inducing the differentiation of Th-17 cells.

We have shown that the arthritis that develops in TS1xHACII mice is
susceptible to CD4+CD25+ Treg cell activity, as the administration of exogenous
CD4+CD25+ cells to 5 to 6 week old TS1xHACII mice can ameliorate or
completely prevent arthritis. The majority of unmanipulated TS1xHACII mice do
not develop arthritis until 10 to 12 weeks of age, and this lag period most likely
reflects the time required to establish the pathogenic immune response (e.g.
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development of IL-17 producing cells, immune response in the popliteal LNs) that
can overcome regulatory mechanisms in TS1xHACII mice. Thus, increasing the
representation of CD4+CD25+ Treg cells during this incipient stage of the
autoimmune response in TS1xHACII mice may be critical for effective
suppression of disease. Indeed, in the CIA model, there appeared to be a limited
time frame in which transferred Treg cells could modulate disease severity.
CD4+Foxp3+ T cells could best ameliorate CIA when they were transferred prior
to the primary immunization with collagen. At later time points, such as after a
secondary immunization, a greater number of transferred Treg cells was required
to achieve a comparable reduction in disease severity, and if transferred after the
booster immunization, the Treg cells had no effect on arthritis development
(Ohata et al. 2007). It remains to be determined whether the administration of
protective CD4+CD25+ Treg cells would be as effective at later time points in
TS1xHACII mice.

5.3 The effect of CD4+CD25+ Treg cell antigen-specificity in preventing
autoimmunity

While studies from our lab and others have shown that interactions with
cognate antigens can direct the thymic selection of CD4+CD25+ Treg cells
(Jordan et al. 2001; Apostolou et al. 2002; Hori et al. 2002; Kawahata et al. 2002;
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Walker et al. 2003), the importance of these interactions in guiding the in vivo
suppressor activity of CD4+CD25+ Treg cells is less clear. Work in multiple
murine autoimmune diseases (e.g. AOD, CIA, colitis, diabetes, gastritis) has
shown that that the adoptive transfer of polyclonal CD4+CD25+ Treg cells can
prevent or ameliorate disease (Olivares-Villagomez et al. 1998; Van de Keere
and Tonegawa 1998; Singh et al. 2001; Sarween et al. 2004; Morgan et al. 2005;
Zwar et al. 2006; Kelchtermans et al. 2009), indicating that CD4+CD25+ Treg
cells that are not necessarily enriched for disease-associated antigen specific
cells can mediate suppression of an organ specific disease. However, there is
also a significant body of work demonstrating that antigen- or disease-specific
CD4+CD25+ Treg cells are more effective than polyclonal CD4+CD25+ Treg cells
at suppressing organ-specific autoimmune diseases (e.g. AOD, diabetes, EAE)
(Hori et al. 2002; Reddy et al. 2004; Tarbell et al. 2004; Samy et al. 2005; Samy
et al. 2008).

Whereas the role of CD4+CD25+ Treg cell specificity in disease
suppression has been better established in other models of murine
autoimmunity, how CD4+CD25+ Treg cell specificity may affect the suppression
of arthritis is unknown. The primary approach to examining the role of antigenspecificity in CD4+CD25+ Treg cell modulation of arthritis development has been
to examine whether modifications to the CD4+CD25+ Treg cell population (i.e.
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depletion or administration of exogenous Treg cells) result in antigen-specific
changes in the autoimmune response. K/BxN mice, which develop arthritis due
to CD4+ T cell recognition of a GPI peptide and the subsequent activation of GPIspecific B cells, exhibit an accelerated accumulation of anti-GPI antibodies when
crossed to Foxp3-sf mice (Nguyen et al. 2007), suggesting that endogenous
CD4+CD25+ Treg cells are tempering the GPI-specific immune response. There
is additional evidence for antigen-specific CD4+CD25+ Treg cell activity in the CIA
model, with observations of increased collagen-specific T and B cell responses
after CD4+CD25+ Treg cell depletion, as well as a reduction in collagen-specific
antibodies after the transfer of exogenous CD4+CD25+ Treg cells (Morgan et al.
2003; Ohata et al. 2007). However, there are also data showing no alterations in
the collagen-specific immune response upon manipulation of CD4+CD25+ Treg
cells in CIA (Morgan et al. 2005; Kelchtermans et al. 2009). In contrast, beyond
the observation that K/BxN mice contain CD4+CD25+Foxp3+ cells that express
Vβ6 (Vβ chain of the KRN Tg TCR) and can mediate in vitro suppression in
response to the GPI peptide (Kang et al. 2008), there is little information
regarding how CD4+CD25+ Treg cell specificity for a target antigen can affect
affect arthritis suppression.

TS1xHACII mice are a useful system to examine how the TCR specificity
of CD4+CD25+ Treg cells can affect their ability to modulate arthritis development
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since we have established the identity of a critical disease target antigen (S1
peptide). Similar to the observations in K/BxN mice, the finding that TS1xHACII
mice contain 6.5+CD4+CD25+Foxp3+ cells (Figure 3-3 B) shows that arthritis can
develop despite the presence of CD4+CD25+Foxp3+ cells that are specific for a
disease target antigen. Moreover, the results from the adoptive transfers of
TS1xHA28 CD4+CD25+ Treg cells into pre-arthritic TS1xHACII mice demonstrate
that CD4+CD25+ Treg cells that are enriched in specificity for S1 peptide fail to
suppress disease (Figures 4-2 and 4-3), whereas polyclonal CD4+CD25+ Treg
cells from HACII or BALB/c mice can prevent arthritis in TS1xHACII mice
(Figures 3-6 and 3-13). Indeed no enrichment in specificity for the S1 peptide
appears to be necessary for Treg cell mediated suppression of arthritis, as
BALB/c CD4+CD25+ Treg cells have not developed in the presence of S1 peptide
or any other HA-derived peptides.

In contrast, studies from the Tung laboratory suggest that CD4+CD25+
Treg cells with specificity for disease-associated antigens possess superior
ability to prevent organ-specific autoimmune diseases than polyclonal
CD4+CD25+ Treg cells. Work in thymectomized mice that develop autoimmune
ovarian disease (AOD) has shown that the transfer of CD4+CD25+ Treg cells
isolated from the draining LNs are more effective suppressors of AOD than
CD4+CD25+ Treg cells from non-draining LNs (Samy et al. 2005; Samy et al.
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2008; Wheeler et al. 2009). Draining LNs have been shown to uniquely present
organ-specific peptides (Hoglund et al. 1999; Gagnerault et al. 2002;
Scheinecker et al. 2002), and CD4+CD25+ Treg cells isolated from the ovarydraining LNs may be more effective at suppressing AOD because they are
enriched for ovarian antigen-specific CD4+CD25+ Treg cells (Samy et al. 2005;
Samy et al. 2008). Moreover, studies in male mice that develop experimental
autoimmune prostatis (EAP) have demonstrated that CD4+CD25+ Treg cells can
acquire the ability to suppress organ-specific autoimmune diseases after
exposure to organ-derived antigens (Setiady et al. 2006). Male mice subjected
to a neonatal orchiectomy do not exhibit normal prostate development due to the
absence of testicular androgen, but re-introduction of the hormone into neonatal
orchiectomized mice can induce normal prostate development and expression of
prostate antigens. Interestingly, CD4+CD25+ Treg cells isolated from male mice
undergoing androgen treatment (and thus experiencing prostate-derived
antigens) can better suppress EAP than CD4+CD25+ Treg cells purified from
male mice subjected to only the neonatal orchiectomy, suggesting that exposure
to the normal prostate antigens confers the ability to suppress prostate-specific
autoimmune disease (Setiady et al. 2006). Thus, it possible that upon transfer
into TS1xHACII mice, BALB/c CD4+CD25+ Treg cells are educated by exposure
to the HA protein and gain specificity to HA derived peptides.
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Given the ability of polyclonal CD4+CD25+ Treg cells to suppress arthritis,
it was surprising that CD4+CD25+ Treg cells from TS1xHA28 and
TS1xHA28.Foxp3EGFP mice, which are enriched for 6.5+Foxp3+ cells, failed to
prevent arthritis in TS1xHACII mice despite expanding, becoming activated, and
trafficking to the joint draining popliteal LNs (Figures 4-4 and 4-10). This finding
is at odds with observations in other murine models of autoimmune disease (e.g.
diabetes, EAE, pneumonitis) where antigen-specific CD4+CD25+ Treg cells are
able to inhibit disease that is initiated by CD4+ T cells of the same specificity
(Hori et al. 2002; Tarbell et al. 2004; Huang et al. 2005). What might explain the
discrepancy in our observations of antigen-specificity requirements for
CD4+CD25+ Treg cell suppression of autoimmunity? Although recognition of S1
peptide by 6.5+CD4+ T cells is a critical step in arthritis development in
TS1xHACII mice, it is possible that other non S1-specific CD4+ T cells are
recruited later in the response and become more important during the effector
stage of arthritis in TS1xHACII mice. Indeed, epitope spreading can play a role
in the pathogenesis of a variety of autoimmune diseases, including arthritis, and
is also a mechanism by which viral infections can trigger the development of
autoimmunity (Vanderlugt and Miller 2002).

Thus it is possible that the cells that must be suppressed in TS1xHACII
mice are not the 6.5+CD4+ T cells, and that CD4+CD25+ cells from HACII or
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BALB/c mice, but not TS1xHA28 or TS1xHA28.Foxp3EGFP mice, contain the
appropriate specificities to mediate suppression, suggesting that in vivo
suppression of CD4+ T cells by CD4+CD25+ Treg cells is antigen-specific. This is
consistent with the finding of antigen-specific CD4+CD25+ Treg cell suppression
of effector CD4+ T cells in a model of fatal autoimmune pneumonitis (Huang et al.
2005). While the adoptive transfer of 6.5+CD4+ T cells into transgenic mice
expressing HA protein in the lungs induces pneumonitis, disease does not
develop if the cells are transferred into mice that express HA in the lungs but also
contain 6.5+CD4+CD25+ Treg cells. Moreover, transfer of 6.5+CD4+CD25+ Treg
cells but not polyclonal CD4+CD25+ Treg cells could prevent pneumonitis in
single transgenic HA mice. Protection, which is mediated by IL-10 and TGF-β,
results in the inhibition of proliferation and cytokine production (IFN-γ) by
pathogenic 6.5+CD4+ T cells (Huang et al. 2005). Interestingly, 6.5+CD4+CD25+
Treg cells could suppress proliferation by 6.5+CD4+ T cells but not CD4+ T cells
of a different specificity (Tanchot et al. 2004; Huang et al. 2005), indicating that
CD4+CD25+ Treg cell suppression of in vivo proliferation by responder CD4+ T
cells is antigen-specific.

However, the ability of TS1xHACII CD4+CD25+ cells to ameliorate arthritis
in TS1xHACII mice when depleted of 6.5+ cells argues that 6.5+CD4+ T cells
continue to play an important role in arthritis development in TS1xHACII mice at
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the time of the exogenous CD4+CD25+ Treg cell transfers (Figure 3-11). In
addition, the co-transfer of a population of conventional 6.5+CD4+CD25- cells
rendered HACII CD4+CD25+ Treg cells less protective in TS1xHACII mice
(Figure 3-12). Furthermore, the development of arthritis in TS1xHACII.RAG-/mice demonstrates that CD4+ T cells of other TCR specificities are not required
for arthritis pathogenesis, and that 6.5+CD4+ T cells alone can mediate arthritis
(Rankin et al. 2008). Collectively, these observations suggest that S1-specific
6.5+CD4+ T cells are a critical pathogenic population not only during disease
initiation, but also in other stages of arthritis in TS1xHACII mice, and it remains
surprising that the administration of CD4+CD25+ Treg cells enriched for 6.5+ cells
are unable to suppress or even ameliorate arthritis in TS1×HACII mice.

Moreover, studies in the NOD diabetes and EAE models provide evidence
that CD4+CD25+ Treg cells can suppress CD4+ T cells that possess specificity for
different antigens. The majority of CD4+CD25+ cells from BDC2.5 mice that were
expanded in vitro with BDC peptide pulsed APCs express the BDC2.5 TCR.
However, the adoptive transfer of these BDC peptide expanded CD4+CD25+ cells
could suppress diabetes development in NOD.scid mice, which is induced by the
adoptive transfer of splenocytes from diabetic NOD mice (Tarbell et al. 2004).
Thus, in this case CD4+CD25+ Treg cells that are enriched for expression of the
BDC2.5 TCR were able to suppress diabetes that is driven by CD4+ T cells with a
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diverse array of pathogenic TCRs, although the CD4+CD25+ Treg cells and
diabetogenic CD4+ T cells may recognize the same target antigen(s). Work in
the EAE model has shown that pre-activated Ig-proteolipid protein 1 (PLP1)
specific CD4+CD25+ Treg cells could suppress EAE driven by responses to
myelin oligodendrocyte glycoprotein (MOG) or myelin basic protein (MBP)
peptides (Yu et al. 2005), again demonstrating that CD4+CD25+ Treg cells could
mediate suppression regardless of the specificity of effector CD4+ T cells.

The question of antigen-specificity and CD4+CD25+ Treg cell function has
primarily been considered in relation to suppression of effector CD4+ T cells.
However, CD4+CD25+ Treg cells can also inhibit innate immune cells (Maloy et
al. 2003), and how the antigen-specificity of CD4+CD25+ Treg cells might
influence this suppression is less clear. While protective HACII CD4+CD25+ cells
suppressed IL-17 production by CD4+ T cells in the popliteal LNs of TS1xHACII
mice (Figure 3-8 B and C), whether the reduction in IL-17, IL-1, and IL-6
production by systemic LN cells (Figure 3-9) is attributed to CD4+CD25+ Treg
cells acting upon CD4+ T cells or other immune cells is unknown. Moreover, in
addition to producing cytokines such as IL-1 or IL-6, innate immune cells can
also produce IL-17 (Buonocore et al. 2010). Indeed, 6.5+CD4+ T cells may
promote arthritis development in TS1xHACII.RAG-/- by inducing inflammation that
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recruits innate immune cells (e.g. neutrophils, macrophages) that can mediate
joint damage (Niki et al. 2001).

Interestingly, S1-specific CD4+CD25+ cells not only failed to suppress IL17 production in TS1xHACII mice, but also appeared to increase production of
IL-1 and IL-6 (Figure 4-7). It has been shown that T cell mediated inhibition of
innate immune cells is MHC dependent (Kim et al. 2007), and more recent work
demonstrates that upon interactions with cognate antigen, memory CD4+ T cells
can induce the production of inflammatory cytokines and chemokines by innate
immune cells, (Strutt et al. 2010). Thus, one can speculate as to whether
interactions between CD4+CD25+ Treg cells and innate immune cells presenting
their cognate antigen could induce a similar induction of inflammatory proteins.
Given that HA expression is driven by a MHC Class II promoter in TS1xHACII
mice, it is likely that innate immune cells expressing MHC Class II can also
present HA-derived peptides (such as S1 peptide) and activate TS1xHA28
CD4+CD25+ cells, which are enriched for expression of the 6.5 TCR. Moreover,
activated TS1xHA28 CD4+CD25+ Treg cells could also promote the
differentiation of pathogenic IL-17-producing CD4+ cells by producing high levels
of the regulatory cytokines TGF-β, which in the context of cytokines such as IL-6
and IL-1, can induce Th-17 differentiation.
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5.4 Plasticity of CD4+CD25+ Treg cells: implications for suppression of
autoimmunity

Recent studies have demonstrated the plasticity of the CD4+CD25+ Treg
cell population, as a subset of CD4+CD25+ Treg cells can lose Foxp3 when
exposed to conditions of lymphopenia or inflammation in an autoimmune setting
(Komatsu et al. 2009; Murai et al. 2009; Zhou et al. 2009). Foxp3 expression is
critical for the maintenance of the CD4+CD25+ Treg cell phenotype (Wann and
Flavell 2007; Williams and Rudensky 2007), and CD4+CD25+ Treg cells that lose
Foxp3 expression can acquire the ability to produce cytokines such as IFN-γ and
IL-17 (Xu et al. 2007; Komatsu et al. 2009; Murai et al. 2009; Zhou et al. 2009).
Work from the Bluestone laboratory has shown that ex-CD4+CD25+ Treg cells
can differentiate into pathogenic CD4+ T cells and mediate diabetes development
in NOD mice (Zhou et al. 2009). Interestingly, upon transfer into NOD mice, a
greater percentage of BDC2.5 TCR expressing CD4+CD25+ Treg cells lost Foxp3
expression than did CD4+CD25+ cells that did not express the Tg TCR,
suggesting that interactions between the TCR and its cognate antigen could
further promote the loss of Foxp3 and the development of effector functions by
CD4+CD25+ Treg cells. Moreover, repetitive in vitro stimulation of human
CD4+CD25+ Treg cells can induce loss of Foxp3 (Hoffman et al. 2009), providing
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additional evidence that TCR engagement can contribute to phenotypic changes
in CD4+CD25+ Treg cells.

TS1xHA28 CD4+CD25+ cells, which are enriched for expression of the 6.5
TCR, rapidly downregulated CD25 upon transfer into TS1xHACII or HACII mice,
which contain high levels of their cognate antigen (Figure 4-10). In contrast,
TS1xHA28 CD4+CD25+ cells were able to maintain high levels of CD25
expression in HA28 mice, which contain low levels of S1 peptide (Figure 4-11).
Interestingly the downregulation of CD25 in response to high levels of S1 peptide
appeared to be delayed if CD4+CD25+ Treg cells expressed a TCR with low
reactivity for S1 peptide (Figure 4-14), suggesting that the lower reactivity of the
TS1(SW) TCR for S1 peptide counteracts the effects of high levels of S1 peptide
in HACII mice, similar to the effect of reducing S1 peptide levels on CD25
maintenance by TS1xHA28 CD4+CD25+ cells. Taken together these data
support a role for strong TCR signals in inducing CD25 downregulation by
CD4+CD25+ Treg cells. Signaling through the IL-2Rα chain has been shown to
potentiate both CD25 and Foxp3 expression (Fontenot et al. 2005; Zorn et al.
2006), and recent work has shown that CD4+CD25-Foxp3+ cells are more prone
to lose Foxp3 expression than CD4+CD25+Foxp3+ cells (Komatsu et al. 2009).
Thus, it is possible that upon exposure to highly stimulatory levels of S1 peptide,
a subset of TS1xHA28 CD4+CD25+ cells loses CD25 and Foxp3 expression, and
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in the context of the inflammatory disease setting, differentiates into pathogenic
effector CD4+ T cells in TS1xHACII mice. Certain inflammatory cytokines, such
as IL-1β (which was elevated in TS1xHACII mice that received TS1xHA28
CD4+CD25+ cells), have been shown to contribute to CD4+CD25+ Treg cell
conversion to Th-17 cells (Deknuydt et al. 2009).

Although the findings presented here suggest that TCR signals can induce
phenotypic changes in CD4+CD25+ Treg cells that could lead to loss of Foxp3
and regulatory function, whether a subset of TS1xHA28 CD4+CD25+ cells loses
Foxp3 expression and acquires cytokine production in TS1xHACII mice remains
to be determined. The adoptive transfer of CD4+CD25+ Treg cells purified from
TS1xHA28.Foxp3EGFP mice into congenically mismatched TS1xHACII mice would
allow us to better address whether 6.5+CD4+CD25+ Treg cells become
pathogenic upon exposure to the high levels of S1 peptide and inflammation
present in TS1xHACII mice, since the congenic marker could be used to detect
all donor CD4+CD25+ Treg cells rather than the use of GFP which only identifies
the cells that have maintained Foxp3 expression. Additionally, recent studies
have shown that the methylation status of the Foxp3 promoter plays an important
role in Foxp3 stability in CD4+CD25+ Treg cells (Kim and Leonard 2007; Janson
et al 2008). However, the signals and mechanisms involved in establishing and
maintaining the demethylation of the Foxp3 promoter remain unknown. It would
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be of interest to determine whether the strength of signal through the TCR could
affect the methylation status of the Foxp3 promoter and therefore the stability of
Foxp3 protein expression in CD4+CD25+ Treg cells. Recent work has linked the
loss of Foxp3 expression in human CD4+CD25+ Treg cells that have been
subjected to repetitive in vitro stimulation to changes in the methylation status of
the Foxp3 promoter (Hoffman et al. 2009).

5.5 Summary and working model

The studies presented in this dissertation demonstrate that the TCR
specificity(s) of CD4+CD25+ Treg cells can be a significant determinant of their
ability to suppress autoimmune disease. Polyclonal CD4+CD25+ Treg cells, but
not CD4+CD25+ Treg cells that are enriched in specificity for a critical disease
target antigen (S1 peptide), are able to prevent arthritis development in
TS1xHACII mice, which is driven by recognition of the S1 peptide by 6.5+CD4+ T
cells (Rankin et al. 2008). Moreover, CD4+CD25+ Treg cells that have not
developed in the presence of S1 peptide or any other HA-derived peptides can
prevent arthritis in TS1xHACII mice, demonstrating that specificity for this
disease target antigen is not required for CD4+CD25+ Treg cell mediated
suppression of arthritis. What might explain the ability of polyclonal CD4+CD25+
Treg cells to prevent disease development in TS1xHACII mice? The
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administration of exogenous CD4+CD25+ cells to pre-arthritic TS1xHACII mice
increases the representation of CD4+CD25+ Treg cells relative to pathogenic
CD4+ T cells in recipient mice, and it is possible that this increase is enough to
shift the balance in favor of regulation and away from autoimmunity.

Yet, if simply altering the balance of CD4+CD25+ Treg cells and effector
cells in favor of the regulatory population is sufficient to prevent arthritis
development, CD4+CD25+ Treg cells that are enriched for 6.5+ cells should also
be able to suppress arthritis in TS1xHACII mice. One possible explanation for
the failure of CD4+CD25+ Treg cells enriched for S1-specificity to prevent arthritis
development in TS1xHACII mice is that the CD4+ T cells mediating the effector
stage of arthritis are not the 6.5+CD4+ T cells, and that CD4+CD25+ Treg cells
that are enriched for S1-specific cells do not possess the appropriate TCR
specificities to suppress the effector CD4+ T cells. This would suggest that
CD4+CD25+ Treg cell suppression of CD4+ T cells is antigen-specific, and thus a
highly diverse population of polyclonal CD4+CD25+ Treg cells may contain the
necessary TCR specificities to suppress the relevant effector CD4+ T cells in
TS1xHACII mice. Indeed, the transfer of exogenous CD4+CD25+ Treg cells into
TS1xHACII mice could serve to increase the diversity of the TCR repertoire of
CD4+CD25+ Treg cells present in TS1xHACII mice, and thereby increase the
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probability of recognizing a critical target peptide to mediate suppression of
arthritis.

However, the ability of CD4+CD25+ cells from TS1xHACII mice to
modulate arthritis when depleted of a small population of 6.5+ cells indicates that
6.5+CD4+ T cells are still active participants in promoting arthritis development at
the time of the exogenous CD4+CD25+ Treg cell transfers into TS1xHACII mice.
Accordingly, if 6.5+CD4+ T cells continue to play an important role in arthritis
pathogenesis in TS1xHACII mice, increasing the representation of CD4+CD25+
Treg cells enriched in expression for the 6.5 TCR should be able to modulate
arthritis development by suppressing the endogenous 6.5+CD4+ T cells.
Furthermore, CD4+ T cells of other TCR specificities are not required for arthritis
development as TS1xHACII.RAG-/- mice also develop disease (Rankin et al.
2008). Thus, the question of why CD4+CD25+ Treg cells enriched for S1-specific
cells are unable to prevent arthritis in TS1xHACII mice remains. Additional data
presented in this dissertation suggest that strong stimulation with cognate
antigen can induce effector functions and/or phenotypic changes in CD4+CD25+
Treg cells that may be detrimental in the context of certain autoimmune diseases.

CD4+CD25+ Treg cells expressing the 6.5 TCR are strongly reactive to the
S1 peptide, and we have shown that the CD4+CD25+ cells enriched for 6.5+ cells
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undergo extensive proliferation and become activated in response to the high
levels of HA present in TS1xHACII mice. CD4+CD25+ Treg cells undergoing
strong stimulation may produce high levels of regulatory cytokines such as TGFβ, which in the context of other inflammatory cytokines (e.g. IL-1, IL-6, IL-23), can
promote Th-17 differentiation. Therefore, activated 6.5+CD4+CD25+ Treg cells
may contribute to the development of pathogenic Th-17 cells in TS1xHACII mice.
Another possibility is that a subset of 6.5+CD4+CD25+ Treg cells loses Foxp3
expression upon exposure to high levels of their cognate antigen, and
differentiates into pathogenic effector CD4+ T cells in TS1xHACII mice. Indeed,
in light of our data suggesting that the ability of CD4+CD25+ Treg cells to
suppress arthritis development in TS1xHACII mice is incredibly sensitive to the
presence of effector 6.5+CD4+ T cells, a population of de-differentiated
6.5+CD4+CD25+ Treg cells may alter the balance of Treg cells and effector cells
in favor of the pathogenic CD4+ T cells and arthritis development in TS1xHACII
mice. A working model of how exogenous CD4+CD25+ Treg cells can affect
arthritis development in TS1xHACII mice is presented in Figure 5-1.

Collectively, these data indicate that CD4+CD25+ Treg cells have the
ability to modulate arthritis, but that the antigen-specificity of the CD4+CD25+
Treg cells is critical for successful suppression of disease. Therefore, while there
is potential for the use of CD4+CD25+ Treg cells in therapeutic settings to treat
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autoimmunity, careful consideration should be given to nature of the autoimmune
disease, both from the perspective of predominant disease-associated antigens
and the inflammatory environment associated with the disease.
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Figure 5-1 Working model: The balance of CD4+CD25+ Treg cells to pathogenic
6.5+CD4+ T cells is a critical parameter for arthritis prevention in TS1xHACII mice
(A) In unmanipulated TS1xHACII mice the balance between CD4+CD25+ Treg cells
and effector CD4+ T cells favors pathogenic 6.5+CD4+ T cells and arthritis development.
(B) The administration of exogenous polyclonal CD4+CD25+ Treg cells increases the
representation of Treg cells relative to the representation of pathogenic 6.5+CD4+ T
cells in TS1xHACII mice, favoring Treg cell activity and suppression of arthritis.
(C) The administration of exogenous CD4+CD25+ Treg cells enriched for 6.5+Foxp3+
cells are unable to prevent arthritis development in TS1xHACII mice. Potential
mechanisms of failure: (1) A subset of 6.5+CD4+CD25+ Treg cells de-differentiates to
lose Foxp3 expression and acquire pathogenic effector function. (2) Strongly activated
6.5+CD4+CD25+ Treg cells produce high levels of TGF-β and promote the differentiation
of pathogenic Th-17 cells.
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